Leydig cell function in Klinefelter's syndrome by Smals$h1935-, A.G.H.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/147713
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.


L E Y D I G C E L L F U N C T I O N 
I N 
K L I N E F E L T E R s S Y N D R O M E 
PROMOTORES 
Dr. P.W.C. KLCPPENBORG 
Dr. Th.J. BENRAAD 
L E Y D I G C E L L F U N C T I O N 
IN 
K L I N E F E L T E R ' s S Y N D R O M E 
PROEFSCHRIFT 
TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE 
GENEESKUNDE AAN DE KATHOLIEKE UNIVERSITEIT TE 
NIJMEGEN, OP GEZAG VAN DE RECTOR MAGNIFICUS 
PROF.MR, F . J . F . M . DUYNSTEE VOLGENS BESLUIT VAN 
HET COLLEGE VAN DECANEN IN HET OPENBAAR TE 
VERDEDIGEN OP 27 JUNI 1974 DES NAMIDDAGS TE 
4 UUR 
DOOR 
ANTONIUS GERARDUS HUBERTUS SMALS 
GEBOREN TE HERTEN 
KRIPS REPRO - MEPPEL 
Dit proefschrift werd bewerkt op de afdeling Endocrinologie van 
de Universiteitskliniek voor Inwendige Ziekten (directeur 
Prof.Dr. C.L.H. Majoor) van het St. Radboud Ziekenhuis te 
Nijmegen. 
aan Thérèse, 
Sacha en Bart 
This thesis is based on the following papers: 
1. Smals, A.G.H., P.W.C. Kloppenborg and Th.J. Benraad, 
Diurnal plasma testosterone rhvthm and the effect of short 
term ACTH administration on plasma testosterone in man. 
J. Clin. Endocr. April 1974. 
2. Smals, A.G.H., P.W.C. Kloppenhorg and Th.J. Benraad, 
Plasma testosterone in Klinefelter's syndrome: diurnal 
variation and response to ACTH and dexamethasone. Acta 
Endocr. (Kbh), accepted for publication. 
3. Smals, A.G.H., P.W.C. Kloppenborg and Th.J. Benraad, 
The effect of short and long term human chorionic 
gonadotropin (HCG) administration on plasma testosterone 
levels in Klinefelter's syndrome. Acta Endocr. (Kbh), 
accepted for publication. 
4. Smals, A.G.H., P.W.C. Kloppenborg, R.M. Lequin and Th.J. 
Benraad, The effect of estrogen administration on plasma 
testosterone, FSH and LH levels in patients with 
Klinefelter's svndrome and normal men. Acta Endocr. (Kbh), 
accepted for publication. 
5. Smals, A.G.H., P.W.C. Kloppenborg and Th.J. Benraad, 
Body proportions and androgenicitv in relation to plasma 
testosterone levels in Klinefelter's svndrome. Acta Endocr. 
(Kbh), in press. 
6 
CONTENTS 
Chapter I Some historical notes. 
Chapter II Specific objectives of the studies in this 
thesis. 
Chapter III Determination of plasma testosterone by competi-
tive protein binding: reliability and evaluation. 
Chapter IV Temporally related changes in plasma testostero-
ne levels in eugonadal males and patients with 
Klinefelter's svndrome. 
Chapter V Diurnal plasma testosterone rhythm and the 
effect of short term ACTH administration on 
plasma testosterone in man. 
Chapter VI Plasma testosterone in Klinefelter's syndrome: 
diurnal variation and response to ACTH and 
dexamethasone. 
Chapter VII The effect of short and long term human chorio-
nic gonadotropin (HCG) administration on plasma 
testosterone levels in Klinefelter's svndrome. 
Chapter VIII The effect of estrogen administration on plasma 
testosterone, FSH and LH levels in patients 
with Klinefelter's svndrome and normal men. 
Chapter IX Body proportions and androgenicitv in relation 
to plasma testosterone levels m Klinefelter's 
syndrome. 
Summary 
Samenvatting 
8 
Chapter I 
SOME HISTORICAL NOTES 
§ 1 A FEW REMARKS ON THE HISTORY OF THE BIOLOGICAL 
IDENTIFICATION AND CHEMICAL QUANTITATION OF TESTOSTERONE 
The male gonad has played a heuristic role in the develop-
ment of endocrinology. In fact, bilateral orchidectomy has been 
the first procedure by which an endocrine organ has been 
removed, as early as in the Neolithic era (Sigerist, 1951). 
During thousands of years castration was used by the Chinese 
emperors and Egyptian pharao's as a means to eliminate the 
generative function of sons of murderers, enemies, war prisoners 
or slaves (cfr Riauet, 1948). In later centuries castration was 
mainly performed in order to abolish the inner secretory effect 
of the testes in harem guards, opera singers and domestic 
animals (Genesis XXXVII, 36, Aristotle 384 - 322 bC, Riquet 
1948). Even as early as in the 11th century AD Chinese 
iatrochemists made use of highly purified urinary extracts from 
adolescent boys and adult males to treat patients with hypogo-
nadism (Gwei-Djen and Needham, 1963). The several methods used 
by these iatrochemists are preserved in chapter 52 of the great 
pharmacopoeia of 1596 (Pen Tshao Rang My) by Li Shih-Chen. 
Scientific evidence for a direct relation between the presence 
of the testes and the occurrence of secondary male sex charac-
teristics was given probably for the first time in the Western 
9 
world by John Hunter at the end of the 18th century (cited from 
Voss, 1973). Fifty years later Berthold (1849) unequivocally 
demonstrated the dependency of the secondary male sex charac-
teristics by the finding of regeneration of the atrophied 
capon's comb after auto- or homoiotransplantation of the testes. 
He therefore was the first to show the phenomenon of internal 
secretion. Brown-Seauard (1889) concluded from the effects of 
castration, testis transplantation and of injections of testi-
cular extracts into himself that the male gonad exerts its 
activity on other organs by the secretion of 'produits ou 
ferments spéciaux' into the bloodstream. Few years later Ancel 
and Bouin (1903) demonstrated this 'inner secretory' effect of 
the testis to be confined to the Leydig cells. 
In Europe Loewe et al (1928) were the first to demonstrate 
the presence of androgenic activity in male urine and 3 years 
later Butenandt (1931) obtained from 25.000 1 of men's urine 
50 mg of a crystalline substance with comb growth promoting 
properties to which he subsequently gave the name 'androsterone' 
assuming it was the essential male hormone. In 1935 Laqueur's 
group in Amsterdam isolated crystalline testosterone from the 
bull's testis and in the same year Butenandt (1935) and Ruzicka 
(1935) succeeded in synthesizing the hormone. Shortly there-
after it became available for therapeutic use in clinical 
medicine. 
The chemical quantitation of androgenic substances in 
biological fluids has been the aim of many investigators. 
Zimmerman (1935) found that extracts of male or female urine 
gave a purple colour when treated with m-dinitrobenzene in the 
presence of alkali and he demonstrated that this colour was 
quantitatively correlated with the bioassayed androgenic 
activity. Though 17-ketosteroids were demonstrated to be the 
major contributors to this socalled Zimmerman reaction, in 
recent years evidence accumulated that testicular androgens do 
not contribute in a greater part to the determination of 17-ke-
tosteroids, which mainly originate from precursors secreted by 
the adrenal cortex. In eugonadal males e.g. roughly one third 
of the total amount of 17-ketosteroids, excreted in the urine 
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has been recognized to represent metabolites of testosterone 
(Loraine and Bell, 1971). Accordingly determinations of urinary 
total 17-ketosteroids or their fractions have not proved to be 
of great value in the diagnosis of male hypogonadism. 
Real progress in the diagnosis and management of the 
different forms of male hypogonadism could be made after the 
development of increasingly more specific methods for the de-
termination of testosterone itself. Earlier methods made use 
of bioassay techniques (capon's comb test, seminal vesicles 
regeneration test or spermatozoon motility test). These tech-
niques will not be discussed as they are obsolete in the field 
of clinical diagnosis and management at the present time. 
Schubert and Wehrberger (I960) were the first who quanti-
tated testosterone in male urine using a spectrophotometric 
technique. The presence of testosterone in blood was firstly 
demonstrated by West et al (1952) who isolated and identified 
circulating testosterone from canine spermatic vein blood. Six 
years later Hollander and Hollander (1958) could demonstrate 
and quantitate it in human spermatic vein blood. The presence 
of circulating testosterone in peripheral blood of normal 
human males was first established by Oertel and Eik-Nes (1959) 
after HCG administration. Finally in 1961 Finkelstein et al 
detected and measured testosterone in peripheral plasma of 
normal human subjects. Still later testosterone also was demon-
strated in adrenal (Burger et al, 1964, Wieland et al, 1965, 
Kirschner and Jacobs, 1971) and ovarian vein blood (Horton et 
al, 1966, Gandy and Peterson, 1968, Kirschner and Jacobs, 
1971). 
A number of methods has been described to measure urinary 
or blood testosterone based on colorimetrie, spectrophotome-
tric, fluorometric, enzymatic, gas chromatographic or double 
isotope derivative dilution techniques. A detailed account of 
these different techniques has been given recently by van der 
Molen (1970). Many of these methods are either outdated and 
lack sensitivity of detection (colorimetrie, fluorometric, 
spectrophotometric and enzymatic techniques) or are too tedious 
and time-consuming (double isotope derivative dilution and gas 
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chromatographic techniques). 
The recognition that certain proteins in human plasma 
possess highly specific binding characteristics for particular 
steroids has permitted the development of sensitive competitive 
protein binding assays for these steroids in analogy with the 
earlier developed radioimmunoassay for peptide hormones. 
In 1959 Slaunwhite and Sandberg demonstrated that testo-
sterone in human plasma is bound not only to albumin, but also 
to another hitherto unknown protein. Chen et al (1961) also 
gave some evidence for the presence in plasma of a protein 
binding testosterone more specific than albumin. Mercier et al 
(1966) (1967) were the first who demonstrated that testosterone 
m plasma is tightly and specifically bound to a ß-globulin 
fraction. Rosenbaum et al (1966) and Tavernetti et al (1967) 
gave clear evidence not only testosterone but also estradiol 
to be bound to a specific ß-globulin. Murphy et al (1968) and 
Barlow et al (1969) presented evidence that the ß-globulin 
binding testosterone and that binding estradiol were actually 
one and the same. This ß-globulin called :'protéine liant la 
testosterone' by Mercier et al (1967), steroid binding ß-globu-
lin (SBßG) by Steeno et al (1968), sex hormone binding globulin 
(SHBG) by Murphy (1969) and testosterone binding protein (TBP) 
by Mayes and Nugent (1968), was demonstrated to be unsaturated 
with these steroids at physiological plasma concentrations. 
Besides testosterone and estradiol this globulin also binds 
other steroids with a 17 ß-hydroxylic group. 
The binding of testosterone has been demonstrated to rise 
steeply during the first trimester of pregnancy and more 
gradually thereafter attaining at term levels about 2 to 3 
times the values found in the non-pregnant state (Pearlman et 
al, 1967, Barlow et al, 1969, Steeno et al, 1970, Anderson et 
al, 1972). Pregnancy plasma therefore is often used as the 
binding agent in the competitive protein binding methods for 
the determination of testosterone in blood or urine. 
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§ 2 KLINEFELTER'S SYNDROME IN RETROSPECT 
Ir 1942 Klinefelter, Reifenstein and Albright described 9 
male patients with small testes, showing hvalinization of the 
seminiferous tubules and in increased number of Levdig cells, 
azoospermia,bilateral gynaecomastia, mental abnormalities and 
an elevated urinary excretion of follicle stimulating hormone. 
Heller and Nelson (1945) extended the syndrome and included 
under the name 'puberal seminiferous tubule failure' also 
patients without gynaecomastia and with variable degrees of 
eunuchoidism in contrast to the patients described bv Klinefel-
ter et al who were masculine in appearance. 
Fresh interest in this type of gonadal dysfunction was 
aroused by the discovery of Plunkett and Barr (1956) and 
Bradbury et al (1956) that some of these patients were chroma-
tin positive bv the method of nuclear sexing. The demonstration 
of positive sex chromatin in patients with Klinefelter's syn-
drome led to the view that manv of these males were genetic 
females (Nelson, 1956). 
Unfortunatelv some of the patients onginallv described 
by Klinefelter et al (1942) and Heller and Nelson (1945) did 
not prove to be chromatin positive (Nelson, 1956 and 1957) . 
Therefore Nelson (1956) and Stewart et al (1959) suggested a 
division of the group of Klinefelter patients into a group with 
'true' and a group with 'false' Klinefelter's syndrome. Clini-
cally and hormonally the two groups resemble and shade into 
each other (Paulsen, 1968). 
The basis for finding sex chromatin bodies in certain 
phenotypic males was clarified by Jacobs and Strong (1959) who 
demonstrated the presence of a 47 XXY chromosomal pattern in a 
patient with Klinefelter's syndrome. During later years a wide 
range of karyotypes has been reported to occur m Klinefelter 
patients. Variations in the most common chromosomal pattern XXY 
involved the number of extra X chromosomes (and Y chromosomes) 
and the presence and distribution of different stem lines. The 
presence of two or more cell lines differing in chromosomal 
pattern (mosaicism) was described for the first time by Ford et 
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al (1959) in a patient with Klinefelter's syndrome and 46 XX/47 
XXY karyotype. Ever since several types of mosaicism have been 
reported in these patients (cfr Paulsen et al, 1968, Fr01and, 
1969). The clinical and laboratory features may be modified if 
mosaicism is present, particularly if one of the stem lines is 
that of the normal male XY (Paulsen et al, 1968). In these 
cases Leydig cell function and spermatogenesis may be less 
severely affected than in the XXY patients. 
The afore-mentioned problem on the existence of a true and 
a false form of Klinefelter's syndrome was solved by Paulsen et 
al (1968) and Gordon et al (1972) by demonstrating the presence 
of a supernumerary X chromosome in the blood and/or the testes 
of 4 chromatine negative patients. In three of these patients 
the extra X chromosome was merely present in the testes tissue, 
not in the blood. Therefore Paulsen (1968a) stated that classi-
fication of Klinefelter patients on the strength of absence or 
presence of buccal sex chromatin is an inappropriate line of 
subdivision, as it is based upon the presence or absence of an 
extra X chromosome in only one tissue, i.e. the buccal mucosa 
(cfr Gordon et al, 1972) . 
Klinefelter's syndrome therefore should be defined on the 
basis of its fundamental underlying etiologic factor, i.e. the 
presence of at least one supernumerary X chromosome in chroma-
tin positive or negative phenotypic males. Nevertheless in 1973 
Klinefelter himself still suggested the name 'Klinefelter's 
disease' for those patients who had a chromatin positive buccal 
smear pattern (80 % ) . 
Information about the incidence of Klinefelter's syndrome 
has been gathered from large scale surveys of phenotypic males. 
In newborn infants the incidence of a chromatin positive buccal 
smear pattern has been reported to be 0.21 % by MacLean et al 
(1964). Hamerton (1972) in a combined survey covering 23.328 
consecutive liveborn infants in Boston, Edinburgh, New Haven, 
London (Ontario) and Winnipeg reported a frequency of XXY 
karyotype of 0.2 % which is in agreement with the 0.2 % found 
by Pantelakis (1970) in 10.412 liveborn babies in Athens. In 
adult non-institutionalized males Paulsen et al (1964) reported 
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a frequency of positive buccal smear pattern of 0.2 %. A higher 
incidence even up to 2 % has been found by several investiga-
tors in seriously mentally retarded individuals (cfr Fr01and, 
1969) and a even higher percentage (5 to 10 %) in sterile men 
(Klinefelter, 1973) . It is evident from these data that Kline-
felter's syndrome is not a rare disease. If one also considers 
the variant form that exhibits a chromatin negative buccal 
smear pattern and sex chromosome mosaicism the actual incidence 
of this syndrome becomes even higher (Paulsen et al, 1968). 
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Chapter II 
SPECIFIC OPJECTIVES OF THE STUDIES IN THIS THESIS 
In chapter III the method for the determination of plasma 
testosterone is described with special emphasis on aspects of 
its reliability. In addition a number of observations in repre-
sentative samples of eugonadal males and patients with 
different forms of hypogonadism are given at the end of this 
chapter. 
In chapter IV a number of observations are collected in 
order to describe some temporally related changes in the peri-
pheral plasma levels of testosterone which might be of influ-
ence on the interpretation of data in literature and of our 
own studies. 
In chapter V a study is presented in which one of the 
temporally related changes in plasma testosterone, e.g. its 
cyclicity, is analysed more thoroughly. At the start of the 
study, in 1970, the analysis of testosterone cyclicity in 
eugonadal males seemed worthwhile in view of literature data 
that were contradictory in several aspects, some authors clai-
ming (Dray et al, 1965, Resko and Eik-Nes, 1966, Southren et 
al, 1965, Saxena et al, 1969, Nieschlag et al, 1970) and others 
denying its existence (Hudson et al, 1965, Kirschner et al, 
1965, Kobayashi et al, 1966, Vermeulen, 1968, Gordon et al, 
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1968). Especially if studying acute effects of tropic hormones 
on plasma Τ levels allowance should be made for the existence 
of temporally related cyclical changes. As an example of possi­
bly erroneous conclusions to be drawn if no due consideration 
were paid to the spontaneous diurnal changes, the effect of 
short term administration of ÍCTH on plasma testosterone levels 
in eugonadal men has been analysed to some detail. This seemed 
the more mandatory in view of literature data indicating plasma 
testosterone levels to decrease spontaneously during a part of 
the day and other data suggesting a decrease of the hormone's 
levels during administration of exogenous ACTH in the same 
period (Sorcini et al, 1963, Rosenfield et al, 1969, Pizarro et 
al, 1970). This study was not merely of theoretical importance. 
If ACTH were of any significane in regulating plasma testoste-
rone levels by changing the adrenal production of androgens, 
then comparison of the testicular function of eugonadal men 
with that of patients with primary hypogonadism would be a 
priori complicated. Indeed, such an ACTH mediated adrenal 
effect on plasma testosterone levels could be surmised the 
better discernible in males with overtly decreased testicular 
production of the hormone. Therefore in chapter VI diurnal and 
ACTH induced changes in plasma testosterone levels in patients 
with Klinefelter's syndrome have been analysed in a similar way 
as in the eugonadal males. In addition in a number of Klinefel-
ter patients the effect of suppression of endogenous ACTH by 
dexamethasone on plasma testosterone levels was evaluated. 
After establishing a qualitatively similar diurnal pattern 
of plasma testosterone levels in eugonadal males and patients 
with Klinefelter's syndrome and excluding a significant contri-
bution of the adrenals to the hormone's levels in plasma, the 
effects of short and long term administration of exogenous 
gonadotropins on plasma testosterone levels were studied m 
both groups and compared with the response observed m patients 
with hypogonadism due to primary failure at the hvpothalamic-
pituitary level (Chapter VII). In view of the endogenous hyper-
gonadotropism in the patients with Klinefelter's syndrome it 
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was interesting to find that at least short term gonadotropin 
administration could increase plasma testosterone levels in 
these patients in a quantitatively similar way as in patients 
with hypogonadotropic hypogonadism. This finding suggested that 
even in the presence of hypergonadotropism, in Klinefelter's 
syndrome the Leydig cells still have functional reserve. 
The occurence of a seemingly inappropriate hypergonadotro-
pism and of normal plasma testosterone levels in at least a 
number of patients with Klinefelter's syndrome has raised the 
question in recent literature if hypothalamic-pituitary control 
of gonadotropin secretion were abnormal (Lipsett et al, 1965, 
1966, Stewart-Bentlev et al, 1971, Capell et al, 1973). It is 
well known that in eugonadal males this control is exerted by 
at least testosterone (Odell et al, 1966, Peterson et al, 1968, 
Lee et al, 1972, Sherins and Loriaux, 1973), and estradiol 
(Swerdloff and Odell, 1968, Stewart-Bentley et al, 1971, Kulin 
and Reiter, 1972, Sherins and Loriaux, 1973 and Walsh et al, 
1973) . It was therefore thought meaningful in view of the above 
described dichotomy between plasma testosterone and gonadotro-
pin levels in some patients with Klinefelter's syndrome to make 
use of the known suppressive effect of estrogens on gonadotro-
pin secretion in normal men, in order to explore the functional 
integrity of the hypothalamic-pituitary-gonadal axis in this 
syndrome. The results of this study are presented in Chapter 
VIII. 
Chapter IX presents a study with the objective to better 
delineate the well known large variation in the phenotype of 
Klinefelter patients. Recently it has been reported that plasma 
testosterone levels in patients with this syndrome range widely 
from very low to quite normal (Lipsett et al, 1965, Paulsen et 
al, 1968, de Kretser et al, 1972, Stewart-Bentley and Horton, 
1973, Smals et al, 1974 (Chapter VI). In a number of studies of 
earlier data before the era of widespread application of testo-
sterone quantitation it has been reported that the clinical 
signs of androgenicity and the body proportions were quite 
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varied between the individual patients (Pasaualini et al, 1957, 
Stewart et al, 1959, Raboch, 1957 and 1964, Court Brown et al, 
1964, Fr01and, 1969). Therefore it seemed worthwhile to relate 
plasma testosterone levels as an index of androgen production 
and some simple body characteristics and signs of androgenicity 
in a number of patients with Klinefelter's syndrome and to 
compare these findings with those obtained in a group of age 
matched eugonadal controls. The establishment of a quantitative 
relationship between plasma testosterone levels and the clini-
cal expression of male phenotype would strongly suggest target 
organ responsiveness to be essentially normal in this syndrome. 
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Chapter III 
DETERMINATION OF PLASMA TESTOSTERONE BY COMPETITIVE 
PROTEIN BINDING: RELIABILITY AND EVALUATION 
§ 1 INTRODUCTION 
The method for the measurement of testosterone used in 
this thesis is based on the competitive protein binding techni-
que. In a paper by Benraad et al (1972) this method has been 
described to some extent and compared with a gas-chromatogra-
phic technique as reported by van der Molen et al (1966). In 
this chapter the competitive protein binding method is descri-
bed in detail and compared with a recently developed radio-
immunoassay which will be published in a forthcoming paper 
(Benraad et al, 1974). The competitive protein binding techni-
que used, employs diluted plasma from third trimester pregnant 
females as a source of testosterone binding protein and salt 
fractionation for separation of unbound and bound testosterone 
(Mayes and Nugent, 1968). The main steps of the assay are: 
I Extraction and purification of plasma testosterone. 
a extraction of alkaline plasma with ether-chloroform 
b separation of testosterone from other steroids competing 
for the binding protein by thin layer chromatography on 
silica gel and subsequent paper chromatography. 
II Quantitation. 
a equilibration of the isolated testosterone with tracer and 
binding protein. 
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b Separation of protein bound and unbound ligand by satura­
ted ammonium sulfate precipitation. 
с counting of the radioactivity present in the unbound 
fraction. 
§ 2 MATERIALS 
The following solvents were used after redistillation: 
ethanol and dichloromethane (Baker, ether and chloroform 
(Analar), methanol (Merck) benzene and petroleum ether (Merck). 
Thin layer chromatography was performed on silica gel G 
(Merck) and the paper used for chromatography was Whatman no. 
1. Before use this paper was washed for several days in a 
Soxhlet apparatus with benzene: ethanol 1 : 1 (v/v). 
Saturated ammonium sulfate was prepared as follows: 
60 gm of ammonium sulfate are stirred for several hours in 100 
ml distilled water and the saturated solution is stored at room 
temperature. 
Purity of 1,2- H-testosterone (46.5 Ci/mMole (New England 
Nuclear Corporation) was checked by paper chromatography in the 
Bush B, system (petroleum ether 80/100 : benzene : methanol : 
water = 667 : 333 : 800 : 200) . The tritiated testosterone was 
solved in ethanol to a final concentration of 0.05 micro Ci/ml. 
Nonradioactive testosterone was obtained from Steraloids, Inc. 
Third trimester pregnancy plasma was used as a binding 
agent and stored in 0.1 ml aliquote at - 10 C. Immediately 
before use the plasma was diluted 1 : 20 with 0.1 M, pH 9,0 
borate buffer. 
Radioactive samples were counted in a Nuclear Chicago 
liquid scintillation spectometer (Mark two). Alcohol solutions 
of the steroid (0.1 ml) were counted in 10 ml scintillation 
fluid (3 gr 2,5-diphenyloxazole and 0.2 gr 1,4 bis-(5-phenyl-
oxazolyl-2)-benzene per L toluene. Aqueous solutions were 
counted in Bray's solution (Bray, 1960). 
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§ 3 METHOD 
Extraction and purification of plasma testosterone. 
After sampling, the heparinized blood was centrifuged, the 
plasma collected and aliquots immediatelv frozen and stored at 
- 20 0C until use. After thawing 22000 dpm 1,2-H -testosterone 
(about 0.06 ng) were added to ^ to 1 ml in case of male plasma 
and 3 to 5 ml in the case of plasma in which low testosterone 
contents are exspected. After addition of 1 N sodium hydroxide 
to the plasma sample ( 1 : 1 , ν/ν), extraction was performed 
three times with 20 ml of ether-chloroform, 3 : 1 (v/v). The 
extract was taken to dryness under a stream of air, the crude 
residue was applied with a 2.5 cm interval on a silica gel 
layer and the chromatogram was developed to a distance of 15 cm 
m the solvent system chloroform-methanol, 99 : 1 (v/v). Radio­
activity was localized with a thin layer scanner and the appro­
priate area (about 2 x 2 cm) was eluated with ethanol according 
to Matthews et al (1962). After evaporation of the eluate the 
residue was dissolved m dichloromethane and applied to the 
starting line of a Whatman no. 1 paper strip. After developing 
the chromatogram in the Bush B, system the radioactivity was 
localized with a paper strip scanner and the appropriate area 
was eluted with methanol-dichloromethane, 3 : 2 (v/v) according 
to the method described by Gams et al (1961) . The eluates were 
collected and dried under a stream of air. 
With each series of plasma samples analysed, standards of 
testosterone (0, 0.4, 0.8 and 1.6 ng) were chromatographed on 
paper (processed standards). To measure the recovery of these 
processed standards tritiated testosterone was added before 
chromatography. 
Quantitation. 
The residues obtained after evaporation of the paper 
chromatogram eluates were resolved in 2.5 ml ethanol, and a 10 
% aliquot was removed for determination of recovery of the 
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tracer. Two separate 1 ml aliquots (tubes A and B) were pro­
cessed as follows: after addition of 33000 dpm tritiated tes­
tosterone, the solvent was removed by a stream of air. Subse­
quently 0.15 ml of dilute testosterone binding protein solution 
was added and the content of the tubes was gently mixed on a 
Vortex mixer. After incubation for 2 h at room temperature, 0.1 
ml of the content of tube A is brought into a scintillation 
vial containing 0.3 ml of distilled water, 0.05 ml saturated 
ammonium sulfate and 10 ml of Bray's scintillation fluid for 
determination of the 'total fraction'. For determination of the 
'unbound fraction' the protein bound testosterone in tube В was 
precipitated by addition of 0.15 ml of saturated ammonium sul­
fate. Ten minutes after the addition the tube was vortexed and 
centrifuged at - 4 0C for 10 minutes at 12000 rpm (17000 g) . 
One tenth ml of the supernatant was added to a scintillation 
vial containing 0.3 ml of distilled water and 10 ml of Bray's 
scintillation fluid. The vials were counted twice for 10 
minutes to measure the radioactivity. 
Construction of the standard curve. 
After taking into account the recovery of the (processed) 
standards and the volume of the aliquots used, the percentage 
unbound testosterone was plotted as a function of the unlabeled 
testosterone present in the incubation tubes (fig. 1). 
Calculation. 
The plasma testosterone concentration can be calculated 
according to the formula: 
Testosterone (ng/100 ml) = ng testosterone read off standard 
100 5 100 
curve χ ^ ^ ™
-
 χ
 —
 χ ^~^~~
-
~^^~~~^~~^^^^^~^~~~ % recovery 2 ml plasma processed . 
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F i g u r e 1 
C a l i b r a t i o n curve of p e r c e n t f r e e 1,2- H - t e s t o s t e r o n e 
vs ng of t e s t o s t e r o n e t a k e n through paper chromatography. 
% unbound 1,2 p H ] testosterone 
60 π 
1.0 1.5 
ng teetoeterone 
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§ 4 EVALUATION OF THE METHOD 
Recovery of the tracer. 
The mean total recovery of 1,2- Η-testosterone in 236 
plasma samples processed through the chromatographic steps was 
70.5 + 6.4 (SD) %. This variation indicates that it is 
necessary to determine the recovery for each plasma sample. 
Reproducibility of the calibration curve with processed 
standards. 
In figure 2 and table 1 the reproducibilitv of 59 standard 
curves obtained on consecutive analyses over a 1^ vear period 
is given. 
From the standard deviation given in table 1 it is obvious 
that the standard curves may vary considerably from day to day. 
By inspection of figure 2 one can easily derive that at a given 
percentage unbound 1,2- Η-testosterone, the amount of testoste­
rone read off the curve may vary substantially due to day-to­
day variations of the position of the standard curve. Therefore 
it is necessary to construct a calibration curve at each assay. 
An appreciable part of the variation of the curve has to be 
ascribed to the variability of the blank. It is because of the 
variability of the blank, which is mainly due to impurities 
introduced by the chromatography, that it is imperative to work 
with processed standards (vide specificity). 
Precision. 
The precision was examined by assaying plasma samples in 
duplicate (interassay duplicate variation, table 2) and by 
carrying out replicate assays in plasma pools (interassay 
replicate variation, table 3) both on separate days. 
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Figure 2 
Reproducibi l i ty of standard curve upon 
consecutive analys i s over a 1^ year period 
% unbound 1,2[эн] testosterone*5D 
60 
50 
4 0 -
3 0 -
20 
10 4 
0.5 
—i r1 
1.0 1.5 
ης" testosterone 
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Table 1 
REPRODUCIBILITY OF THE STANDARD CURVE ON CONSECUTIVE 
ANALYSES OVER A 1^ YEAR PERIOD (n = 59) 
ng TESTOSTERONE 
STANDARD 
0 
0.4 
0.8 
1.6 
% 1,2- H-TESTOSTERONE 
UNBOUND + SD 
13.4 + 2.1 
21.7 + 2.7 
32.0 + 5.3 
53.9 + 3.6 
Table 2 
INTERASSAY DUPLICATE VARIATION 
RANGE OF TESTOSTERONE 
LEVELS IN THE PLASMA 
SAMPLES (ng/100 ml) 
< 35 
100 - 300 
300 - 500 
500 - 600 
800 - 1200 
NUMBER OF 
DUPLICATE 
ASSAYS 
5 
6 
10 
6 
7 
STANDARD 
DEVIATION (%) 
15.1 
6.0 
4.5 
2.9 
4.4 
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According to the formula: 
SD (%) = y — 
(xil - xi2> 
χ 100 
2n i=l \ U x i l + x i 2) 
where x.. and x._ are the values of the i-th duplicate and η is 
the number of duplicate pairs, the interassay duplicate varia­
tion was calculated to be 15.1 % for plasma testosterone values 
below 35 ng/100 ml (n = 5), and 2.9 to б % in the range 100 to 
1188 ng/100 ml (n = 29) (table 2). The interassay duplicate 
variation of plasma testosterone values above 314 ng/100 ml, 
i.e. the lowest level found in normal men, was 4.1 % (n = 23). 
From the results of the replicate analyses (table 3) it appears 
that the coefficient of variation of about 5 % does not differ 
substantially in the different plasma pools analysed. 
Table 3 
INTERASSAY REPLICATE VARIATION 
REPLICATE ASSAY 
OF â PLASMA 
PLASMA I 
II 
III 
NUMBER OF 
REPLICATE 
ASSAYS 
7 
5 
11 
PLASMA 
TESTOSTERONE 
(ng/100 ml) 
MEAN + SD 
963 + 39 
640 + 37 
573 + 32 
COEFFICIENT OF 
VARIATION (%) 
4.1 
5.8 
5.6 
Accuracy. 
The accuracy of the method was evaluated by adding known 
amounts of testosterone within the range 2 to 4 ng to 2 ml of 
distilled water carried through the procedure and 4 ng of 
testosterone to 1 ml of male plasma. 
The mean recovery of the testosterone added to water was 
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98.7 + 9.3 (SD) % (η = 9) and of the testosterone added to 
plasma 93.4 + 7.8 (SD) % (η = 12). 
The accuracv was further evaluated by measuring testoste­
rone levels in different volumes of the same male or female 
plasma (table 4). The data illustrate that the correlation 
between the levels in the lower and higher volumes was satis­
factory. 
Specificity. 
The Bush B, system, as demonstrated by Kato and Horton 
(1968) adeauately separates testosterone from other steroids 
which are known to be bound with high affinity by the testoste­
rone binding protein. 
Non-specific interference was assessed by processing 2 ml 
of distilled water or steroid free plasma through the whole 
procedure. The processed residue had no significant effect on 
the distribution of 1,2- Η-testosterone between the bound and 
unbound fraction in the incubation mixture as compared to the 
zero point of the processed standard curve (13.4 + 2.1 (SD) %) 
(cfr table 1), the % unbound testosterone after processing H-0 
being 12.6 + 3.6 (SD) % (η = 18) and after processing steroid 
free plasma 9.2 + 0.6 (SD) % (η = 4). Thus using this method of 
processed standards the water blank was virtually zero. 
The specificity of the competitive protein binding method 
for measuring plasma testosterone levels has further been 
evaluated bv comparison with two other methods, a gas-chromate-
grafic techniaue (van der Molen et al, 1966) and a radioimmuno­
assay technique (Benraad et al, 1974). Whereas the coefficient 
of correlation between plasma testosterone levels assayed bv 
the competitive protein binding and the gas-chromatografic 
method was reasonable (r = 0.93, η = 24, y = 0.83 χ + 55) 
(Benraad et al, 1972), the correlation with the recently 
developed radioimmunoassav method was high (r = 0.99, η = 36) 
with a slope near to the line of eaualitv, (v = 0.95 χ + 16) 
(Fig. 3 (Benraad et al, 1974). 
41 
Table 4 
TESTOSTERONE ASSAYED IN DIFFERENT VOLUMES 
OF THE SAME PLASMA SAMPLES BY COMPETITIVE 
PROTEIN BINDING ANALYSIS 
ML OF PLASMA USED 
PLASMA SAMPLE 
1 5 
8 
6 
8 
0.25 
0.50 
0.50 
0.50 
0.50 
1.00 
1.00 
1.00 
0.50 
1.00 
0.50 
0.50 
1.00 
1.00 
TESTOSTERONE 
(ng/100 ml) 
ESTIMATED 
67 
66 
23 
25 
69 
69 
1182 
1005 
636 
609 
570 
606 
578 
547 
375 
399 
263 
395 
399 
420 
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Figure 3 
Comparison of a competitive protein binding (СРВ) 
and a radioimmunoassay techniaue (RIA) for the 
assay of testosterone in peripheral human plasma. 
The dotted line represents the line of equality. 
plasma testosterone (PIA) ng/100 m I 
1500 η у = 0 . 9 5 х + 1 б 
г, 099 
π» 36 
1000-
5 0 0 
ι ι ι 1 1 1 ι ι ι 1 1—ι 1 1—' 
500 1000 1500 
plaetna teetoetenone(СPB ) лг /100ml 
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Sensitivity. 
The interassay duplicate testosterone values found in 5 
different plasma samples with low testosterone content are 
shown m table 5. 
Table 5 
DUPLICATE ANALYSIS OF PLASMA SAMPLES WITH LOW 
PLASMA TESTOSTERONE CONTENT ON DIFFERENT DAYS 
PLASMA TESTOSTERONE (ng/100 ml) 
PLASMA 1st ASSAY 2nd ASSAY 
1 14 12 
2 20 30 
3 22 25 
4 27 32 
5 36 34 
From these data the precision, s, was calculated according to 
the formula: 
s (ng/100 ml) ='\/— Σ (χ - χ ) 
2n 1 = 1 
where χ , and χ ,. are the values of the i-th duplicate and η is il i2 ' 
the number of duplicate determinations made. The precision s 
was found to be 3.8 ng/100 ml (n = 5) in the range 12 to 36 
ng/100 ml. From this precision, the sensitivitv of the method 
in a duplicate assav was calculated according to the formula: 
t χ s 
sensitivity (ng/100 ml) = 
V 2 
where t is the critical value at the 5 % level of Student's t 
value for η degrees of freedom. The sensitivity is the smallest 
duplicate mean value differing significantly (P < 0.05) from 
zero. It was calculated to be about 7 ng/100 ml corresponding 
to about 250 pg in the plasma samples used at the start of the 
procedure. 
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§ 5 PLASMA TESTOSTERONE LEVELS IN NORMAL MALES AND FEMALES 
AND IN GROUPS OF PATIENTS WITH WELL DEFINED FORMS OF MALE 
HYPOGONADISM 
As biological control of the described method for determi-
nation of testosterone in plasma, levels of the hormone in 
normal men and women and patients with either primary or secon-
dary hypogonadism both before and after short or long term 
human chorionic gonadotropin (HCG) administration (Pregnyl, 
Organon) are given in the tables 7, 8 and 9. 
Basal 8 a.m. plasma testosterone levels in 58 eugonadal 
males aged 19 to 62 years (mean + SD : 32.4 + 9.8 years) ranged 
from 314 to 1337 ng/100 ml (mean + SD: 568 + 198 ng/100 ml 
(table 7) and in 30 eugonadal females aged 17 to 64 years 
(mean + SD: 29.1 + 11.1 years) from 12 to 69 ng/100 ml (mean + 
SD: 30 + 15 ng/100 ml). The mean testosterone concentrations 
and ranges in the eugonadal males and females obtained by the 
competitive protein binding method described here, are in 
accordance with similar values reported by most other authors 
utilizing a competitive protein binding technique (table 6). 
Mainly those investigators who did not apply one or more 
chromatographic purification steps (Horton et al, 1967, 
Pizarro et al, 1969 and Anderson et al, 1970) noted higher 
values by their radioligand methods, especially in low testo-
sterone samples of women. 
Besides data in eugonadal males and females table 7 
presents basal testosterone levels in 6 patients with bilateral 
anorchia, aged 16 to 69 years (mean + SD: 35.5 + 20.1 years). 
In 5 of these 6 patients the diagnosis had been surgically 
proven. The remaining patient was a 69 year old male patient 
with XY karyotype who lacked secondary male sex characteristics 
and scrotal testes and who was observed for osteopenia. The 
mean plasma testosterone level in the 6 anorchics, 28 + 10 (SD) 
ng/100 ml (range 16 to 45 ng/100 ml) did not differ signifi-
cantly (P* = 0.71) (P*: Wilcoxon's two sample test) from the 
mean value found in eugonadal females (30 + 15 (SD) ng/100 ml. 
It is noted that the testosterone levels of proven anorchics 
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TABLE Б 
Hortonetal (1967) 
Katoand Horton (1968) 
Mayes and Nugent (1968) 
Halberg et al (1968) 
Rosen ireld et al (1969) 
Meada et al (1968) 
August et al (1969) 
Heyns et al (1969) 
Frickand Kniel (1969) 
¿t Pizarroet al (1969) 
^ Demetnou et al (1970) 
Anderson et al (1970) 
Roger et al (1971) 
Dessypnset al (1972) 
Winter and Grant (1972) 
Andre and James (1972) 
Jan and Gold (1972) 
Benraadetal (1972) 
Stnckalnd et al (1972) 
Barberia et al (1973) 
Pirke (1973) 
CHROMATO 
GRAPHY SEPARATION 
BOUND/UNBOUND 
_ 
Pc 
Pc + Tic 
Pc + Tic 
Tic 
Pc 
Tic + Tic 
Tic + Pc 
Tic + Tic 
-
Tic 
-
Pc 
column 
Tic 
Pc 
Tic 
Tic + Pc 
Tic 
Tic 
Tic 
dextran-charcoal 
sephadex G-25 
sat. amm. suif. 
florisil 
dextran-charcoal 
sat. amm. sulf. 
flonsil 
sephadex G-10 
florixil 
dextran-charcoal 
florisol 
fioristi 
flonsil 
flonsil 
sat. amm. sulf. 
sat. amm. sulf. 
sat amm sulf. 
sat amm suit 
ZnSOí + Ba(OH)j 
sephadex G-25 
sat. amm. sulf 
COEFFICIENT OF 
VARIATION % 
DUPL REPL 
-
-
7 
-
-
-
3.7 - 8 0* 
10.2 
-
-
-
1 0 5 - 13 2 
-
-
3 . 6 - 10 9* 
9.7 
-
4.1 - 15.1* 
-
-
-
5.8 
13 0* 
3 . 8 -
-
1 4 -
10" 
6.5 
4.7 
9.0 
52 
11 
-
-
9 1 -
7 .5 -
7.3 
8 3 -
4.1 -
37 
12.5 
98 
5.3* 
14.7 
•11.4' 
11.2 
12.0* 
5.8 
SENSITIVITY 
(PGI 
_ 
-
-
100 
200 
200 
300 
-
_ 
-
-
-
-
-
120 
60 
120 
250 
-
150 
142 
PLASMA TESTOSTERONE (nq/IOOml) 
NORMAL MALES _ ^ 
MEAN ± SD RANGE 
813 + 71 
680± 180 
320 
533 ± 259 
-
625 ± 104 
503± 136 
740 ± 290 
644± 179 
-
1030 ± 390 
584 + 40 
740 
680 + 210 
800 + 360 
568+198 
684 
575-
520-
450-
200-
238-
273-
524-
-
-
360-
460-
490-
398-
430-
300-
— 
314-
492-
395-
-1075 
-1000 
-960 
-400 
-1001 
- 1211 
-893 
- 110O 
- 1340 
-2150 
-791 
-960 
-100O 
-1337 
-722 
- 1210 
NOR M AL FEM ALES 
MEAN ±SD RÄNGE 
37 ±8 
40 ±14 2 0 - 7 6 
100 6 0 - 1 3 0 
47 ±19 32 - 70 
45+ 18 
46 ±30 
41 +24 
34 ± 10 
37 ± 15 
30 ± 15 
1 6 - 7 6 
10 ±41 4 4 - 1 8 0 
3 2 - 1 2 9 
136 ±68 40 - 275 
42 ± 7 11 - 63 
1 0 - 7 8 
1 2 - 6 9 
17 - 7 8 
•females COMPARISON OF 21 COMPETITIVE PROTEIN BINDING TECHNIQUES 
FOR THE DETERMINATION OF PLASMA TESTOSTERONE 
Table 7 
BASAL PLASMA TESTOSTERONE LEVELS IN EUGONADAL MALES AND FEMALES, PATIENTS 
WITH PRIMARY OR SECONDARY HYPOGONADISM AND BOYS WITH DELAYED PUBERTY 
I EUGONADAL MALES 
FEMALES 
NUMBER OF 
SUBJECTS 
58 
30 
AGE (YEARS) 
MEAN + SD 
32.4 + 9.θ 
29.1 + 11.1 
RANGE 
19 - 62 
17 - 64 
PLASMA TESTOS 
MEAN + SD 
568 + 198 
30 + 15 
iTERONE (ng/100 
RANGE 
314 - 1337 
12 - 69 
ml) 
lb 
»J 
II PATIENTS WITH: 
A PRIMARY HYPOGONADISM 
BILATERAL ANORCHIA 35.5 + 20.1 16 - 69 28 + 10 16 45 
В SECONDARY HYPOGONADISM 
1 ISOLATED GONADOTROPIN 
DEFICIENCY 
a without hyposmia 
b with hyposmia 
(Kallmann's syndrome) 
с fertile eunuch 
syndrome 
2 MULTIPLE PITUITARY 
DEFICIENCIES 
III 'MALE DELAYED PUBERTY' 
14 23.5 + 4.6 
20.7 + 4.5 
27 
46 + 21 
17.6 + 1.1 
20 - 35 
18 - 17 
17 - 62 
17 - 20 
58 + 50 
50 + 51 
46 
39 + 27 
198 + 108 
12 - 165 
23 - 126 
12 - 88 
52 - 387 
Table θ 
THE EFFECT OF SHORT TERM HCG ADMINISTRATION (1500 IU DAILY FOR 3 DAYS) ON 
PLASMA TESTOSTERONE LEVELS IN NORMAL MEN, PATIENTS WITH HYPOGONADISM AND 
BOYS WITH 'DELAYED' PUBERTY. 
I EUGONADAL MALES 
NUMBER 
10 
BASAL 
MEAN + SD RANGE 
522 + 144 314 - 704 
AFTER HCG (1500 IU/DAY FOR 3 DAYS) 
MEAN + SD 
1189 + 327 
RANGE 
863 + 1827 
II PATIENTS WITH: 
A PRIMARY HYPOGONADISM 
BILATERAL ANORCHIA 27 + 11 16 - 45 28 + 17 13 57 
В SECONDARY HYPOGONADISM 
1 ISOLATED GONADOTROPIN 
DEFICIENCY 
a without hyposmia 
b with hyposmia 
(Kallmann's syndrome) 
с fertile eunuch 
syndrome 
2 MULTIPLE PITUITARY 
DEFICIENCY 
4 
9 
54 + 
57 + 
50 
56 
12 -
12 -
- 165 
- 165 
248 + 189 
257 + 201 
40 -
65 -
524 
660 
49 + 51 
46 
39 + 27 
23 - 126 
12 - 88 
156 + 103 
524 
273 + 169 
40 267 
73 - 532 
III 'MALE DELAYED PUBERTY' 7 190 + 114 52 - 387 733 + 371 378 - 1480 
Table 9 
EFFECT OF LONG TEIW HCG ADMINISTRATION ON PLASMA TESTOSTERONE LEVELS IN ΡΑΤΙΕΝτς 
WITH HYPOGONADOTROPIC HYPOGONADISM 
PATIENTS WITH 
SECONDARY HYPOGONADISM 
1. ISOLATED GONADOTROPIN 
DEFICENCY 
a WITHOUT HYPOS4IA Ja 
Ha 
VW 
dR 
Ve 
Gr 
He 
El 
b WITH HYPOSMIA 
(KALLMANN'S SYNDROME) 
AGF 
(YEARS) 
21 
23 
20 
21 
25 
23 
30 
24 
23.4 + 3.9 
с FERTILE EUNUCH SYNDROME PI 
VF 
MO 
My 
Wi 
18 
18 
19 
27 
20.5 + 4 
27 
PLASMA TESTOSTERONE LEVFL (ng/100 ml) 
BASAL* AFTER 6 WEEKS OF HCG 
(3 X 1500 ID/WEEK) 
12 + 28 
16 + 20 
18 + 17 
24 
31 
55 
141 + 142 
165 + 174 + 172 
59 + 60 
20 + 23 
23 
19 
126 
48 + 52 
46 
894 
487 
519 
340 
654 
445 
336 
895 
552 + 
450 
377 
228 
702 
439 + 
1134 
2. MULTIPLE PITUITARY 
DEFICIENCY GO 
Ro 
21 
18 
12 
74 
311 
1085 
* If determined in plasma samples from different days, the individual values are given. 
represent the extragonadal contribution to the plasma testoste­
rone concentration, either by direct secretion by the adrenals 
or by peripheral conversion of precursors originating from the 
adrenals. The data found in this group of anorchics are in 
accordance with data in literature (Stewart-Bentley et al, 
1971, Nieschlag et al, 1971 and Winter et al, 1972). 
Data on basal plasma testosterone levels in 26 patients 
with hypogonadotropic hypogonadism have also been given in 
table 7. In 7 of these patients multiple pituitary deficiencies 
were found. In б of them hypophysectomy had been performed 
earlier for pituitary tumors. The 7th patient was a 17 year old 
boy who spontaneously developed diabetes insipidus first, 
followed in several weeks by signs of anterior pituitary fai­
lure. This picture was preceeded by a febrile illness of so 
far unknown origin with meningeal signs and an elevated number 
of mononuclear cells in the cerebrospinal fluid. Probably this 
case of nultiple pituitary deficiencies has been caused by a 
viral meningitis. In the 7 patients with multiple pituitary 
deficiencies the mean basal plasma testosterone concentration 
was 39 + 27 (SD) ng/100 ml with a range of 12 to 88 ng/100 ml. 
This mean did neither significantly differ from the mean value 
found in eugonadal females (P* = 0.37) nor from that found in 
patients with isolated gonadotropin deficiency (P* = 0.77). 
The remaining 19 patients had secondary hypogonadism 
without overt signs of pituitary failure except gonadotropin 
deficiency. In one of these patients who was clearly eunuchoid 
the volume of the testes was normal as was his karyotype (XY). 
Histology of the testes revealed active spermatogenesis with 
reduced maturation and a highly diminished number of Leydig 
cells. The plasma FSH level was normal, the LH level in the 
lower range of eugonadal males and the total urinary gonadotro­
pin excretion below 10 mouse units. The diagnosis 'fertile 
eunuch syndrome' was made. The plasma testosterone level in 
this patients was 46 ng/100 ml. 
In 4 patients with secondary hypogonadism the gonadotropin 
deficiency was accompanied by hyposmia and one or more congeni­
tal anomalies (unilateral renal hypoplasia, short metacarpal 
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IV, syndactylia, bilateral hypoplasia of the 3rd phalanx of the 
3rd finger, vertebral anomalies, color blindness, cataract) 
were found in three of the patients m whom a thorough investi-
gation could be made. Evidently these patients represented 
Kallmann's syndrome. The mean plasma testosterone level in 
these 4 patients was 50 + 51 (SD) ng/100 ml (range 23 to 126 
ng/100 ml) which is in accordance with similar data reported by 
Bardin et al (1969), Boyar et al (1973), Santen and Paulsen 
(1973), Hamilton et al (1973) and Chaussain et al (1974). In 
the remaining 14 patients with isolated gonadotropin deficiency 
(mean age + SD: 23.5+4.6 years, range 20 to 36 years) the 
mean plasma testosterone level was 58 + 50 (SD) ng/100 ml 
(range 12 to 165 ng/100 ml) which value did not differ signi-
ficantly from the mean concentration found in the group of 
multiple pituitary deficiencies (P* = 0.48). 
In a representative sample (8) of a large group of boys 
in the age group 17 to 21 years who complained of delay of 
puberty and in whom clear signs of delayed puberal development 
were found, the plasma testosterone concentration ranged from 
52 to 387 ng/100 ml with a mean of 198 + 108 (SD) ng/100 ml. 
This mean value was significantly higher than the mean in the 
group of patients with isolated gonadotropin deficiency with 
or without hyposmia (P*< 0.01). 
In tables 8 and 9 data on plasma testosterone levels 
before and after stimulation by human chorionic gonadotropin 
(HCG, Pregnyl, Organon) are collected from eugonadal male 
controls and representative patients of well defined forms of 
primary or secondary hypogonadism. For comparison some data 
have been added obtained in boys with delayed puberty. 
As expected, in 5 anorchic patients HCG administration for 
at least 3 days did not increase plasma testosterone levels, 
the values being 27 + 11 (SD) ng/100 ml before and 28 + 17 (SD) 
ng/100 ml) after stimulation. 
After short term HCG administration plasma testosterone 
levels increased in all patients with secondary hypogonadism. 
The mean level in the 9 patients with isolated gonadotropin 
deficiency without hyposmia increased from 57 + 56 (SD) 
51 
ng/100 ml to 257 + 201 (SD) ng/100 ml. In the 4 patients with 
Kallmann's syndrome a similar rise was observed from 49 + 51 
(SD) ng/100 ml before to 156 + 103 (SD) ng/100 ml after 3 days 
of HCG stimulation. An overt testosterone response to HCG was 
also observed in the patient with fertile eunuch syndrome. No 
significant differences were detected between the testosterone 
response to HCG in patients with isolated gonadotropin defi­
ciency with or without hyposmia and the patients with multiple 
pituitary deficiencies (P* = 0.31). The finding that in the 
Kallmann patients the HCG induced testosterone increase was not 
significantlv different from the response m the multiple 
pituitary deficiencies group (P* = 0.27) is at variance with 
data of Bardin et al (1969) who reported an absent response to 
short term HCG stimulation in the former group. Santen and 
Paulsen (1973) however also found a distinct plasma testostero­
ne increase in response to short term HCG stimulation in 5 out 
of 6 patients with Kallmann's syndrome. 
In 7 boys with the controversial diagnosis delayed puberty 
short term HCG stimulation increased plasma testosterone levels 
from 190 + 114 (SD) ng/100 ml to 733 + 371 (SD) ng/100 ml. The 
mean testosterone increase in these boys was significantly 
higher (P* < 0.01) than in the patients with secondary hypogo­
nadism with or without hyposmia. 
Long term HCG stimulation (3 χ 1500 of HCG per week for 6 
weeks) increased plasma testosterone in all 15 patients with 
secondary hypogonadism and in all but two of these patients 
plasma testosterone levels were in the normal range after 6 
weeks of HCG treatment (table 9). 
In this short survey data on basal and HCG stimulated 
plasma tesLosterone values, obtained in a series of 28 patients 
with Klinefelter's syndrome have been deliberately omitted. 
These data will be given and discussed in the chapter VI, VII, 
VIII and IX. 
52 
REFERENCES 
Anderson, D.C., A simple and clinically useful method for 
plasma testosterone-like substances by competitive protein 
binding. Clin. Chim. Acta 29 (1970) 513. 
André, CM. and V.H.T. James, A method for the assay of testo-
sterone and androstenedione in human female plasma by competi-
tive protein binding. Clin. Chim. Acta 40 (1972) 325. 
August, G.P., M. Thachuk and M.M. Grumbach, Plasma testosterone 
binding affinity and testosterone in umbilical cord plasma, 
late pregnancy, prepubertal children and adults. J. Clin. 
Endocr. 29 (1969) 891. 
Barberia, J.M., J. Giner, V. Cortes-Gallegos, Diurnal variation 
of plasma testosterone in men. Steroids 22 (1973) 615. 
Bardin, C.W., G.T. Ross, A.B. Rifkind, CM. Cargille and M.B. 
Lipsett, Studies of the pituitary-Leydic cell axis in young 
men with hypogonadotropic hypogonadism and hyposmia: comparison 
with normal men, prepuberal boys and hypopituitary patients. 
J. Clin. Inv. 48 (1969) 2046. 
Benraad, Th.J., F.H. de Jong, H.J. van der Molen and A.G.H. 
Smals, Comparison and evaluation of a competitive protein 
binding and gas-chromatographic method for the assay of testo-
sterone in peripheral human plasma. J. Steroid. Biochem. 3 
(1972) 325. 
Benraad, Th.J., D.C. Lozekoot, E.K. Wilms and A.G.H. Smals, 
Radioimmunoassay of plasma testosterone with a double antibody 
53 
solid phase technique. To be published (1974). 
Boyar, R.M., J.W. Finkelstein, M. Witkin, S. Kapon, E. 
Weitzman and L. Hellman, Studies of endocrine function in 
isolated gonadotropin deficiency. J. Clin. Endocr. 36 (1973) 64. 
Bray, G.A., A simple efficient liquid scintillator for counting 
aqueous solutions in a liquid scintillation counter. Anal. 
Biochem. 1 (I960) 279. 
Chaussain, J.L., P.E. Garnier, E. Binet, J. Vassal, R. Scholier 
and J.E. Job, Effect of synthetic luteinizing hormone releasing 
hormone (LH - RH) on the release of gonadotropins in hypophyso-
gonadal disorders of children and adolescents III hypopituita-
rism. J. Clin. Endocr. 38 (1974) 58. 
Demetriou, J.A. and F.G. Austin, Quantitation of plasma testo-
sterone by improved competitive protein-binding technique. 
Clin. Chem. 16 (1970) 111. 
Dessypris, A. and H. Adlercreutz, Routine clinical determina-
tion of testosterone in plasma by competitive protein binding. 
J. Ster. Biochem. 3 (1972) 19. 
Frick, J. and F.A. Kind, The measurement of plasma testostero-
ne by competitive protein binding assay. Steroids 13 (1969) 495. 
Ganis, S.M., M. Hendrickson, P.D. Giunta and J.W. Howland, 
Evaluation of factors in the elution of hydrocortisone from 
paper chromatograms. AEC Research and development Report UR-
601 University of Rochester, New York (1961). 
Hallberg, M.C., E.M. Zorn and R.G. Wieland, A sensitive testo-
sterone assay by protein binding. Steroids 12 (1968) 241. 
Hamilton, CR., R.I. Henkln, G. Weir and B. Kliman, Olfactory 
status and response to clomiphene in male gonadotrophin 
54 
defiency. 
Heyns, W., G. Verhoeven, H. van Baelen and P. de Moor, 
Measurement of testosterone in plasma by competitive protein 
binding. Ann. d'Endocr. (Paris) 30 (1969) 153. 
Horton, R., T. Kato and R. Sherins, A rapid method for the 
estimation of testosterone in male plasma. Steroids 10 (1967) 
245. 
Jan, W. and N.I. Gold, Serum testosterone analysis by compati-
tive protein binding: chromatography on silica-impregnated 
fiberglass and protein precipitation with ammonium sulfate. 
Bioch. Med. 6 (1972) 7. 
Kato, T. and R. Horton, A rapid method for the estimation of 
testosterone in female plasma. Steroids 12 (1968) 631. 
Maeda, R., M. Okamoto, L. Wegienka and P.H. Forsham, A clini­
cally useful method for plasma testosterone determination. 
Steroids 12 (1969) 83. 
Matthews, J.S., V. Pereda and P. Aquilera, The quantitative 
analysis of steroids by thin layer chromatography. J. Chromatog. 
9 (1962) 331. 
Mayes, D. and C.A. Nugent, Determination of plasma testosterone 
by the use of competitive protein binding. J. Clin. Endocr. 28 
(1968) 1169. 
van der Molen, H.J., De Groen and A. Peters In: Α. Vermeulen 
and D. Exley eds.. Androgens in normal and pathological condi­
tions. Proceedings Und symposium on steroid hormones 1965. 
Excerpta Med. Int. Congress series 101 (1966) 1. 
Pirke, K.M., A comparison of three methods of measuring testo­
sterone in plasma: competitive protein binding, radio-immuno-
55 
assay without chromatography and radioimmunoassay including 
thin layer chromatography. Acta Endocr. 74 (1973) 168. 
Pizarro, M.A. and R. Arredondo, Measurement of plasma testoste-
rone by competitive protein binding. Ann. Endocr. (Paris) 30 
(1969) 159. 
Roger, P., G. Beauchamps, H.P. Mathieu, P. Blanquet et J. 
Riviere, Dosage de la testosterone plasmatique par radio-
compétition. Applications cliniques. Rev. Franc. Endocr. Clin. 
12 (1971) 326. 
Rosenfield, R.L., W.R. Eberlein and A.M. Bongiovanni, Measure-
ment of plasma testosterone by means of competitive protein 
binding analysis. J. Clin. Endocr. 29 (1969) 689. 
Santen, R.J. and C.A. Paulsen, Hypogonadotropic eunuchoidism II 
gonadal responsiveness to exogenous gonadotropins. J. Clin. 
Endocr. 36 (1973) 55. 
Stewart-Bentley, M., W. Odell and R. Horton, FSH-LH feedback 
in normal and hypergonadotropic men. 53rd Mtg. Endocr. Soc. 
1971, A 80. 
Winter, J.S.D., S. Taraska and C. Faiman, The hormonal response 
to HCG stimulation in male children and adolescents. J. Clin. 
Endocr. 34 (1972) 348. 
Winter, J.S.D. and D.R. Grant, A rapid and sensitive assay for 
plasma testosterone in adults and children. Anal. Biochem. 40 
(1971) 440. 
56 
Chapter IV 
TEMPORALLY RELATED CHANGES IN PLASMA TESTOSTERONE LEVELS 
IN EUGONADAL MALES AND PATIENTS WITH KLINEFELTER's SYNDROME 
§ 1 INTRODUCTION 
A number of investigators have analysed to some extent and 
with conflicting results the diurnal changes (cfr chapter V) 
and the seemingly independent episodical changes of the testo-
sterone concentration in peripheral venous blood in healthy 
males (Evans et al, 1971, Naftolin et al, 1973, Murray and 
Corker, 1973, Judd et al, 1974). 
In order to better define temporally related phenomena it 
was felt necessary to analyse not merely the changes in plasma 
testosterone concentration throughout the day but also the 
day-to-day variation in both eugonadal males and .patients with 
Klinefelter's syndrome. 
The temporally related phenomenon most extensively studied 
in literature is the possible decrease of plasma testosterone 
levels with advancing age as an expression of decreasing Leydig 
cell function in normal males. 
In this chapter an account is given of a number of obser-
vations which were thought to be relevant in studying tempo-
rally related changes both in healthy eugonadal controls and 
in patients with Klinefelter's syndrome. 
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§ 2 DIURNAL CHANGES 
In chapters V and VI the diurnal cyclicity of plasma 
testosterone in eugonadal males and patients with Klinefelter's 
syndrome\has been described and discussed. In both groups 
evidence for a systemic diurnal variation was found with peak 
levels in the morning and the nadir in the afternoon or 
evening. In these studies in which blood samples were collected 
two or six times daily, no clear indication of interfering 
pulsatile changes was found as reported by the authors mentio­
ned in ί 1. These investigators sampling blood every 10 to 30 
minutes during the night or day-time reported the occurrence 
of episodic fluctuations in plasma testosterone levels to the 
extent of about 100 - 300 %! They claim these pulsatile 
changes might explain the discrepancies in literature reports 
regarding diurnal variation of circulating testosterone in men. 
A study of this phenomenon has not been performed so far in 
this laboratory. 
§ 3 INTRAPERSONAL DAY-TO-DAY VARIATION 
The intrapersonal day-to-day variation of plasma testoste­
rone levels was studied in 16 eugonadal males and 8 patients 
with Klinefelter's syndrome. Blood samples were taken between 
8 and 10 a.m. on three non-consecutive days within a period 
ranging from 5 to 90 days with a mean of 26 + 27 (SD) days in 
the eugonadal males and from 6 to 56 days with a mean of 
33 + 17 (SD) days in the Klinefelter patients (P* = 0.98) (P*: 
Wilcoxon's two sample test). 
The absolute intrapersonal day-to-day variation was calcu­
lated according to the formula: 
(ng/?00 гаігУ— jj^il " Xi2 ) 2 + (xi2 " X i 3 ) 2 + (хіЗ " X i l ^ 
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and the relative intrapersonal variation using the formula: 
3° = 10о!\/— Σ (xil - X i 2 ) 2 + (xi2 - X i 3 ) 2 + (ХІЗ - X i l ) 2 
( % )
 '' 6n i=l x.2 
1 
wherein (χ., - χ.-,)/ (x.
n
 - χ.,) and (χ.-. - χ..) are the il i2 i2 i3 i3 il 
absolute differences between the plasma testosterone levels on 
the respective days, i is the i-th person, na is the number of 
- 2 
subjects and x. is the mean of the plasma testosterone levels 
of the i-th person. 
Data of the plasma testosterone levels on the separate 
days in the individual subjects and patients are given in table 
1. In addition in this table the intrapersonal variation for 
each subject has been compared with the interassay duplicate 
variation. 
The overall absolute intra-individual day-to-day variation 
in the eugonadal males was calculated to amount to 92 ng/100 ml 
and the corresponding relative variation 13.7 %. In the Kline­
felter patients the absolute and relative variations were 37 
ng/100 ml and 14 % respectively. These intra-personal day-to­
day variations cannot be simply explained by the methodological 
interassay duplicate variation which was found to be 6 % for 
plasma testosterone levels between 100 and 300 ng/100 ml, 4.5 % 
between 300 and 500 ng, 2.9 % between 500 and 800 ng/100 ml and 
4.4 % at levels above 800 ng/100 ml (cfr chapter III). Compa­
ring the relative intrapersonal variation (table 1), for each 
individual with the interassay duplicate variation, in 11 out 
of 16 eugonadal males and 4 out of 8 Klinefelter patients a 
significant difference was found. From these data the conclu­
sion is inevitable that in men intra-individual day-to-day 
variations in plasma testosterone levels indeed exist though 
their amplitude is low in most of them. This is in contrast 
with the wide day-to-day variations observed in rats (Barthe et 
al, 1973). It is of interest to note that the mean intrapersona] 
day-to-dy variation in the studied group of healthy eugonadal 
males (13.7 %) did not differ significantly (P* = 0.34) from 
that in Klinefelter patients (14.0 % ) . 
Literature data on the occurrence of intrapersonal day-to-
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Table 1 
INTRAPERSnNAL VARIATION 
8 AM PLASMA TESTOSTERONE LEVELS ON 3 NON-CONSECUTIVE DAYS WITHIN A PERIOD OF 3 
MONTHS IN NORMAL MALES AND PATIENTS WITH KLINEFELTER'S SYNDROME 
SUBJECT PLASMA TESTOSTERONE LEVELS 
(ng/100 ml) 
σι 
is 
1 
2 
3 
4 
5 
6 
7 
β 
9 
10 
11 
12 
13 
14 
15 
16 
DAY 1 DAY 2 DAY 3 
NORMAL MALES 
349 
411 
441 
400 
374 
533 
398 
472 
580 
627 
635 
772 
780 
940 
756 
975 
422 
427 
457 
471 
585 
477 
512 
570 
603 
570 
1000 
704 
848 
664 
804 
739 
391 
422 
416 
535 
461 
432 
537 
614 
608 
722 
568 
743 
697 
753 
809 
746 
MEAN 
387 
420 
438 
469 
473 
481 
482 
552 
597 
640 
734 
740 
775 
786 
790 
814 
COEFFICIENT OF 
INTRAPERSONAL 
VARIATION 
SD * 
V (%) 
9 
1 
4 
14 
22 
10 
MEAN 
15.4 
13.2 
2. 
12. 
31, 
4. 
9, 
17, 
3. 
15, 
= V 
8 
89 
3 
22 
208 
502 
111 
236 
173 
6.3 
144 
1002 
21 
95 
321 
14 
232 
INTERASSAY 
DUPLICATE 
VARIANCE 
2## 
20.3 
8.4 
INTRAPERSONAL VARIANCE 
VS DUPLICATE VARIANCE 
19.4 
4.42 
0.19 
1.10 
10.25 
24.78 
5.47 
11.65 
20.60 
0.74 
17.11 
119.05 
2.53 
11.31 
38.18 
1.63 
11.97 
2.10 
2.6 
II 
II 
π 
„ 
„ 
tl 
II 
2.7 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
< 
0.05 
NS 
NS 
0.01 
0.01 
0.05 
0.01 
0.01 
NS 
0.01 
0.01 
NS 
0.01 
0.01 
NS 
0.01 
KLINEFELTER PATIENTS 
1 
2 
3 
4 
5 
6 
7 
8 
1 to 8 
108 
175 
151 
188 
272 
357 
416 
507 
90 
116 
222 
176 
229 
371 
510 
563 
98 
112 
198 
201 
263 
399 
375 
474 
99 
134 
190 
188 
255 
376 
434 
515 
9.1 
26.3 
19.0 
6.6 
8.9 
5.7 
16.0 
8.7 
14.2 
84 
690 
360 
44 
79 
32 
255 
76 
36. 
„ 
„ 
II 
„ 
20. 
20, 
8. 
.0 
.3 
.3 
.4 
2.33 
19.65 
10.00 
1.22 
2.20 
1.60 
12.58 
9.08 
2.6 
II II 
Il M 
II II 
II II 
2.10 
II 
2.7 
< 
< 
< 
< 
NS 
0.01 
0.01 
NS 
NS 
NS 
0.01 
0.05 
* cfr formula on page 59 
** cfr chapter III, table 2 
··· 
···· 
df 
2 2 
=5 . / S, : Ratio of coefficients of variation, used as statistic for approximate test 
numbers of freedom of F 
day variations in plasma testosterone levels are sparse for 
eugonadal males and are completely lacking with regard to 
patients with Klinefelter's syndrome. In the few reports a mean 
coefficient of variation of 12 to 16 % (Kirschner et al, 1965, 
Rivarola et al, 1966 and Kreuze and Rose, 1973) was mentioned 
although a detailed statistical analysis was not given. These 
and our data illustrate that plasma testosterone levels in men 
are fairly stable over a short period, which is irreconcilable 
with the reported impressive episodic fluctuations throughout 
the day. 
§ 4 EFFECT OF AGE ON PLASMA TESTOSTERONE LEVELS IN NORMAL MEN 
AND PATIENTS WITH KLINEFELTER'S SYNDROME 
No significant correlation was found between the 8 a.m. 
plasma testosterone levels and age in the eugonadal males 
(n = 58) (age range 19 to 62 years, r „ = + 0.155, 
•'
 J
 * Spearman 
Ρ > 0.10). In table 2 the mean morning testosterone values + SD 
are given for each decade studied. The lack of a significant 
correlaticn between age and plasma testosterone levels in the 
eugonadal males is in accordance with data of Kent and Acone 
(1965), Gandy and Peterson (1968), Robinson et al (1971) and 
Stearns et al (1973) . It has to be admitted however that the 
age range in our material was limited. Vermeulen et al (1972), 
Nieschlag et al (1973) and Bayard et al (1973) reported a sig­
nificant decrease of total plasma testosterone levels after the 
6th decade and an even earlier decrease of the free testostero­
ne concentration after the 5th decade (Vermeulen et al, 1972, 
Stearns et al, 1973). Their data suggest a decline of Leydig 
cell function with advancing ages in the eugonadal males. 
In the Klinefelter patients as in the eugonadal males no 
significant correlation was found between the 8 a.m. plasma 
testosterone levels and age (n = 28, age range 15 to 55 years, 
r
 с =v-~, = - 0.28, Ρ > 0.10). In table 3 the mean plasma Spearman r 
testosterone levels + SD are given for each decade studied. 
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Table 2 
EFFECT OF AGE ON PLASMA TESTOSTERONE LEVELS IN 
NORMAL MALES. 
AGE GROUPS 
(YEARS) 
MEAN AGE NUMBER PLASMA TESTOSTERONE (ng/100 ml) 
+ SD (YEARS) OF SUBJECTS MEAN + SD 
553 + 142 
563 + 236 
552 + 161 
589 + 183 
587 + 166 
< 20 
21 - 30 
31 - 40 
41 - 50 
> 50 
MEAN + SD 
19.3 
24.3 
34.8 
43.2 
53.0 
32.4 
+ 
+ 
+ 
+ 
+ 
+ 
0.6 
1.8 
2.9 
3.3 
2.8 
9.2 
3 
25 
16 
10 
4 
58 568 + 198 
RANGE 
407 - 690 
332 - 1337 
314 - 814 
337 - 953 
462 - 842 
314 - 1337 
Table 3 
EFFECT OF AGE ON PLASMA TESTOSTERONE LEVELS IN PATIENTS WITH 
KLINEFELTER'S SYNDROME. 
AGE GROUPS 
(YEARS) 
< 20 
21 - 30 
31 - 40 
41 - 50 
51 - 60 
MEAN + SD 
MEAN AGE 
+ SD 
17.6 
25.0 
35.5 
42.5 
53.3 
30.6 
(YEARS) 
+ 
+ 
+ 
+ 
1.7 
3.7 
2.7 
1.5 
+ 11.2 
NUMBER OF 
SUBJECTS 
5 
11 
7 
2 
3 
28 
PLASMA TESTOSTERONE 
MEAN + SD 
342 
301 
232 
247 
276 
283 
+ 110 
+ 163 
± 137 
+ 165 
+ 139 
RANGE 
246 
93 
72 
255 
86 
72 
-
-
-
+ 
-
_ 
(ng/100 ml) 
517 
684 
384 
239 
383 
684 
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Paulsen et al (1968) studying a group of 25 patients with 
chromatin positive and chromatin negative Klinefelter's 
syndrome aged from 17 to 66 years reported a tendency of the 
plasma testosterone levels to decline with age. 
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ABSTRACT 
In a group of 14 healthy male subjects significant diurnal 
cyclicity of plasma testosterone has been assessed by sampling 
blood either twice a day or six times a day. 
A significant decrease of plasma testosterone concentra-
tion has been observed during short term administration of ACTH 
to 10 normal males. However this seemingly significant ACTH 
effect could be fully explained by the diurnal rhythm in the 
plasma testosterone levels. In evaluating the acute effect of 
drug administration on the plasma testosterone level allowance 
should be made for its diurnal cyclicity. 
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Data on the effect of short term ACTH administration on 
plasma testosterone in healthy men are scant and controversial. 
A definite ACTH induced fall in plasma testosterone concentra­
tion was found by Sorcini et al (1), Rosenfield et al (2) and 
Pizarro and coworkers (3), while Southren et al (4) and Hudson 
and coworkers (5) observed no change et all. 
Evaluating the acute effect of ACTH, the presence of a 
diurnal variation in plasma testosterone has to be taken into 
account. However, controversy exists with regard to diurnal 
cyclicity of plasma testosterone in men. A number of workers 
have reported its presence (6 - 12), while others failed to 
show it (5, 13 - 17). In view of these contradictions it was 
deemed important to study plasma testosterone levels at 
different times of the day in a number of adult healthy males 
and to relate the effect of short term ACTH administration on 
plasma testosterone with spontaneous variations in the level 
of this hormone throughout the day. 
MATERIAL AND METHODS 
In 7 normal males blood was drawn from the antecubital 
vein at 8 a.m., noon, 4 p.m., 8 p.m., midnight and 4 a.m. 
successively. In a second series of 7 healthy men blood samples 
were collected only at 8 a.m. and 4 p.m.. These experiments 
were spread over several days. After sampling the heparinized 
blood was centrifugea, the plasma removed and aliquots 
immediately frozen and stored at - 20 С Plasma testosterone 
was assayed by the competitive protein binding method of Mayes 
and Nugent (18) with slight modifications (19). From duplicate 
analysis of male plasma samples processed the same day (n = 7) 
or on separate days (n = 21) a standard deviation of respecti­
vely 3.2 % (intra-assay variation) and 4.2 % (inter-assay 
variation) was calculated, according to the formula: 
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/ 1 η / χ. χ 
S.D. (%) =\ Σ
 ν
1 1
 — χ 20 
V
 2η i = 1 \ il + Xi2 
where Χ and χ., are the values of the i-th duplicate consi­
dered and η is the number of duplicate pairs. Replicate assays 
(n = 11) of pooled male plasma from different subjects yielded 
a mean plasma testosterone concentration of 573 + 32 (SD) 
ng/100 ml (coefficient of variation: 5.6 % ) . 
Normal plasma testosterone values found at 8 a.m. in 33 
adult men ranged from 337 to 958 ng/100 ml with a mean of 557 
+ 181 (SD) ng/100 ml and from 12 to 69 ng/100 ml with a mean of 
3 0 + 1 5 (SD) ng/100 ml in 23 healthy women. The intrapersonal 
day-to-day variation in plasma testosterone levels (the stan­
dard deviation within persons in samples taken from 14 normal 
males at 8 a.m. on 3 to 5 non-consecutive days) was 77 ng/100 
ml (= 11.7 % ) . 
ACTH (Cortrophin, Organon) 120 I.U. in 500 ml 5 % glucose 
was administered intravenously over 8 hours to 10 healthy male 
subjects, starting the infusion at 8 a.m.. Immediately before 
and after the infusion, blood was drawn for 11-hydroxycortico-
steroids and testosterone determination. 
In 8 of these 10 men diurnal variation in plasma testos­
terone concentration had been assessed by collecting blood 
samples at 8 a.m. and 4 p.m. on a control day before ACTH 
administration. 
Determination of plasma 11-hydroxycorticosteroids was 
performed by the method described by De Moor et al (20). 
Statistical analysis was performed using the following 
non-parametric methods: Wilcoxon's signed rank test (21) (two-
sided P-values denoted by Ρ), the Mann and Whitney U-test (22) 
(P*) and Friedman's non-parametric analysis of variance (23) 
(P**). The F-test for the ratio of variances was used to 
compare the daily variance of the plasma testosterone concen-
2 
tration of each subject (S, ) with the interassay variance of 
о 
the plasma pool (S, = 1024) (degrees of freedom 5,10) (P***). 
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RESULTS 
The concentrations of plasma testosterone in 7 males at 
different times of the day are collected in table 1. 
table 1 
diurnal variation in plasma testosterone 
concentration (ng/100 ml) in? normal men 
subject 
Aa 
Ko 
01 
Wi 
Sm 
Ke 
Ge 
mean 
S.D 
SEM 
8 am. 
462 
4Θ0 
537 
806 
697 
741 
398 
see 
±157 
± 59 
noon 
472 
316 
517 
743 
771 
533 
460 
544 
i 161 
± 60 
time 
4 pm. 
448 
374 
512 
712 
654 
495 
237 
490 
ІІ61 
± 60 
8 p.m. 
347 
353 
439 
376 
504 
479 
134 
375 
±123 
±46 
midnight 
560 
343 
391 
488 
577 
479 
334 
453 
±99 
±37 
4 a.m. 
529 
413 
404 
929 
615 
475 
520 
555 
±180 
± 68 
The data show a diurnal rhythm in plasma testosterone concen­
tration (P** = 0.01, according to Friedman's nonparametric 
analysis of variance) with peak levels in the morning. As it is 
evident from table 2 the daily fluctuations were not overruled 
by the interassay variability. From 8 a.m. to 4 p.m. (times of 
blood sampling frequently used in this study) a significant 
decrease (17.1 + 14.8 (SD) %) in plasma testosterone levels 
was observed (P = 0.02). A much larger decrease was observed 
from 8 a.m. to 8 p.m. (35.9 + 17.3 (SD) % ) . Because frequent 
blood sampling could have an influence on the diurnal testo­
sterone rhythm, in a second-series of 7 healthy males blood 
samples were only drawn at 8 a.m. and 4 p.m.. The mean values 
found were 690 + 210 (SD) ng/100 ml and 567 + 210 (SD) ng/100 
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table 2 
significance of the daily variance of plasma testosterone concentrations 
within subjects when compared to interassay variance 
„ 2 plasma Τ (ng/100 ml) measured 
6 times daily at 4 h intervals 
daily variance vs 
interassay variance 
->* 
Subject mean + SD variance (S. ) 
Aa 
Ko 
01 
Wi 
Sm 
Ke 
Ge 
(5.10) P*** value 
470 
380 
467 
676 
636 
534 
347 
74 
59 
63 
206 
93 
104 
143 
5476 
3481 
3969 
42436 
8649 
10816 
20449 
5.34 
3.39 
3.87 
41.44 
8.44 
10.56 
19.96 
< 0.05 
< 0.05 
< 0.05 
< 0.01 
< 0.01 
< 0.01 
< 0.01 
* 11 consecutive measurements of a plasma pool (from different subjects) 
2 
Mean + SD = 573 + 32 ng/100 ml. Interassay variance S 2 = 102' 
ml respectively. The mean percentage fall from 8 a.m. to 4 p.m. 
(18 + 11.8 (SD) % (Ρ < 0.05) in this group did not differ sig­
nificantly from that in the frequent sampling experiment shown 
in table 1 (P* = 0.95). From these data it is concluded that a 
diurnal variation in male plasma testosterone concentration 
indeed exists. 
During acute ACTH administration plasma 11-hydroxycortico-
steroids increased and plasma testosterone decreased in all 10 
males tested. The concentrations of 11-hydroxycorticosteroids 
increased from 14.0 + 3.9 (SD) pg/100 ml to 46 + 9.4 (SD) 
pg/100 ml. Mean plasma testosterone levels fell from 562 + 136 
(SD) ng/100 ml to 443 + 146 (SD) ng/100 ml (P = 0.002). In 8 
out of these 10 subjects a control study of diurnal variation 
in plasma testosterone had been made before. Mean control 
plasma testosterone levels at 8 a.m.(685 + 209 (SD) ng/100 ml) 
were significantly higher than at 4 p.m. (566 + 234 (SD) 
ng/100 ml) (0.01 < Ρ < 0.02) with a mean percentage fall of 
19.4 + 13.8 (SD) %. Mean pre- and post- ACTH plasma testoste­
rone concentrations in these 8 subjects were 610 ~+ 101 (SD) 
ng/100 ml and 494 + 132 (SD) ng/100 ml respectively, represen­
ting a mean percentage fall of 19.7 + 11.7 (SD) % (table 3). 
No systematic difference in 8 a.m. plasma testosterone concen­
trations was seen between the control and the ACTH day (P*= 
0.31). Statistically no indication was found for a difference 
between the absolute or relative decreases in plasma testos­
terone observed during ACTH administration and the spontaneous 
diurnal fall in the same subjects, over the same period (P*> = 
0.84). Therefore, the fall in plasma testosterone concentra­
tion observed during short term ACTH administration can be 
fully explained by the spontaneous diurnal variation in the 
level of this hormone. 
DISCUSSION 
This study demonstrates the presence of a diurnal cycle 
in plasma testosterone concentrations in the human male, still 
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table з 
plasma testosterone levels (ng/100 ml) in 8 normal males : 
diurnal variation and "effect" of ACTH 
subject 
Wi 
Sm 
Ge 
v.d.W 
ßi 
Fl 
Во 
v.d.P 
m e a n 
ÌS.D. 
iS.EM. 
CONTROL d a y 
t ime 
8α.τη 4 p m 
806 712 
697 654 
398 237 
580 487 
957 707 
940 953 
661 447 
441 328 
665 566 
+209 234 
+ 74 + 8 3 
Δ 
ng/100 ml 
- 9 4 
- 4 3 
-161 
- 93 
-250 
+ 13 
-214 
-113 
-119 
+ 87 
+ 31 
Δ 
% 
-11 
- 6 
-40 
-16 
- 2 6 
+ 1 
-32 
-25 
-19.4 
+ 13.8 
1 4.9 
ACTH*day 
t ime 
8 a m 4 p m 
686 623 
756 698 
512 407 
608 546 
666 4 0 6 
664 549 
531 427 
457 297 
610 494** 
+ 101 +132 
+ 3 6 + 4 7 
Δ 
ng/lOOml 
- 6 3 
- 5 8 
-105 
- 6 2 
-260 
-115 
-104 
-160 
-116 
+ 68 
+ 24 
Δ 
% 
- 9 
- 8 
-20 
-10 
-39 
-17 
-20 
-35 
-19.7 
±11.7 
+ 4 2 
« ACTH 120 I U iv over 8 hr from β am. to 4 pm. 
• • Ρ <0.02 compared to the 8 a.m value 
·•« Ρ < 0.01 compared to the 8 a.m. value 
a matter of controversy in recent literature. The mean percen­
tage changes of 17.1 + 14.8 (SD) % from 8 a.m. to 4 p.m. and 
35.8 + 17.3 (SD) % from 8 a.m. to 8 p.m. found in this study, 
are comparable with similar values of 22.1 + 9.9 (SD) % and 
33.8 + 9.1 (SD) % observed by Resko and Eik-Nes (7). The 
presence of diurnal cyclicity in plasma testosterone levels is 
not only interesting from a physiological point of view, but 
also has clinical implications, especially in evaluating the 
acute effect of drug administration on plasma testosterone. In 
the few reports published on the effect of short term ACTH 
administration attention has not always been paid to the 
presence of a diurnal rhythm in plasma testosterone. 
Sorcini et al (1) noted a 40 % decrease in plasma testos­
terone in 4 healthy males, given 25 U ACTH i.v. in 6 to 8 
hours, but found no change after mere glucose administration 
in two of them. Rosenfield et al (2) observed a definite fall 
in plasma testosterone concentration 4 to б hours after intra-
2 
muscular injection of 30 U ACTH/m , without considering diur­
nal variation. Pizarro et al (3) studying the effect of acute 
intravenous ACTH administration in 10 normal males found a 20 
% fall in plasma testosterone concentration after 4 and 8 
hours of ACTH infusion and mentioned this effect to be more 
pronounced than the 10 % diurnal decrease in plasma testoste­
rone between 8 a.m. and 8 p.m. in 5 controls. Contrarily, 
Southren et al (4) and Hudson and coworkers (5) did not find a 
change in plasma testosterone concentration in response to 
acute intravenous ACTH administration in, respectively, 2 and 
10 normal men. However evaluating the effect of acute ACTH 
administration the former did not consider the presence of 
diurnal plasma testosterone variation while the latter authors 
denied the presence of such a rhythm. 
In this study short term ACTH administration during 8 
hours seemed to induce a fall in plasma testosterone concentra­
tion in all tested males. However statistically there was no 
indication at all for a difference in the mean percentage fall 
of 19.7 + 11.7 (SD) % during ACTH administration and the 
spontaneous diurnal decrease of 19.4 + 13.8 (SD) % in the same 
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subjects over the same period. 
This study illustrates that the decrease of plasma 
testosterone observed during short term ACTH administration 
can be fully explained by the diurnal variation in the level 
of this hormone. This however does not mean that chronic ACTH 
administration to normal males has no effect on plasma testos-
terone. In fact sorcini et al (1) and Rivarola et al (24) 
observed a significant fall in plasma testosterone levels 
after intramuscular ACTH administration for several days, 
although Hudson and coworkers (5) did not find such a decrease. 
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ABSTRACT 
The mean basal plasma testosterone level in 28 patients 
with chromatin positive Klinefelter's syndrome was significant-
ly lower than in 58 healthy male controls. In 12 of the 
patients the hormone's levels were in the normal range. In 
both the eugonadal males and the Klinefelter patients plasma 
testosterone levels spontaneously decreased throughout the day, 
the relative decrease in both groups being of the same order 
of magnitude. 
Short term ACTH infusion and administration of dexametha-
sone did not significantly influence the plasma testosterone 
concentration in the Klinefelter patients. These findings do 
not favour a major role of the adrenal cortex in contributing 
to the circulating plasma testosterone levels in this syndrome. 
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Testicular androgen secretion in most patients with 
Klinefelter's syndrome has been reported to be deficient 
despite Leydig cell hyperplasia and hypergonadotropism (Lipsett 
et al (1966), Paulsen et al (1968), Jeffcoate et al (1967), de 
Kretser et al (1972), Stewart-Bentley and Horton (1973) and 
Smais et al (1974 a). In fact by different approaches some 
authors collected indirect evidence pointing to a largely 
adrenal origin of the circulating androgens in this disorder 
(Decourt et al (1961), Jeffcoate et al (1967) and Lederer 
(1970). Lipsett et al (1965) administering pharmacological 
amounts of a synthetic androgen to Klinefelter patients failed 
to detect a significant suppression of the production rate of 
testosterone, in contrast to the findings in normal males 
(Davis et al (1965) . They therefore reasoned that there must 
be a significant extratesticular production of testosterone in 
these patients. Other investigators however (Dupré et al 
(1964), Sebaoun et al (1965), Paulsen et al (1968) and Smais 
et al (1974 b and e) concluded to a predominantly testicular 
origin of the androgens in Klinefelter's syndrome by finding 
a distinct testicular arterio-venous plasma testosterone 
gradient (Dupré et al (1964) and by the observation that 
exogenous gonadotropins could raise plasma testosterone levels 
in these patients (Sebaoun et al (1965), Paulsen et al (1968), 
Smals et al (1974 b) . Furthermore estrogens administration 
suppressed plasma testosterone levels, a suppression which 
could be readily overridden by exogenous gonadotropins (Smals 
et al (1974 с). То establish a possible role of the adrenal 
cortex in contributing to circulating plasma testosterone 
concentration in the present study the effect of short term 
stimulation of the adrenal cortex by ACTH and its suppression 
by dexamethasone on plasma testosterone levels was measured in 
a number of patients with Klinefelter's syndrome. In an 
earlier report from this laboratory (Smais et al (1974d) 
evaluation of the effect of short term ACTH administration on 
plasma testosterone levels in normal males, necessitated to 
take into account the diurnal variation of plasma testosterone 
leve Is.In that study it was found that the decrease in plasma 
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testosterone levels after 8 hours of ACTH infusion could be 
fully accounted for by this diurnal variation itself. There-
fore, in order to evaluate the short term ACTH effect on plasma 
testosterone in Klinefelter's syndrome, first it was necessary 
to assess the possible spontaneous diurnal changes of the 
plasma testosterone concentration in these patients. 
MATERIALS AND METHODS 
Basal 8 a.m. plasma testosterone levels were measured in 
28 chromatin positive patients with Klinefelter's syndrome 
(karyotype 26 XXY, 1 XY/XXY, 1 XXYY) referred to the endocrine 
clinic. All patients had small testes and in most of them 
plasma and/or urinary gonadotropins were elevated. Mean age 
was 30.6 + 11.2 SD years (range 15 to 55 years). 
ACTH (Cortrophin, Organon) 120 IU in 500 ml 5 % glucose 
was administered intravenously over 8 hours to 6 of these 
patients (karyotype XXY, mean age + SD 28 + 8.7 years, range 
20 to 37 years) starting the infusion at 8 a.m.. Immediately 
before and after the infusion blood was drawn for 11-hydroxy-
corticosteroid and testosterone determinations. In 4 of the 
patients (Fr, Ko, Oo and Ro) and 5 other XXY individuals the 
spontaneous diurnal change in plasma testosterone levels 
between 8 a.m. and 4 p.m. was assessed and compared with the 
corresponding spontaneous variation in 10 eugonadal males over 
the same period. All six patients who had prior ACTH stimula-
tion were given dexamethasone on 4 consecutive days starting 
with a dose of 2 mg daily (h mg q.i.d.) during two days and 8 
mg daily (2 mg q.i.d.) on the 3rd and 4th day. After each of 
both courses blood was sampled at 8 a.m. for testosterone and 
ll-hydroxycorticosteroid determination. Urine for 17 ketoste-
roid assay was collected on a control day, on the day of ACTH 
administration and on the second day of each dexamethasone 
course. 
Plasma testosterone was assayed by a competitive protein 
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binding method as described by Benraad et al (1972). From 
duplicate analysis of male plasma samples processed the same 
day or on separate days a standard deviation of respectively 
3.2 % (intra-assay variation) and 4.2 % (inter-assay variation) 
was calculated. Replicate assays (n = 11) of pooled male plasma 
from different subjects yielded a mean plasma testosterone 
concentration of 573 + 32 (SD) ng/100 ml (coefficient of 
variation 5.6 % ) . Normal male plasma testosterone levels found 
at 8 a.m. in 58 adult men (aged 32.4 + 9.8 SD years, range 19 
to 62 years) ranged from 314 to 1337 ng/100 ml with a mean of 
568 + 198 (SD) ng/100 ml and from 12 to 69 ng/100 ml with a 
mean of 30 + 15 (SD) ng/100 ml in 30 healthy women. Determina­
tion of plasma 11-hydroxycorticosteroids was performed by the 
method described by De Moor et al (1960) . Urinary 17-ketoste-
roids on the relevant days were assayed according to the method 
of Callow et al (1938). 
Statistical analyses were performed using Wilcoxon's 
signed rank test (two-sided Ρ values denoted by Ρ), Wilcoxon's 
two sample test (P*) and Spearman's rank correlation test 
(P**). 
RESULTS 
In figure 1 the 8 a.m. plasma testosterone levels in 28 
Klinefelter patients have been compared with the values found 
in the 58 eugonadal male controls. The mean plasma testosterone 
concentration in the patients with Klinefelter's syndrome 
(283 + 139 (SD) ng/100 ml, range 72 to 684 ng/100 ml) was 
significantly lower than the mean value of the eugonadal males 
(568 + 198 (SD) ng/100 ml , range 314 to 1337 ng/100 ml) 
(P* < 0.0001). In 12 of the Klinefelter patients however plasma 
testosterone levels were in the normal range. 
In table 1 data are given on the 8 a.m. and 4 p.m. plasma 
testosterone levels in 9 Klinefelter patients and 10 eugonadal 
males. Both the 8 a.m. and 4 p.m. plasma testosterone levels 
in the Klinefelter patients (288 + 159 and 240 + 125 (SD) 
85 
Figure 1 
8 AM PLASMA TESTOSTERONE LEVELS IN 28 PATIENTS 
WITH KLINEFELTER'S SYNDROME AND 58 EUGONADAL MALES 
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Table 1 
DIURNAL VARIATION IN PLASMA TESTOSTERONE LFVELS ΒΕΤίΕΕΝ θ AM AND 4 PM 
IN 10 EUGONADAL MALES AND 9 PATIENTS WITH KLINEFELTER·S SYNDROME 
EUGONADAL MALES 
PLASMA TESTOSTERONE LEVELS (ng/100 ni) 
KLINEFELTER PATIENTS 
PLASMA TESTOSTERONE LEVELS (ng/100 ml) 
00 
SUBJECT 
Во 
Bi 
Fl 
Ja 
Jo 
Kl 
Pu 
Sm 
Vo 
VW 
MEAN 
+ 
S.D. 
8 AM 
661 
957 
940 
780 
848 
472 
441 
853 
411 
580 
694 
+ 
209 
4 PM 
447 
707 
953 
608 
710 
440 
328 
773 
296 
487 
575 
+ 
210 
Δ 
-
-
+ 
-
-
-
-
-
-
-
-
abs 
214 
250 
13 
172 
138 
32 
113 
80 
115 
93 
119 
+ 
79 
Δ % 
- 32 
- 26 
+ 1 
- 22 
- 15 
- 7 
- 26 
- 9 
- 28 
- 16 
- 18. 
+ 
10. 
.0 
2 
PATIENT 
Fr 
Ko 
Oo 
Ro 
Si 
Ja 
W 
vE 
vH 
MEAN 
+ 
S.D. 
8 AM 
282 
494 
82 
182 
496 
108 
450 
272 
224 
288 
+ 
159 
4 Ρ" 
314 
328 
51 
177 
387 
76 
393 
229 
205 
240 
+ 
Δ abs. 
+ 32 
- 166 
- 32 
5 
- 109 
- 32 
- 57 
- 43 
- 19 
- 48 
+ 
Δ % 
+ 11 
- 34 
- 38 
- 3 
- 22 
- 30 
- 13 
- 16 
- 8 
- 17.0 
+ 
125 58 15.7 
ng/100 ml resp.) were significantly lower (Ρ* < 0.01) than the 
corresponding values in the eugonadal controls (694 + 209 (SD) 
ng/100 ml and 575 + 210 (SD) ng/100 ml). Between 8 a.m. and 4 
p.m. mean plasma testosterone levels significantly decreased 
in both the Klinefelter patients (P < 0.05) and the eugonadal 
controls (P < 0.01) the mean percentage fall in the former 
(17.0 + 15.7 %) being of the same order of magnitude as in the 
latter (18 + 10.2 (SD) % (Ρ* = 0.97). No significant correla­
tion (P** > 0.10) was found between the 8 a.m. plasma testos­
terone levels and the relative diurnal fall neither m the 
eugonadal males (r = - 0.37) nor in the Klinefelter patients 
(r = - 0.33) . 
During short term ACTH infusion (table 2) plasma 11-
hydroxycorticosteroids distinctly increased from a mean of 
15.2 + 7.2 (SD) pg/100 ml at 8 a.m. to 53.1 + 13.7 (SD) ид/100 
ml at the end of the infusion. In contrast plasma testosterone 
levels did not change significantly, the mean values before 
ACTH infusion benig 249 + 177 (SD) ng/100 ml and 234 + 145 
(SD) ng/100 ml at the end of the infusion (P* = 0.81). 
Dexamethasone in the lower dosage of 2 mg daily signifi­
cantly (P < 0.05) suppressed plasma 11-hydroxycorticosteroid 
levels in all 6 Klinefelter patients as m normal subjects to 
a mean of 1.3 + 0.5 yg/100 ml. Plasma testosterone levels how­
ever did not change significantly, the mean postdexamethasone 
values (225 + 157 (SD) ng/100 ml) being not significantly 
different from the basal values (249 + 177 (SD) ng/100 ml 
(P = 0.69). Even after the higher dose of 8 mg dexamethasone 
the mean plasma testosterone levels essentially remained 
unchanged (256 + 176 (SD) ng/100 ml) when compared to the 
pretreatment level (P = 0.84). 
The effects of ACTH and dexamethasone administration on 
the urinary 17-ketosteroid excretion are shown in table 3. In 
all the patients studied ACTH induced a definite increase m 
the 17-ketosteroid excretion, while dexamethasone administra­
tion at each of both doses resulted in a definite decrease. 
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Table 2 
THE EFFECT OF SHORT TERM ACTH (120 IU CORTROPHIN IN 500 ML GLUCOSE 
FOR 8 HOURS) AND DEXAMETHASONE ADMINISTRATION (2 AND 8 MG DAILY 
BOTH FOR 2 DAYS) ON PLASMA 11 HYDROXYCORTICOSTEROID AND 
TESTOSTERONE LEVELS IN 6 PATIENTS WITH KLINEFELTER'S SYNDROME 
SUBJECT 
Fr 
Ko 
VL 
00 
Ro 
vS 
MEAN 
+ 
S.D. 
BEFORE AFTER AFTER DXM AFTER DXM 
ACTH i.V. ACTH I.V. (2 MG DAILY (8 MG DAILY 
FOR 2 DAYS) FOR 2 DAYS) 
PLASMA 11 HYDROXYCORTICOSTEROID LEVELS (pg/100 ml) 
11.9 
14.4 
10.8 
11.5 
29.8 
13.0 
15.2 
+ 
7.2 
39.6 
51.8 
39.9 
69.1 
-
65.1 
53.1 
+ 
13.7 
1.1 
1.8 
0.7 
1 .1 
2.2 
1.1 
1 .3 
+ 
0.5 
2.2 
2.2 
1 .1 
2.5 
4.3 
1.4 
2.3 
+ 
1 .1 
PLASMA TESTOSTERONE LEVELS (ng/100 ml) 
SUBJECT 
Fr 
Ko 
vL 
Oo 
Ro 
VS 
MEAN 
+ 
S.D. 
394 
520 
116 
61 
257 
151 
249 
+ 
177 
394 
429 
145 
65 
211 
158 
234 
+ 
145 
364 
453 
137 
26 
202 
166 
225 
+ 
157 
445 
447 
117 
32 
326 
167 
256 
+ 
176 
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Table 3 
THE EFFECT OF SHORT TERM ACTH STIMULATION (120 IU CORTROPHIN ORGANON IN 
500 ML 5 % GLUCOSE DURING 8 HOURS) AND DEXAMETHASOFE ADMINISTRATION (DXM) 
(2 MG (Q.I.D.) AND 8 MG (O.I.D.) DAILY BOTH FOR 2 DAYS) ON URINARY 17-
KETOSTEROID EXCRETION IN 6 PATIENTS WITH KLINEFELTER'S SYNDROME. 
URINARY 17 KETOSTEROID EXCRETION (MG/GRAM CREATININE) 
О 
PATIENT 
Fr 
КО 
vL 
Oo 
Ro 
vS 
MEAN 
+ 
S.D. 
CONTROL DAY 
6.7 
11.5 
10.8 
6.7 
5.7 
7.1 
ACTH DAY 
8.1 
+ 
2.3 
20.5 
16.5 
8.7 
10.4 
11.5 
13.5 
+ 
4.9 
2МП DAY OF 
2 MG DXM 
6.0 
6.5 
5.0 
3.0 
3.7 
5.3 
4.9 
+ 
1.4 
DATLY 
2ND 
8 MG 
DAY OF 
DXM DAILY 
3.0 
3.4 
3.9 
2.1 
0.7 
5.3 
3.1 
+ 
1.6 
DISCUSSION 
The finding of lowered plasma testosterone levels in most 
of a relatively large group of Klinefelter patients is in 
agreement with similar data reported by Paulsen et al (1968) 
who also studied a substantial number of Klinefelter patients. 
There is growing consensus now that in normal men plasma 
testosterone levels show a circadian rhythm with peak levels 
in the morning and the nadir in the late afternoon or evening 
(Resko and Eik-Nes (1966), Faiman and Winter (1971), de Lacerda 
et al (1973) and Smals et al (1974 d). The current study con­
firms the presence of a diurnal variation in plasma testoste­
rone levels in healthy men and in addition shows this variation 
to occur also in patients with Klinefelter's syndrome, the 
relative amplitude being of the same order of magnitude as in 
the eugonadal males. A similar spontaneous fall of plasma tes­
tosterone levels throughout the day in Klinefelter patients was 
reported by Nieschlag et al (1971). The data of these authors 
and ours are however at variance with the findings of Stewart-
Bentley and Horton (1973) who ignored diurnal plasma testoste­
rone cyclicity in their 8 patients with Klinefelter's syndrome, 
4 of whom had very low plasma testosterone levels. 
The finding of a diurnal variation in plasma testosterone 
levels in Klinefelter patients is in line with earlier obser­
vations from this laboratory, strongly indicating the hypo-
thalamic-pituitary-gonadal axis to be qualitatively operating 
normally in this syndrome (Smais et al (1974 с). In these 
observations plasma testosterone levels appeared to be 
suppressible by estrogen administration (Smais et al (1974 с) 
and could be raised by HCG stimulationg (Smais et al (1974 b) . 
These findings lead us to reject the viewpoint of other 
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investigators claiming a principal abnormality of the hypo-
thalamic-pituitary-gonadal axis in Klinefelter's syndrome 
(Stewart-Bentley et al (1971), Capell et al (1973). 
In the present study ACTH administration did not 
significantly change plasma testosterone levels in Klinefel-
ter' s syndrome. In a prior study (Smais et al (1974 d) acute 
ACTH administration was demonstrated to significantly decrease 
plasma testosterone levels in normal men, but this decrease 
could be fully explained by the spontaneous fall of the 
hormone's levels throughout the day. During short term ACTH 
administration to the Klinefelter patients plasma testosterone 
levels decreased in 2 patients and remained essentially 
unchanged in the 4 other patients. In view of the expected 
spontaneous diurnal decrease described in Klinefelter patients 
(vide supra) these findings might point to a small adrenal 
contribution to the circulating plasma testosterone levels m 
these patients, either by direct secretion or indirectly by 
increased formation and periterai conversion of androstenedione 
and dehydroepiandrosterone to testosterone. Nevertheless the 
lack of a significant plasma testosterone suppression during 
administration of both lower and higher doses of dexamethasone 
is not in favour of a major role of the adrenal cortex in 
contributing to the circulating testosterone pool. These data 
are in accordance with findings of Sebaoun et al (1965) and 
Stewart-Bentley and Horton (1973) who failed to demonstrate a 
distinct stimulatory effect of ACTH (Sebaoun et al (1965) or a 
suppressive effect of dexamethasone (Stewart-Bentley and Horton 
(1973) on plasma testosterone levels in two patients with 
Klinefelter's syndrome. ACTH distinctly (70 %) increased and 
dexamethasone (40 and 70 %) decreased urinary 17-ketosteroid 
excretion in the Klinefelter patients whereas plasma testoste-
rone levels did not change significantly. This observation 
reconfirms that urinary 17-ketosteroid excretion can hardly be 
considered a reliable parameter of androgenic activity. Some 
studies which rely on data of urinary excretion of 17-keto-
steroids or fractions thereof erroneously concluded the 
androgens in Klinefelter's syndrome to originate almost 
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exclusively from the adrenal cortex. 
Jeffcoate et al (1967) measuring plasma testosterone or 
its production rate observed a minor stimulatory effect of ACTH 
in one patient and a subtle decrease after dexamethasone 
administration in 2 other patients with Klinefelter's syndrome 
and they suggested from additional evidence in other hypogona-
dal men that the adrenal cortex might contribute significantly 
to the circulating testosterone levels in these patients. The 
present study does not favour such a concept. 
Summarizing a diurnal variation in plasma testosterone 
levels has been demonstrated in patients with Klinefelter's 
syndrome. This variation can hardly be ascribed to changing 
adrenal activity throughout the day as pharmacological doses 
of ACTH as well as dexamethasone did not influence plasma 
testosterone levels significantly. Therefore these findings 
are not in favour of a significant role of the adrenal cortex 
to circulating testosterone levels in patients with Kline-
felter' s syndrome. In fact the earlier from this laboratory 
reported estrogen suppressibility of plasma testosterone and 
gonadotropin levels and the rise of testosterone after HCG 
stimulation along with the indirect evidence from the data of 
this study lead to the conclusion that in patients with 
Klinefelter's syndrome the testicles remain the principal 
source of the hormone testosterone. 
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ABSTRACT 
The effect of acute (1500 I.U./day for 3 days) and 
chronic HCG administration (1500 I.U., 3 times weeklyjon plasma 
testosterone levels in patients with Klinefelter's syndrome was 
compared with the response observed in patients with hypogona-
dotropic eunuchoidism and in eugonadal male controls. Basal 
plasma testosterone levels in the Klinefelter patients were 
significantly lower than in the control subjects and signifi-
cantly higher than in the patients with secondary hypogonadism. 
In all but one Klinefelter patient plasma LH levels were 
strongly elevated even in the presence of normal testosterone 
levels. No significant correlation could be demonstrated 
between plasma testosterone concentrations and LH levels in the 
Klinefelter patients. Short term HCG administration resulted in 
a significant increase of plasma testosterone levels in each of 
the 3 groups studied, independent on the basal value. The 
absolute increase in the Klinefelter patients was quantitative-
ly comparable to that in the patients with secondary hypogona-
dism, but significantly lower than in the eugonadal controls. 
During long term HCG treatment plasma testosterone levels 
definitely increased in both patient groups, but remarkably in 
the Klinefelter patients testosterone levels tended to decline 
on continuing treatment, though in most patients testosterone 
levels remained higher than the pretreatment values. The data 
on the effect of acute and chronic HCG administration on plasma 
testosterone levels in this study reillustrate that Leydig 
cells in Klinefelter's syndrome still have functional reserve, 
though less than in eugonadal males. 
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Klinefelter's syndrome is a common type of hypogonadism, 
in which varying degrees of Leydig cell insufficiency have been 
found. The finding of elevated urinary and plasma gonadotropins 
levels in most of the affected patients has led various authors 
to conclude the origin of this disorder to be primarily testi-
cular (Leach et al (1957), Franchimont (1970), Jeffcoate 
(1972), Stewart-Bentley and Horton (1973). Despite the appa-
rently primary nature of the hypogonadism in Klinefelter 
syndrome short term HCG administration has been reported to 
definitely increase urinary testosterone excretion (Sebaoun et 
al (1965), Mahoudeau and associates (1970), Scurry c.s. (1971) 
and plasma testosterone concentration (Lipsett et al (1966), 
Paulsen and coworkers (1968), Nieschlag c.s. (1971), Weinstein 
et al (1971) , Anderson and associates (1972) . Other authors 
however only observed a poor and inconsistent response to HCG 
or no response at all (Dupré c.s. (1964), Briefer et al (1965), 
Hudson et al (1967), Futterweit c.s. (1970), Vermeulen (1973), 
Stewart-Bentley and Horton (1973). Lipsett et al (1965) 
administering 5000 I.U. of HCG/day for 5 days reported a 
definite increase of the testosterone production rate in 2 out 
of 4 patients with Klinefelter's syndrome but failed to 
demonstrate any consistent effect on plasma testosterone 
levels. 
To our knowledge no reports have appeared on the effect 
of chronic HCG administration on plasma testosterone levels in 
patients with Klinefelter's syndrome. Leach et al (1957), Leon 
and associates (1959) and Paulsen (1965) observed a significant 
increase in the urinary excretion of 17-ketosteroids and 
estrogens and clinical evidence of increased androgen activity 
in Klinefelter patients treated with high doses of HCG for a 
prolonged time. 
This study describes the effects of short and long term 
HCG administration on plasma testosterone levels in patients 
with Klinefelter's syndrome and compares these data with the 
responses observed in eugonadal male controls and in patients 
with hypogonadotropic hypogonadism. 
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MATERIALS AND METHODS 
In the short term experiment 1500 I.U. of HCG (Pregnyl, 
Organon)/day was administered i.m. at 9 a.m. for 3 days to 15 
patients with Klinefelter's syndrome (14 XXY, 1 XY/XXY) aging 
17 to 46 years (mean + S.D. 28.1 + 8.6 years). The response of 
plasma testosterone in these patients was compared with that 
observed m 15 patients with isolated hypogonadotropic hypogo­
nadism (17 to 30 years (mean + S.D.: 22.3 + 3.6 years) 4 of 
whom had concomitant hyposmia (subjects Wi, Ny, Mo, vE) and 
with the response in 10 eugonadal male controls (21 to 41 
years, mean + S.D. 32.4 + 9.7 years). 
Blood samples for testosterone determination were collec­
ted on the first day just before the first injection and on 
the day following the third HCG dose. In the Klinefelter 
patients in addition blood for LH determination was drawn 
before the first HCG dose. 
In the long term experiment 3 χ 1500 I.U. of HCG/week was 
administered for at least 6 and for maximally 18 weeks to 5 
patients with Klinefelter's syndrome (XXY) and 5 patients with 
hypgonadotropic eunuchoidism. Blood samples for plasma testos­
terone determination were collected between 8 and 10 a.m. 
before and after 2,4 and 6 weeks of HCG treatment and in some 
patients also after 10 and 18 weeks. 
Plasma testosterone was assayed by the competitive protein 
binding method described by Benraad et al (1972) . From dupli­
cate analysis of plasma samples processed the same day (n = 7) 
or on separate days (n = 21) a standard deviation of respec­
tively 3.2 % (intra-assay variation) and 4.2 % (inter-assay 
variation) was calculated. Replicate analysis of a male plasma 
pool (n = 11) yielded a mean + S.D. of 573 + 32 ng/100 ml 
(coefficient of variation: 5.6 % ) . Normal plasma testosterone 
values found at 9 a.m. in 56 adult men ranged from 314 - 1337 
ng/100 ml with a mean of 568 + (S.D.) 198 ng/100 ml, and from 
12 to 69 ng/100 ml with a mean of 30 + 15 (S.D.) ng/100 ml in 
100 
30 healthy women. 
Plasma LH was measured by radioimmunoassay using an anti-
HCG serum carefully selected for minimal crossreactivity of 
human FSH and TSH. The Second International Reference Prepara­
tion of Human Menopausal Gonadotropin was used as the reference 
standard and results were expressed as mIU/ml. For labeling 
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with I, a highly pnfied HLH preparation was used, prepared 
according to Closset et al (1972). t^iis HLH preparation showed 
high biological activity (6000 - 8000 mU/mg (OAAD test, Parlow 
(1961). A detailed account of the specificity of the antiserum 
chosen is given by Rolland et al (to be published). Normal LH 
values found at 9 a.m. in plasma from 17 eugonadal males ranged 
from 7 to 41 mIU/100 ml. The mtra-assay duplicate variation 
was 11.5 %. 
Statistical analysis was performed using the following 
non-parametric methods: Wilcoxon's two sample test (P ) and 
Spearman's rank correlation test (P ). 
s 
RESULTS 
Short term HCG administration (table 1, figure 1). The 
mean basal plasma testosterone level in the 15 patients with 
Klinefelter's syndrome was 286 + 117 (S.D.) ng/100 ml (range 
90 - 517 ng/100 ml), which is significantly lower than the mean 
of the control subjects (522 + 144 (S.D.) ng/100 ml, Ρ < 0.01) 
and significantly higher than the mean value found in the 15 
patients with hypogonadotropic eunuchoidism (51.6 + 49.7 (S.D.) 
ng/100 ml) (P < 0.001). In 5 of the Klinefelter patients basal 
plasma testosterone levels (327 to 517 ng/100 ml) were in the 
normal range. 
In table 2 data are given on plasma testosterone versus 
LH levels in the 15 patients with Klinefelter syndrome. Both 
LH and testosterone were measured in the same plasma sample. 
With one exception (subject dW) all LH levels (range 57 to 144 
mIU/ml) were high as compared to the values found in male 
controls. In 5 patients plasma LH levels (60 to 132 mIU/ml) 
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TABLE 1 
THE EFFECT OF SHORT TERM HCG ADMINISTRATION (1500 I.U. 
PREGNYL/DD FOR 3 DAYS) ON PLASMA TESTOSTERONE LEVELS IN 
EUGONADAL MALES, PATIENTS WITH HYPOGONADOTROPIC HYPOGONADISM 
AND PATIENTS WITH KLINEFELTER'S SYNDROME 
PLASMA TESTOSTERONE LEVEL (ng/100 ml) 
SUBJECT AGE 
(YRS) 
10 EUGONADAL MALES 
Ba 
Sm 
Ob 
Ja 
St 
Kl 
Dr 
Du 
Me 
Sp 
Mean 
+ 
S D. 
15 PATI EN 
El 
He 
Wi 
Gr 
PI 
Be 
Ve 
Ra 
Ny 
Mo 
vE 
dB 
Pe 
vWe 
Ja 
Mean 
± 
S.D. 
15 PATI EN 
De 
Si 
Th 
Ko 
dL 
Fr 
Kr 
Lo 
uE 
vWa 
vS 
dW 
vH 
Sw 
Ja 
Mean 
+ 
S D. 
40 
37 
36 
49 
21 
41 
26 
19 
25 
30 
3274 
+ 
9.7 
ITS WITH HYPO 
24 
30 
27 
23 
27 
20.5 
25 
22 
20 
18 
19 
20.5 
17 
21 
21 
22.3 
± 
3.6 
BEFORE 3 
DAYS 1500 
I.U. HCG 
704 
685 
669 
577 
561 
540 
430 
407 
332 
314 
522 
± 
144 
IGONADOTROP 
165 
141 
126 
55 
46 
44 
31 
25 
24 
23 
23 
21 
20 
18 
12 
51.6 
± 
49 7 
TS WITH KLINEFELTER'S SYN 
18 517 
23 
38 
22 
21 
19 
32.5 
25 
17 
46 
35 
30 
30 
26 
39 
28.1 
+ 
8.6 
474 
403 
338 
327 
308 
301 
290 
263 
255 
198 
197 
182 
150 
90 
286 
± 
117 
AFTER 3 
DAYS 1500 
I.U HCG 
1047 
1163 
1070 
863 
1234 
1250 
1663 
860 
1827 
914 
1189 
+ 
327 
1С HYPOGONA 
660 
342 
267 
188 
524 
65 
254 
105 
40 
103 
215 
81 
147 
152 
473 
241 
± 
184 
IDROME 
620 ' 
570 
715 
345 
548 
397 
380 
535 
390 
428 
314 
381 
225 
333 
121 
420 
± 
155 
л 
ABSOLUTE 
343 
478 
401 
286 
673 
710 
1233 
453 
1495 
600 
667 
± 
396 
DISM 
495 
201 
141 
133 
478 
21 
223 
80 
16 
80 
192 
60 
127 
134 
461 
189 
+ 
161 
103 
96 
312 
7 
221 
89 
79 
245 
127 
173 
116 
184 
43 
183 
31 
Î34 
± 
87 
Δ 
% 
49 
70 
60 
50 
120 
131 
287 
111 
450 
191 
152 
± 
128 
-
_ 
_ 
_ 
-
_ 
_ 
-
_ 
_ 
_ 
_ 
_ 
_ 
-
19 
20 
77 
2 
68 
29 
26 
84 
48 
68 
58 
93 
23 
125 
34 
52 
± 
34 
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Figure 1 
Effect of short term HCG administration (Pregnyl, 1500 
I.U./day for 3 days) on plasma testosterone levels in 
eugonadal males, patients with Klinefelter's syndrome 
and patients with hypogonadotropic hypogonadism. 
Pregnyl 15001U 
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Pregnyl 1500 lU 
TT 
1655 
controls Klinefelter hypogonadotropic 
hypogonadism 
103 
Table 2 
PLASMA TESTOSTERONE VERSUS LH LEVELS IN 15 PATIENTS WITH 
KLINEFELTER'S SYNDROME 
SUBJECT PLASMA TESTOSTERONE 
LEVEL (ng/100 ml) 
De 517 
Si 474 
Th 403 
Ko 338 
dL 327 
Fr 308 
Kr 301 
Lo 290 
VE 263 
vWa 25 5 
vS 198 
dW 197 
vH 182 
Sw 150 
Ja 90 
Mean + S.D. 286 + 117 
Normal range 314 - 1337 
(males) 
PLASMA LH LEVEL 
(] 
(2nd 
91.· 
7 
mIU/ml) 
IRP.HMG) 
105 
97 
121 
132 
60 
66 
97 
122 
87 
57 
71 
40 
144 
90 
82 
4 + 29.3 
- 41 
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were elevated despite normal plasma testosterone levels. It 
should be noted that there was no significant correlation 
between plasma testosterone and LH levels (p = + 0.29, Ρ > 
0.10, η = 15) in the 15 Klinefelter patients. 
After short term HCG administration (table 1, figure 1) 
plasma testosterone levels increased in each subject of the 
three groups. In 8 out of 10 Klinefelter patients previously 
subnormal testosterone levels normalized. The mean absolute 
(134 + 87 (S.D.) ng/100 ml) and the mean relative (52 + 34 
(S.D.) %) testosterone increase in the 15 Klinefelter patients 
were significantly lower than the corresponding figures in the 
eugonadal controls (672 + 396 (S.D.) ng/100 ml and 152 + 128 
(S.D.) %, Ρ < 0.001 and < 0.01 respectively). The mean abso­
lute increase of the testosterone levels in the Klinefelter 
patients however was not significantly different from the 
corresponding mean value in the patients with hypogonadotropic 
hypogonadism (189 + 161 (S.D.) ng/100 ml, Ρ = 0.22). Neither 
in the Klinefelter patients (p = - 0.10, Ρ > 0.10), nor in 
the patients with secondary hypogonadism (p = + 0.29, Ρ > 
0.10) and in the eugonadal controls (p = - 0.61, 0.05 < Ρ < 
0.10) any significant correlation could be demonstrated between 
basal plasma testosterone levels and the absolute testosterone 
increase in response to HCG. The absolute testosterone increase 
in the Klinefelter patients also proved to be independent on 
the basal LH level (p = - 0.26, Ρ > 0.10). 
s s 
Chronic HCG administration (table 3, figure 2). Before 
HCG administration any of the 5 Klinefelter patients had sub­
normal plasma testosterone levels (range 90 to 284 ng/100 ml) 
(mean + S.D.: 210 + 87 ng/100 ml). After two weeks of HCG 
treatment plasma testosterone levels were normal in all these 
patients (range 315 to 773 ng/100 ml, mean + S.D.: 483 + 199 
ng/100 ml).After 4 and 6 weeks of HCG administration the indi­
vidual and mean plasma testosterone levels still were definite­
ly higher than the basal levels (range 238 to 542 ng/100 ml, 
mean 357 + 138 (S.D.) ng/100 ml and range 179 to 397, mean 290 
+ 86 (S.D.) ng/100 ml respectively) but in 3 of the 5 patients 
levels were subnormal again. Therefore, in the Klinefelter's 
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Table 3 
EFFECT OF LONG TERM HCG ADMINISTRATION (PREGNYL 3 X 1500 I.U./WK) ON PLASMA TESTOSTERONE 
LEVELS IN PATIENTS WITH HYPOGONADOTROPIC HYPOGObftDISM AND KLINEFELTER PATIENTS 
О 
σι 
II 
PLASMA TESTOSTERONE LEVELS (ng/100 ml) 
WEEKS OF HCG TREATMENT 
SUBJECT AGE (YEARS) 
I HYPOGONADOTROPIC HYPOGONADISM 
Bo 
Lo 
Ja 
VW 
VE 
Mean 
+ 
S.D. 
29 
25 
39 
40 
17 
30 
+ 
9.7 
10 
El 
Ha 
He 
Ve 
Ro 
Mean 
+ 
S.D. 
KLINEFELTER' 
24 
22.5 
30 
26 
18 
24.1 
+ 
3.9 
'S SYNDROME 
169 
16 
141 
31 
74 
86 
+ 
67 
736 
227 
272 
329 
466 
406 
+ 
205 
832 
397 
259 
496 
873 
571 
+ 
270 
895 
487 
336 
654 
1085 
691 
+ 
302 
936 
977 
900 
596 
-
852 
+ 
174 
12 
279 
284 
90 
145 
253 
210 
+ 
87 
773 
393 
607 
315 
330 
483 
+ 
199 
473 
542 
238 
273 
257 
357 
+ 
138 
397 
349 
179 
258 
270 
290* 
+ 
86 
432 
269 
197 
346 
-
311* 
+ 
101 
445 
288 
190 
-
-
308 
+ 
128 
Ρ < 0.05 (II vs I) 
Figure 2 
Effect of chronic HCG administration (Pregnyl, 3 χ 1500 
I.U./week) on plasma testosterone levels in Klinefelter 
patients (solid line) and patients with hypogonadotropic 
hypogonadism (broken line). The asteriks indicate sig­
nificant differences of testosterone means between the 
two patient groups (P < 0.05). 
HCG (Pregnyl) 3x1500 lU/week 
b 
E 
in 
β 
iL 6 θ 10 18 
w e e k s of HCG administration 
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patients testosterone levels tended to decline after an initial 
rise despite continuing HCG administration. Notwithstanding, 
even after 10 and 18 weeks of HCG administration testosterone 
levels of most patients still were higher than the pretreatment 
values and reflecting these increased androgen levels subjecti-
ve evidence of enhanced libido, increased number of erections 
and increased facial hair growth was given. In contrast to the 
pattern of response observed in the Klinefelter patients, in 
the group of patients with hypogonadotropic hypogonadism plasma 
testosterone levels steadily increased throughout the 10 weeks 
of HCG treatment. Plasma testosterone levels already differed 
significantly from the corresponding values in Klinefelter pa-
tients 6 and 10 weeks after starting HCG treatment (P., < 0.05). 
DISCUSSION 
In any of the 15 patients with Klinefelter's syndrome from 
this study short term HCG administration resulted in an increa-
se of the plasma testosterone levels. The mean increase in 
these patients was of the same order of magnitude as observed 
in the patients with secondary hypogonadism, but significantly 
lower than in the eugonadal controls. The absolute rise of 
testosterone proved to be independent on the pretreatment 
levels in any of the 3 groups. In contrast Anderson et al 
(1972) reported the highest testosterone increase in response 
to HCG to occur in Klinefelter patients with highest basal 
values. The mean absolute HCG induced testosterone increase in 
the Klinefelter patients in this study was comparable to that 
reported by Nieschlag et al (1971) (244 ng/100 ml) (range 58 
to 881 ng/100 ml) but definitely less than the rise observed by 
Paulsen et al (1968) in 6 out of their 8 patients (mean rise: 
410 ng/100 ml, range 260 to 730 ng/100 ml). In contrast, other 
authors only found a very poor and inconsistent androgen res-
ponse or no response at all and they therefore suggested the 
Leydig cells of Klinefelter patients to be already under 
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maximum physiologie stimulation by excessive endogenous gonado-
tropins (Decourt et al (1961), Dupré and coworkers (1964), 
Lipsett et al (1965), Hudson et al (1967). ^he testicular 
response to HCG treatment reported in literature and in the 
present study reillustrates that in Klinefelter's syndrome 
Leydig cells are not maximally stimulated and therefore still 
have functional reserve, though less than in eugonadal males. 
In the short term experiment Leydig cell reserve of the Kline-
felter patients was quantitatively comparable to that in 
secondary hypogonadism. Chronic HCG administration however 
disclosed a distinct dissimilarity between these two groups. 
During long term HCG treatment plasma testosterone levels in 
the Klinefelter patients rose initially to clearly normal 
values, but declined on continued treatment,in contrast to the 
pattern of testosterone response observed in secondary hypo-
gonadism, in which a steady rise was found up to 10 weeks of 
treatment. Paulsen et al (1968) administering HCG in a higher 
dose of 5000 I.U. for 4 consecutive days to 8 patients with 
Klinefelter's syndrome noted a distinct testosterone peak on 
day 3 and a subsequent decline on day 4. In contrast such 
biphasic response was not observed in tne eugonadal controls 
throughout the 4 days of HCG treatment. Leon et al (1959) 
described a similar biphasic response of the urinary estrogen 
excretion in a single patient with Klinefelter's syndrome 
during chronic HCG administration. We have no explanation for 
this interesting phenomenon. It has to be noted however that 
in most Klinefelter patients from the present study plasma 
testosterone levels were still definitely higher than before 
treatment even after 10 to 18 weeks of HCG stimulation, which 
was clinically evidenced by increased androgenicity. 
In a recent study Reiter et al (1972) reported testoste-
rone and estradiol concentration in the blood of eugonadal 
males to rise during short term HCG administration along with 
FSH suppression. In agonadal patients peripheral FSH levels 
remained essentially unchanged as well as the concentrations 
of testosterone and estradiol. Therefore they suggested HCG 
induced gonadal hypersteroidism to be an essential link in the 
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chain of events leading to HCG induced FSH suppression. If 
these data are extrapolated to an interpretation of testostero-
ne response to HCG stimulation in Klinefelter patients these 
behave like eugonadal males rather than as agonadal patients. 
In support of this viewpoint is the observation that the eleva-
ted FSH levels obtained in 2 of the Klinefelter patients 
studied decreased upon HCG stimulation (Smais et al, unpublish-
ed observations). In a recent study in this laboratory it was 
illustrated along another line of reasoning that hypothalamic-
pituitary-gonadal feedback is still operative in Klinefelter's 
syndrome and qualitatevely comparable with that in eugonadal 
males. In that study small amounts of estrogens appeared to 
decrease plasma testosterone and gonadotropin levels in Kline-
felter patients and in eugonadal males qualitatively similarly 
(Smais et al (1974). 
It is of interest to note that the plasma testosterone 
increase observed after short and long term HCG treatment 
occurred despite clearly elevated endogenous LH levels in most 
of the Klinefelter patients. This is in accordance with similar 
findings of Paulsen et al (1968) and Anderson and associates 
(1972). The testosterone increase proved independent on the 
basal LH level. In the present study no significant correlation 
could be demonstrated between basal plasma testosterone and LH 
levels in the 15 patients with Klinefelter's syndrome. A 
similar absence of a significant correlation between plasma 
testosterone and LH levels could be calculated from data pre-
sented by Paulsen et al (1968) in 20 patients with Klinefelter' 
s syndrome. It is quite possible that episodic fluctuations of 
both testosterone and LH may obscure such mutual interdepen-
dency (Nankin c.s. (1971), Boyar and coworkers (1972), Naftolln 
and associates (1973). Some authors however (Franchimont 
(1970), Franchimont et al (1972), and Crosignani c.s. (1972) 
reported a significant inverse correlationship between plasma 
testosterone and LH levels in a small number of patients with 
Klinefelter's syndrome and they therefore suggested these 
findings to reflect Leydig-cell insufficiency to be the prime 
cause of the elevated LH levels in this disorder. From our 
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experience the excessive LH levels in Klinefelter's syndrome 
do not seem to depend on the degree of Leydig cell insufficien-
cy. 
In summary it is evident from the data presented in this 
study that in patients with Klinefelter's syndrome plasma tes-
tosterone levels can be raised by short or long term HCG 
administration despite hypergonadotropism. By this and circum-
ferential evidence (Smais et al (1974) it is quite plausible 
to assume the pituitary-gonadal axis in this syndrome to the 
qualitatively functioning similar to that in eugonadal males. 
Ill 
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ABSTRACT 
In 6 eugonadal males and 6 patients with Klinefelter's 
syndrome the effect of increasing amounts of ethinylestradiol 
(ЕЕ) (15,30 and 150 \ig daily for 7 days) on plasma levels of 
LH, FSH and testosterone was studied. Control levels of LH and 
FSH in the Klinefelter patients were significantly higher than 
in the normal males, whereas plasma testosterone levels were 
significantly lower. In 3 of the 6 Klinefelter patients plasma 
gonadotropin levels were clearly elevated despite normal plasma 
testosterone concentrations. After ЕЕ administration a dose 
dependent decrease of plasma FSH and testosterone levels was 
observed in both the control subjects and the Klinefelter 
patients, whereas the LH decrease was dose dependent in the 
Klinefelter patients, not however in the eugonadal males. 
Despite significant testosterone suppression plasma LH and FSH 
levels in the Klinefelter patients remained supranormal when 
compared with the levels of the control subjects. Amounts of 
ЕЕ, roughly equivalent to the physiological estrogen production 
(15 \ig of ЕЕ daily) in men, decreased plasma LH and testoste­
rone levels in the normal males, not however in the Klinefelter 
patients. The suppression of plasma testosterone by ЕЕ in both 
the normal subjects and the Klinefelter patients could readily 
be overridden by exogenous gonadotropin administration, 
favouring the concept that the ЕЕ induced testosterone decrease 
is predominantly gonadotropin mediated. It is concluded that 
small amounts of estrogens play a role in the pituitary-gonadal 
axis in normal males. Although higher doses are needed to 
modulate this axis in Klinefelter's syndrome, hypothalamic-
pituitary-gonadal feedback in this disorder is still operative, 
though at a higher setting. 
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Plasma testosterone levels in Klinefelter's syndrome have 
been reported to range from very low to clearly normal depen-
ding on the degree of Leydig cell insufficiency (Lipsett et al 
(1965), Paulsen and coworkers (1968), de Kretser et al (1972), 
Stewart-Bentley and Horton (1973), Smals et al (1974 a). It has 
been demonstrated that even in the presence of normal testoste-
rone concentrations plasma gonadotropin levels are strongly 
elevated in many of these patients (Paulsen et al (1968), 
Anderson et al (1972), Stewart-Bentley and Horton (1973), Smals 
et al (1973, 1974 b). This apparently inappropriate hypergona-
dotropism suggests that at least in a number of Klinefelter 
patients hypothalamic-pituitary-control of the gonadotropin 
secretion is abnormal. In fact by different approaches Lipsett 
et al (1965, 1966), Stewart-Bentley et al (1971) and Capell et 
al (1973) adduced direct and indirect evidence of a defective 
feedback mechanism in Klinefelter * s syndrome. Other authors 
however presented scant data which do not support this concept 
(Burger et al (1969), Franchimont (1972) and Jeffcoate (1972). 
In normal men gonadotropin feedback has been thought to be 
largely mediated by testosterone (Odell et al (1966) , Peterson 
et al (1968), Swerdloff and Odell (1968), Lee et al (1972), 
Sherins and Loriaux (1973) and estradiol (Adler et al (1968), 
Swerdloff and Odell (1968), Peterson et al (1968), Stewart-
Bentley et al (1971), Kulin and Reiter (1972) and Sherins and 
Loriaux (1973), Walsh et al (1973). 
In this study the effect of varying doses of a synthetic 
estrogen (ethinylestradiol) on plasma testosterone, LH and FSH 
levels has been evaluated in patients with Klinefelter's syn-
drome and the results are compared with those obtained in 
eugonadal males. 
MATERIALS AND METHODS 
Subjects and procedure. 
Six eugonadal male volunteers (nos 1 to 6), aging 26 to 41 
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years (mean + S.D. 34.5 + 5.8 years) and six patients with 
Klinefelter's syndrome (XXY) (nos 1 to 6) aging 18 to 38 years 
(mean + S.D. 27.5 + 8.2 years) were sequentially given 15, 30 
and 150 yg of ethinylestradiol (ЕЕ) daily in 3 divided doses 
for 7 days. After each course there was a drugfree interval of 
at least 5 days. All subjects were active and had normal 
sleeping habits. Blood samples for testosterone, LH and FSH 
determination were collected between 8 and 10 a.m. on the day 
starting ЕЕ treatment and after 7 days. In addition 3 of the 
eugonadal controls (nos 3, 4 and 6), 2 of the Klinefelter 
patients (nos 2 and 5) and 3 other XXY patients (nos 7, 8 and 
9) received 150 \ig of ЕЕ daily for 10 days and daily 1500 I.U. 
of HCG (Pregnyl, Organon) during the last 3 days of this 
regimen. In an earlier experiment the same dose of HCG had 
been administered for the same period to these subjects with­
out concomitant ЕЕ administration. Blood samples for testoste­
rone determination were collected immediately before and after 
ЕЕ and/or HCG administration. 
Measurements. 
Plasma testosterone was assayed by the competitive protein 
binding method described by Benraad et al (1972) . From dupli­
cate analysis of plasma samples processed the same day or on 
separate days a standard deviation of respectively 3.2 % 
(intra-assay variation) and 4.2 % (mter-assay variation) was 
calculated. Replicate analysis of a male plasma pool yielded 
a mean + S.D. of 573 + 32 ng/100 ml (coefficient of variation 
5.6 % ) . Normal plasma testosterone levels found at 9 a.m. in 
56 adult men ranged from 314 to 1337 ng/100 ml with a mean + 
S.D. of 568 + 198 ng/100 ml and from 12 to 69 ng/100 ml with a 
mean + S.D. of 30 + 15 ng/100 ml in 30 healthy women. 
Radioimmunoassay of plasma FSH and LH was performed by 
one of us (R.L.). Human FSH in plasma was measured using an 
anti-hFSH serum, (Batch fi 3, provided by the U.S. National 
Pituitary Agency). This antiserum was used in a final dilution 
of 1 : 30.000. A highly purified hFSH preparation (code CPDS/2, 
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gift from Dr. W. Butt, Birmingham), was used for radioactive 
labelling. This preparation has a biological activity of 5400 
lU/mg and an immunological activity of 6200 lU/mg (2 nd IRP-
HMG). The immunological measured LH contamination is 435 lU/mg 
(LH 68/40, MRC, London) . Five \ig of this preparation is 
125 iodinated with 2 mCi Na I (Amersham IMS30) in the presence 
of 5 \ig Chloramine-T (Merck) according to the method of 
Greenwood et al (1963). Specific activities obtained ranged 
from 170 to 250 yCi/pg. After initial passage over a small 
Sephadex G - 25 column (Pharmacia) to remove the non-reacted 
iodide, aliquote of the labelled hormone were purified on a 
small cellulose column (Whatman CF 11, 0.5 χ 20 cm) just prior 
to assay. The labelled product, in 0.02 M phosphate buffered 
0.15 M NaCl solution (PBS) containing 1 % Bovine serum albumin 
(BSA, Poviet, Amsterdam), is placed on top of this cellulose 
column. Then the column is washed with 20 ml of PBS without 
addition of BSA; desorption is done by passage of PBS contai­
ning 4 % BSA. In this procedure the non-absorbed fraction 
contains most of the highly immunoreactive labelled hFSH with 
minimal cross-contamination of LH or TSH. 
hLH was determined using an antiserum directed against 
intact HCG. For radioactive labelling a highly purified hLH 
preparation (code hLH/LN) was used, prepared as described by 
Closset et al (1972). This preparation has a biological 
activity of 8000 lU/mg (2nd IRP-HMG as measured by the ovarian 
ascorbic acid depletion test). Its immunological activity is 
16000 lU/mg (2nd IRP-HMG) and it is minimally cross-contamina-
125 ted with FSH (less than 10 lU/mg, bioassay). Two mCi Na I 
were reacted with 5 ug of hLH in the presence of 5 yg of chlo-
ramine-T. Specific activities of 170 to 200 pCi/ug were usually 
125 -
obtained. The removal of non-reacted I and purification of 
the labelled hLH just prior to assay were performed by the 
125 -
methods described above for I hFSH. In this procedure the 
desorbed radioactive peak contains the labelled hLH which is 
highly immunoreactive. The anti-HCG serum used for the deter­
mination of LH was carefully selected. Testing the reactivity 
of highly purified pituitary LH (hLH/LN) and FSH (hFSH - CPDS/ 
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2) preparations as well as a crude LH/FSH preparation (LER 907) 
and a crude urinary preparation (2nd IRP-HMG) with two anti-
HCG sera, it was found that one of the antisera ft 349 (gift 
from Dr. Schuurs, Organon, Oss) reacted less with highly puri­
fied FSH than the other antiserum. Consequently, the crude 
pituitary and urinary preparations were less reactive on a mass 
basis. Details on the selection of the anti-HCG serum used are 
given elsewhere (Rolland et al (1974). For the determination 
of plasma LH and FSH levels the urinary 2nd IRP of HMG was 
chosen as a standard, the reason for this being that dilution 
curves of plasma samples of menstrual cycle peaks or from post-
menopausel women and patients with Klinefelter's syndrome gave 
the best fit of parallelism with the 2nd IRP as standard, i.e. 
gave the smallestcoefficient of variation. It should be 
mentioned here that the standard curves were set up with plasma 
from a long term castrated male sheep. The volume of sheep 
plasma was equal to that of the test samples (100 μΐ). After 
incubation, the antibody bound (B) and free (F) fractions were 
separated by means of a double antibody solid phase technique 
(DASP, Organon, Oss). The standard curve and the amount of 
hormone present in the test samples were calculated by means of 
a computer program, kindly made available by Dr. David Rodbard, 
N.I.H. Bethesda. Normal LH levels found in 132 plasma samples 
from 17 eugonadal males ranged from 7 to 55 mlU/ml (mean + S.D. 
27.8 + 12.9 mlU/ml). FSH levels in these subjects ranged from 
0.8 to 13 mlU/ml (mean + S.D.: 4.1 + 2.2 mlU/ml). From dupli­
cate analyses of plasma samples the intra-assay variation was 
calculated to be 11.5 % for both LH and FSH. Statistical 
analyses were performed using Wilcoxon's signed rank test (Ρ), 
Wilcoxon's two sample test (P*) and Spearman's rank correlation 
test (P**). 
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RESULTS 
Effect of three different doses of ethinylestradiol (ЕЕ) on 
plasma testosterone levels (Table 1 and 2, Figure 1, 2 and 3). 
The mean basal plasma testosterone levels did not show 
significant day-to-day variation, neither in the eugonadal 
males (P*> 0.30), nor in the Klinefelter patients (P*> 0.50). 
In each of the 3 ЕЕ courses mean pretreatment testosterone 
levels in the Klinefelter patients were significantly (P*< 
0.05) lower than the corresponding means in the eugonadal 
controls. 
Each dose of ЕЕ administration, even the lowest of 15 yg 
daily induced a significant decrease of plasma testosterone 
(P < 0.05) in all male controls. The mean percentage testoste­
rone suppression after 150 pg of ΈΈ daily (79.6 + 10.'4 (S.D.) 
%) was significantly more pronounced (P*< 0.01) than the 
decrease of the hormone's level observed after both 30 yg 
(31.3 + 19.3 (S.D.) %) and 15 pg of ЕЕ daily (23.2 + 14.5 
(S.D.) % ) . The difference in the relative decreases of testos­
terone induced by both lower doses was not statistically sig­
nificant (P*= 0.50). 
In each of the 6 Klinefelter patients a clear suppression 
of plasma testosterone levels was obtained after 30 and 150 yg 
of ЕЕ daily (P < 0.05). No consistent decrease was observed 
after 15 yg. The mean absolute (110 + 43 (S.D.) ng/100 ml vs 
193 + 40 (S.D.) ng/100 ml) and relative (32.5 + 18.6 (S.D.) % 
vs 60.9 + 7.6 (S.D.) %) (P < 0.05) plasma testosterone decreas­
es observed after administration of 30 yg of ЕЕ daily were 
significantly lower than the corresponding decreases observed 
after 150 yg of ЕЕ daily. It should be noted that the mean 
percentage fall in the Klinefelter patients after the highest 
ЕЕ dose (60.9 + 7.6 (S.D.) %) was slightly, though significant-
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TABLE 1 
THE EFFECT OF ETHINYLESTRADIOL (ЕЕ) ADMINISTRATION (15, 30 AND 150 дд DAILY 
FOR 7 DAYS) ON PLASMA TESTOSTERONE, LH AND FSH LEVELS IN 6 EUGONADAL MALES 
15 ¿ig OF ЕЕ DAILY FOR 7 DAYS 30 цд OF ЕЕ DAILY FOR 7 DAYS 150 μ9 OF ЕЕ DAILY FOR 7 DAYS 
SUBJECT 
1 
2 
3 
4 
5 
6 
MEAN 
± 
S D 
1 
2 
3 
4 
5 
6 
BEFORE 
627 
391 
1154 
533 
568 
772 
674 
± 
266 
24 1 
23 8 
2 1 8 
7 5 
8 1 
20 9 
AFTER 
511 
323 
631 
342 
475 
727 
501 
+ 
159 
185 
138 
119 
9 6 
5 8 
162 
Δ A B S * 
-116 
- 68 
-523 
-191 
- 93 
- 45 
- 1 7 2 
± 
178 
- 5 6 
- 100 
- 9 9 
+ 2 1 
- 2 3 
- 4 7 
Δ%* 
- 1 8 5 
- 174 
- 4 5 3 
- 3 5 9 
- 1 6 4 
- 6 
- 2 3 2 
+ 
145 
- 2 3 2 
- 4 3 0 
- 4 5 4 
+ 28 0 
- 2 8 3 
- 2 9 0 
MEAN 
+ 
S D 
1 
2 
3 
4 
5 
6 
MEAN 
+ 
S D 
177 
7 8 
126 
4 6 
- 5 1 
4 6 
•23 5 
26 6 
5 3 
3 3 
1 1 
2 6 
1 0 
3 6 
2 8 
t 
1 6 
5 3 
2 4 
0 5 
1 5 
0 5 
2 5 
2 1 
+ 
18 
- 0 
- 0 9 
- 0 6 
- 1 1 
- 0 0 
- 1 1 
- 0 7 
± 
0 4 
- 0 
- 2 7 2 
- 5 4 5 
- 4 2 3 
- 5 0 0 
- 3 0 6 
- 3 4 1 
± 
198 
BEFORE 
570 
422 
1162 
477 
1000 
704 
722 
± 
298 
20 1 
23 8 
193 
12 1 
10 6 
219 
18 0 
AFTER 
492 
407 
557 
310 
520 
456 
457 
+ 
89 
184 
158 
160 
8 8 
105 
127 
137 
Δ ABS 
- 78 
- 15 
-605 
-167 
-480 
-248 
-265 
± 
232 
- 1 7 
- 8 0 
- 3 3 
- 3 3 
- 0 1 
- 9 2 
- 4 3 
Δ % 
- 13 7 
- 3 5 
- 5 2 6 
- 3 5 0 
- 4 8 0 
- 3 5 2 
- 3 1 3 
± 
193 
- 8 5 
- 3 3 6 
- 1 7 0 
- 2 7 2 
- 1 0 
- 4 2 
- 2 1 6 
5 4 3 7 3 6 155 
5 1 
3 5 
0 9 
2 5 
1 1 
1 9 
2 5 
± 
1 6 
2 4 
1 9 
0 5 
1 1 
0 3 
0 8 
1 2 
± 
0 8 
- 2 7 
- 1 6 
- 0 4 
- 1 4 
- 0 8 
- 1 1 
- 1 3 
± 
0 8 
- 5 2 9 
- 4 5 7 
- 4 4 4 
- 5 6 0 
- 7 2 0 
- 5 7 9 
- 5 4 8 
± 
100 
BEFORE 
722 
349 
489 
383 
833 
693 
578 
± 
198 
22 3 
23 7 
190 
115 
128 
18 9 
180 
± 
4 9 
5 5 
4 0 
1 7 
2 4 
0 8 
1 7 
2 7 
± 
1 7 
AFTER 
230 
65 
29 
92 
95 
212 
120 
± 
81 
137 
124 
112 
8 8 
11 4 
15 1 
12 1 
± 
2 2 
0 8 
0 6 
< 0 2 
0 3 
< 0 2 
0 9 
0 5 
+ 
0 3 
Δ ABS 
-492 
-284 
-460 
-291 
-738 
-481 
458 
± 
166 
- 8 6 
- 11 3 
- 7 8 
- 2 7 
- 1 4 
- 3 8 
- 5 9 
± 
3 9 
- 4 7 
- 3 4 
- 1 5 
- 2 1 
- 0 6 
- 0 8 
- 2 2 
+ 
1 6 
л% 
- 6 8 1 
- 8 1 3 
- 9 4 0 
- 7 6 0 
- 8 8 6 
- 6 9 4 
79 6 
± 
104 
- 3 8 6 
- 4 7 7 
- 4 1 0 
- 2 3 5 
- 109 
- 2 0 1 
- 3 0 3 
± 
14 2 
- 8 5 4 
- 8 5 0 
- 8 8 2 
- 8 7 5 
- 7 5 0 
- 4 7 0 
- 7 8 
+ 
159 
*Δ abs and Δ % mean the absolute and relative decrease respectively 
TABLE 2 
THE EFFECT OF ETHINYLESTRADIOL(EE) ADMINISTRATION (15, 30 AND 150 дд DAILY 
FOR 7 DAYS) ON PLASMA TESTOSTERONE, LH AND FSH LEVELS IN 6 PATIENTS WITH 
KLINEFELTER'S SYNDROME 
15 ¿ig OF ЕЕ DAILY FOR 7 DAYS 30 дд OF ЕЕ DAILY FOR 7 DAYS 150 μ 9 OF ЕЕ DAILY FOR 7 DAYS 
SUBJECT 
1 
2 
3 
4 
5 
6 
MEAN 
+ 
S D 
1 
2 
3 
4 
5 
6 
MEAN 
± 
S D 
1 
2 
3 
4 
5 
6 
MEAN 
± 
S D 
BEFORE 
371 
507 
223 
300 
333 
416 
358 
± 
98 
122 0 
618 
70 6 
128 6 
1175 
87 0 
97 9 
± 
28 5 
98 0 
30 5 
27 0 
49 4 
31 1 
45 5 
46 9 
± 
26 6 
AFTER 
234 
515 
299 
155 
234 
458 
316 
± 
141 
122 5 
71 6 
79 1 
84 3 
94 8 
111 0 
93 9 
± 
196 
84 4 
24 0 
42 9 
26 9 
24 7 
36 5 
39 9 
± 
23 0 
Δ ABS * 
-137 
+ 8 
+ 76 
- 145 
- 99 
+ 42 
- 42 
± 
96 
+ 0 5 
+ 9 8 
+ 8 5 
- 4 4 3 
- 2 2 7 
+ 24 0 
- 4 0 
+ 
25 0 
- 1 3 6 
- 6 5 
+ 159 
- 2 2 5 
- 6 4 
- 90 
- 7 0 
+ 
12 7 
Δ % * 
- 3 7 0 
+ 1 6 
+ 34 0 
- 4 8 0 
- 3 0 0 
+ 100 
- 1 1 5 
+ 
31 7 
+ 0 4 
+ 158 
+ 120 
- 3 4 5 
- 1 9 3 
+ 27 5 
+ 0 3 
+ 
23 0 
- 1 3 9 
- 2 1 3 
+ 58 9 
- 4 5 5 
- 2 0 6 
- 1 9 7 
- 1 0 3 
± 
35 7 
BEFORE 
342 
563 
288 
254 
307 
510 
377 
± 
127 
134 4 
88 0 
72 2 
120 1 
137 1 
104 3 
109 3 
± 
26 0 
83 6 
39 8 
32 0 
62 3 
35 4 
70 7 
53 9 
+ 
21 2 
AFTER 
253 
445 
226 
115 
131 
437 
267 
± 
144 
1189 
79 3 
69 8 
88 5 
122 6 
98 2 
9 6 ? 
± 
213 
43 3 
196 
34 3 
30 7 
22 0 
34 7 
30 8 
+ 
8 8 
Δ ABS 
- 89 
-118 
- 62 
-139 
-176 
- 73 
-110 
± 
43 
- 1 5 4 
- 8 7 
- 2 4 
- 3 1 6 
- 14 5 
- 6 1 
- 1 3 1 
± 
103 
- 4 0 3 
- 2 0 2 
+ 2 3 
- 3 1 6 
- 134 
- 3 6 0 
- 2 3 2 
± 
160 
Δ % 
- 2 6 0 
- 2 0 9 
- 2 1 5 
- 5 4 7 
- 5 7 3 
- 143 
- 3 2 5 
± 
186 
- 1 1 4 
- 9 9 
- 3 3 
- 2 6 3 
- 1 0 6 
- 5 8 
- 1 1 2 
+ 
8 0 
- 4 8 2 
- 5 0 7 
+ 7 0 
- 5 0 7 
- 3 7 8 
- 5 0 8 
- 3 8 6 
± 
22 9 
BEFORE 
357 
474 
258 
224 
263 
375 
325 
+ 
94 
1170 
109 6 
63 4 
124 0 
1120 
127 0 
108 8 
± 
27 1 
123 9 
30 0 
22 1 
60 6 
33 7 
59 0 
54 9 
± 
37 3 
AFTER 
167 
207 
87 
73 
80 
176 
132 
± 
58 
96 0 
66 9 
45 8 
73 1 
25 1 
69 8 
62 8 
± 
24 4 
33 8 
7 1 
128 
154 
5 2 
135 
14 6 
± 
102 
Δ ABS 
- 190 
-267 
-171 
-151 
-183 
-199 
-193 
± 
40 
- 2 1 0 
- 4 2 7 
- 1 7 6 
- 5 0 9 
- 8 6 9 
- 5 7 2 
- 4 6 0 
+ 
25 5 
90 1 
- 2 2 9 
- 9 3 
- 4 5 2 
- 2 8 5 
- 4 5 5 
- 4 0 3 
+ 
28 0 
Δ % 
- 5 3 2 
- 5 6 3 
- 6 6 2 
- 6 7 4 
- 6 9 6 
- 5 3 0 
- 6 0 9 
± 
7 6 
- 1 8 0 
- 3 9 0 
- 2 7 7 
- 4 1 0 
- 7 7 6 
- 4 5 0 
- 4 1 4 
± 
20 3 
- 7 2 5 
- 7 6 3 
- 4 2 0 
- 7 4 6 
- 8 5 4 
- 7 7 1 
- 7 1 3 
± 
150 
* Δ abs and Δ % mean the absolute and relative decrease respectively 
Figure 1 
Summary of the effect of 3 different doses cf ethinylestradiol 
on plasma testosterone, LH and FSH levels in 6 eugonadal males. 
The shaded areas represent the normal ranges (plasma testoste­
rone 314 to 1337 ng/100 ml, plasma LH 7 to 55 mIU/ml and plasma 
FSH 0.8 to 13 mIU/ml). 
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Figure 2 
Summary of the effect of 3 different doses of ethinylestradiol 
on plasma testosterone, LH and FSH levels in 6 patients with 
Klinefelter's syndrome. The shaded areas represent the normal 
ranges (cfr. fig. 1) . 
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Figure 3 
The relative changes of plasma testosterone, FSH and LH levels 
in 6 patients with Klinefelter's syndrome and б eugonadal male 
controls by 3 different doses of ethinylestradiol. 
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ly less than in the eugonadal males (79.6 + 10.4 (S.D.) %) 
(P*< 0.02) . 
Effect of three different doses of ethinylestradiol (ЕЕ) on 
plasma LH and FSH levels (Table 1 and 2, Figure 1, 2 and 3) . 
Mean plasma LH and FSH levels before estrogen treatment 
did not show significant day-to-day variation, neither in the 
eugonadal males (P*> 0.75) nor in the Klinefelter patients 
(P*> 0.35). In each of the 3 ЕЕ courses the mean basal LH and 
FSH levels in the Klinefelter patients were significantly 
higher (P*< 0.05) than the corresponding values in the control 
subjects. Neither in the eugonadal males (p = - 0.16 (P** > 
0.10) and - 0.41 (0.05 < P** < 0.10) respectively) nor in the 
Klinefelter patients (p = - 0.16 (P** > 0.10) and +0.18 (P** 
s 
> 0.10) respectively) basal testosterone levels were signifi­
cantly correlated with the corresponding LH and FSH levels. 
After administration of 30 and 150 vg of ЕЕ daily plasma 
LH levels significantly decreased (P < 0.05) in the eugonadal 
males. Even after the lowest dose a distinct LH decrease was 
observed in 5 of the 6 subjects studied. The absolute and per­
centage decreases after 15, 30 and 150 \ig of ЕЕ daily were of 
the same order of magnitude and were not differing significant­
ly (P*> 0.30) . 
In the Klinefelter patients a significant suppression 
(P < 0.05) of the elevated LH levels was obtained with doses 
of 30 and 150 yg of ЕЕ daily. The response after administration 
of 15 ]sg was inconsistent. The mean absolute (46.0 + 25.5 (S.D.) 
mlU/ml vs 13.1 + 10.3 (S.D.) mIU/ml) and relative (41.4 + 20.3 
(S.D.) % vs 11.2 + 8.0 (S.D.) %) LH decreases after 150 yg of 
ЕЕ daily were significantly higher (P*< 0.01) than the corres­
ponding decreases after 30 yg. The relative decline of LH 
values in the Klinefelter patients after both higher doses of 
ЕЕ (30 and 150 yg daily) was of the same order of magnitude as 
in the eugonadal males (P*= 0.31 and 0.42 respectively). Never­
theless in all Klinefelter patients the LH levels remained 
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clearly supranormal even after the highest dose of ЕЕ, except 
in two patients (nos 3 and 5). Although higher doses of estro-
genshad a significantly stronger suppressive effect on both 
plasma testosterone and LH levels in the Klinefelter patients, 
no significant correlation could be demonstrated between the 
estrogen induced LH and testosterone decreases (P** > 0.10) in 
any of the 3 ЕЕ courses. 
In the eugonadal males plasma FSH levels lowered signifi­
cantly after administration of 30 and 150 ug of ЕЕ daily. Even 
after the lowest dose of 15 yg daily a distinct FSH decrease 
was found in 5 of the 6 subjects. Interestingly the ЕЕ induced 
relative FSH decreases appeared to be dose dependent, the mean 
decrease after 150 yg being significantly higher than after 30 
and 15 yg of ЕЕ daily (P* < 0.05 and < 0.02 respectively). It 
is noteworthy that the mean relative FSH decreases in response 
to the administration of 30 and 150 yg of ЕЕ were significantly 
higher than the corresponding LH decreases (P*< 0.01 and < 0.01 
respectively). 
In the Klinefelter patients a significant suppressive 
effect on plasma FSH levels was observed after 150 yg of ЕЕ 
daily. In 5 of the 6 patients the lower doses also induced a 
distinct FSH decrease. Interestingly, the estrogen induced FSH 
suppression proved to be dose related, the higher relative 
decrease being observed after the higher dose (71.3 + 15.0 
(S.D.) % after 150 yg of ЕЕ > 38.6 + 22.9 (S.D.) % after 30 yg 
(P* < 0.05) > 10.3 + 35.7 (S.D.) % after 15 yg (P*< 0.05). 
It should be noted that after the administration of 150 yg 
of ЕЕ daily in 3 of the patients previously elevated FSH levels 
fell into the normal range. However, by comparing the patients' 
FSH levels with those of the controls both after estrogen 
administration, it appeared that the patients' levels still are 
significantly higher. Although in the Klinefelter patients the 
estrogen induced FSH suppression after 30 and 150 yg of ЕЕ 
tended to be more pronounced than the corresponding suppression 
of LH the difference lacked convincing significance (0.05 < P* 
< 0.10). Comparing the relative estrogen induced FSH and testo­
sterone decreases no significant correlation (P** > 0.10) was 
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found in any of the 3 courses, though it has to be reminded 
that FSH and testosterone decreases were more pronounced the 
higher the ЕЕ dose. 
Effect of gonadotropin administration on plasma testosterone 
levels with and without prior ЕЕ treatment (Table 3, Figure 4). 
After short term HCG administration plasma testosterone 
levels distinctly increased not only in the control subjects 
but also, though definitely less, in the Klinefelter patients. 
The absolute testosterone increase in the eugonadal males 
ranged from 478 to 1233 ng/100 ml (mean 807 ng/100 ml) and in 
the Klinefelter patients from 89 to 245 ng/100 ml (mean 135 ng/ 
100 ml). 
After ЕЕ administration (150 yg daily) plasma testosterone 
levels in the control subjects clearly declined from a mean 
value of 522 ng/100 ml before to 111 ng/100 ml after 7 days of 
estrogen treatment and in the Klinefelter patients from 324 to 
141 ng/100 ml. Despite continuing ЕЕ administration, simulta­
neously given HCG induced a distinct rise in plasma testostero­
ne levels in both the eugonadal males (851 ng/100 ml) and the 
Klinefelter patients (281 ng/100 ml). These increments were 
quantitatively comparable with those observed in both groups 
after HCG administration without concomitant estrogen treat­
ment. 
DISCUSSION 
The feedback control of pituitary gonadotropin release 
has been the objective of many studies in recent years. Besides 
a role of androgens (Lipsett et al (1966), Odell et al (1966) , 
Swerdloff and Odell (1968), Lee et al (1972) and Sherins and 
Loriaux (1973) more recently an important role of estrogens in 
the regulation of LH and FSH and thereby of testicular function 
has become apparent (Swerdloff and Odell (1968), Alder et al 
(1968), Stewart-Bentley et al (1971), Kulin and Reiter (1972) 
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Table 3 
PLASMA TESTOSTERONE (T) RESPONSE TO HCG (PREGNYL, 1500 IЛІ. FOR 3 DAYS) 
ADMINISTRATION WITHOUT AND DURING 3 X 50 ug OF ETHINYLESTRADIOL (ЕЕ) DAILY 
RESPONSE TO HCG 
WITHOUT ЕЕ ADMINISTRATION 
Τ BEFORE HCG 
(ng/100 ml) 
Τ DURING HCG 
(ng/100 ml) 
RESPONSE TO HCG 
DURING ЕЕ ADMINISTRATION 
Τ BEFORE ЕЕ 
BEFORE HCG 
(ng/100 ml) 
Τ DURING ЕЕ 
BEFORE HCG 
(ng/100 ml) 
Τ DURING ЕЕ 
DURING HCG 
(ng/100 ml) 
ui 
о 
EUGONADAL 
MALES 
no 3 
4 
6 
mean (ng/100 
+ 
S.D. 
KLINEFELTER 
PATIENTS 
no 2 
5 
7 
8 
9 
mean (ng/100 
+ 
S.D. 
ml) 
ml) 
540 
430 
685 
552 
+ 
128 
474 
263 
308 
290 
520 
371 
+ 
117 
1250 
1663 
1163 
1359 
+ 
269 
570 
390 
397 
535 
640 
506 
+ 
113 
489 
383 
693 
522 
+ 
149 
496 
253 
257 
284 
333 
324 
+ 
102 
29 
92 
212 
111 
+ 
93 
207 
80 
132 
166 
121 
141 
+ 
48 
743 
1000 
1144 
962 
+ 
203 
503 
270 
416 
436 
486 
422 
+ 
92 
Figure 4 
Plasma testosterone response to HCG (pregnyl, 1500 IU daily for 
3 days) administration without and during 3 χ 50 ug of 
ethinylestradiol (ЕЕ) daily in eugonadal males and patients 
with Klinefelter's syndrome. 
0 2 0 2 Μ 6 β 1 0 0 2 
days 
ι ι ι ι ι ι ι Γ 
0 1 M 6 β 10 
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and Sherins and Lonaux (1973). 
In this study the effects of varying doses of the orally 
admimstrable estrogen, ethinylestradiol (ЕЕ) , on plasma tes­
tosterone and gonadotropin levels have been evaluated. As 
appears from our results plasma testosterone, LH and FSH levels 
were clearly suppressed by every dosage used in this study in 
almost all normal subjects. Interestingly, in contrast to the 
decrease of LH, the decrease of plasma testosterone and FSH 
levels appeared to be roughly dose related. 
It is clear from the data reported here that even low 
doses of estrogens can modulate pituitary gonadotropin produc­
tion and release and thereby testicular androgen secretion. 
Kulm and Reiter (1972) who also utilized ethinylestradiol as 
an oral estrogen, observed a significant suppression of FSH 
levels, but no consistent effect on LH after daily administra­
tion of 30 and 40 ug of this drug for 7 days. Using the 
naturally occurring steroid estradiol = in a dose of 40 yg of 
E2/1.7m2/day intravenously for 2 days = Stewart-Bentley et al 
(1971) reported a significant fall of plasma testosterone and 
LH levels in 7 eugonadal males. In a comparable study, Sherins 
and Lonaux (1973) observed a distinct suppression of plasma 
testosterone (50 %) and both LH and FSH levels (30 %) in 4 out 
of 5 normal males after 4 days infusion of estradiol at a 
dosage of 90 yg daily. 
The physiological estradiol production in normal men has 
been estimated to be about 40 pg daily (Baird et al (1968) , 
Kelch et al (1972) and Kirschner and Taylor (1972) primarily 
resulting from peripheral conversion of testosterone (Baird et 
al (1968) but also from direct secretion by the testis (Kelch 
et al (1972), Kirschner and Taylor (1972). 
With regard to the lowest dose of the synthetic estrogen 
ethinylestradiol, used in this study, it should be noted, that 
15 yg of ЕЕ have been reported to be roughly equivalent to 4 5 
yg of estradiol (Burger et al (1972). Therefore the results 
obtained with the lowest dose of 15 yg ЕЕ strongly suggest a 
role of endogenous estrogens m the pituitary-gonadal axis 
although it has to be admitted that a final proof of this 
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statement would necessitate measuring the endogenous estrogen 
levels. 
Recently, arguments have been given that in Klinefelter's 
syndrome abnormalities in the pituitary-gonadal axis are not 
confined to the well known testicular lesion, but are also 
discernible at the level of the feedback control of LH and FSH 
production and release (Stewart-Bentley et al (1971), Capell et 
al (1973) . With this literature in mind it was thought worth­
while to study estrogen suppression of pituitary-gonadal 
function in patients with Klinefelter's syndrome and to compare 
the results with those reported above for normal subjects. 
Plasma LH and FSH levels in the patients with Klinefelter's 
syndrome appeared to be strongly elevated even in the presence 
of normal plasma testosterone levels, confirming earlier data 
reported by a number of investigators (Paulsen et al (1968), 
de Kretser et al (1972), Anderson et al (1972), Stewart-Bentley 
and Horton (1973) and Smais et al (1973) (1974 b) . Despite this 
hypergonadotropism a clear dose dependent suppression of plasma 
testosterone, LH and FSH levels was observed after administra­
tion of 30 and 150 pg of ЕЕ daily. The decline in plasma tes­
tosterone levels is noteworthy in view of the fact that the 
gonadotropin levels, though distinctly decreasing, rarely 
reached normal values and remained clearly supranormal in com­
parison with the estrogen suppressed gonadotropin levels in the 
eugonadal controls. This concomitant decrease of plasma FSH, LH 
and testosterone levels in Klinefelter's syndrome indicates a 
regulatory role of these pituitary factors on gonadal function. 
Earlier it was reported from this laboratory (Smais et al 
(1974 b) that exogenous administration of gonadotropins (HCG) 
can significantly increase plasma testosterone levels in 
Klinefelter's syndrome though distinctly less than in normal 
men. This suggests that gonadotropins still can modulate gona­
dal function in patients with Klinefelter's syndrome. Whereas 
this regulatory function is qualitatively similar to that in 
eugonadal controls, the results in this study indicate that in 
a quantitative sense plasma LH and testosterone levels are less 
suppressible by estrogens than in eugonadal males. Indeed after 
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the lowest dose (15 yg daily) of ЕЕ, LH and testosterone levels 
did not decrease in the patients with Klinefelter's syndrome, 
in contrast to the effect in the male controls. 
Therefore in Klinefelter's syndrome both the stimulation 
by gonadotropins at the gonadal level as well as the suppres­
sion of gonadotropin release at the hypothalamic-pituitary 
level are still possible, though at a higher setting. Additio­
nal arguments for this thesis are provided by the finding of 
elevated gonadotropin levels in the presence of normal testos­
terone concentrations in a number of patients with Klinefelter' 
s syndrome. Furthermore, if both testosterone and estrogens 
suppress gonadotropin levels in normal males and in Klinefelter 
patients, the individual data clearly show that during admini­
stration of identical quantities of estrogens similar plasma 
testosterone levels do not lead to a state in which LH and FSH 
levels in both groups are about equal (cfr for instance plasma 
testosterone, LH and FSH levels after 30 \¡g of ЕЕ in normal 
subjects 2 and 6 with the corresponding values in the patients 
2 and 6 (tables 1 and 2). 
In several aspects our data are at variance with earlier 
findings. Very recently Capell et al (1973) reported studies 
in which the effect of short term administration of pharmaco­
logical amounts of testosterone on serum levels of LH, FSH and 
testosterone was evaluated. In their study the effect of andro­
gens on the FSH levels in patients with Klinefelter's syndrome 
and in eugonadal controls appeared to be comparable. However, 
the LH levels showed a biphasic response, an initial decrease 
being followed by a rebound increase to baseline levels or even 
higher during continued supranormal testosterone levels. There­
fore these authors concluded that there is a dichotomy between 
LH and FSH levels observed in Klinefelter's syndrome following 
testosterone administration. They suggested this response 
pattern to indicate that both gonadotropins had separate feed­
back control mechanisms. Comparing our data of the effect of 
estrogen administration with those of Capell et al, regarding 
the effect of testosterone, it does not seem that an analogous­
ly dichotomous feedback regulation of both LH and FSH emanates 
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from our estrogen experiments. This could mean that in Kline­
felter' s syndrome the effect of estrogens in the feedback 
control of production and release of gonadotropins is princi­
pally different from that of androgens. In this context it is 
added that after the higher doses of ЕЕ administration to both 
the Klinefelter patients and the eugonadal males the relative 
decrease of FSH levels tended to be more pronounced than the 
LH decrease. This finding is in accordance with earlier obser­
vations (Peterson et al (1969), Kulin and Reiter (1972) 
claiming a specific role of estrogens in the preferential 
suppression of FSH release. 
The concomitant decrease of both the plasma gonadotropins 
and the testosterone levels during ЕЕ administration in normal 
males and in patients with Klinefelter's syndrome from this 
study do not point to a predominant effect of estrogens at the 
level of the gonads as was claimed in a number of studies 
(Oshima et al (1967), Harper and coworkers (1971), Yanaihara 
and Troen (1972) and Danutra et al (1973), or to an effect on 
the peripheral handling of testosterone (Bird et al (1969), and 
Clark et al (1973) . Indeed the finding that the suppression of 
plasma testosterone levels by ЕЕ could be readily overridden 
by exogenous gonadotropin administration both in the normal 
subjects and the Klinefelter patients is taken as indirect 
evidence of a predominantly gonadotropin mediated plasma tes­
tosterone decrease by ЕЕ (table 3, figure 4). 
In summary, the present study indicates that small amounts 
of estrogens play a role in the pituitary-gonadal axis in 
normal males. Moreover, it illustrates that in patients with 
Klinefelter's syndrome hypothalamic-pituitary-gonadal feedback 
is still operative and is qualitatively comparable with that 
found in eugonadal males. However a number of findings point to 
a higher setting of this feedback mechanism: 1. supranormal 
gonadotropin levels can concur with normal testosterone concen­
trations. 2. estrogens congruently decrease plasma testosterone 
and gonadotropin levels despite persisting hypergonadotropism. 
3. using small amounts of estrogens plasma LH and testosterone 
levels are less suppressed than in normal males. 4. in a number 
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of patients with Klinefelter's syndrome identical amounts of ЕЕ 
lead to plasma testosterone concentrations similar to those 
found in eugonadal controls, despite significantly higher gona­
dotropin levels in the former. 
As a final comment it is added that in this thesis it is 
assumed that peripheral levels of gonadotropins indeed reflect 
the activity of the hypothalamic-pituitary function and plasma 
testosterone levels the gonadal activity. 
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ABSTRACT 
Basal plasma testosterone levels (mean + SD 290 + 141 
ng/100 ml (range 72 - 684 ng/100 ml) in 25 chromatin positive 
patients with Klinefelter's syndrome (23 XXY, 1 XXYY, 1 XY/XXY) 
were significantly lower than in 25 age matched controls (mean 
+ SD 603 + 169 ng/100 ml). In 11 out of the 25 Klinefelter 
patients however, plasma testosterone levels were in the normal 
range and these patients differed significantly from the 
patients with low testosterone levels with respect to the 
clinical state of androgenicity. In the group of Klinefelter 
patients, but not in the controls, a significant negative 
correlationship was found between plasma testosterone levels 
and each of the variables: body weight, arm span, length of the 
lower body segment and the ratio's lower/upper and span/upper 
body segment. 
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Tall stature, longleggedness and increased arm span are 
well known features in a number of patients with Klinefelter's 
syndrome (Pasqualini et al (1957), Stewart et al (1959), Raboch 
(1964), Court Brown et al (1964) Fr01and (1969), Zuppinger et 
al (1967). Some investigators have related these features to 
androgen dificiency for which indirect evidence has been 
obtained by the fact that scanty growth of facial hair has been 
found to be more frequent in patients with eunuchoid body pro-
portions (Pasqualini et al (1957), Court Brown et al (1964), 
Fr01and (1969). Fr01and (1969) however could not demonstrate 
any significant difference in the excretion of the weak 
androgen androsterone between patients with or without 
eunuchoidism. Androsterone excretion however is a poor index 
of the production of more potent androgens. As plasma testoste-
rone levels have been reported to range widely from very low to 
quite normal in patients with Klinefelter's syndrome (Lipsett 
et al (1965), Paulsen et al (1968) it was thought worthwhile 
to study body proportions and the clinical state of androgeni-
city in relation to the levels of this very potent androgen in 
a group of patients with Klinefelter•s syndrome. 
MATERIAL AND METHODS 
Twenty-five white patients with Klinefelter's syndrome 
refered to the endocrine clinic were studied. The mean age was 
31.3 + 11.4 years (range 17 to 55 years). All patients had 
positive sex chromatin bodies and small testes while most of 
them had elevated urinary excretion of gonadotrophins. In all 
but two cases the modal number of chromosomes was 47 and the 
sex chromosome combination XXY. Evidence for mosaicism was 
found in patient number 19 in whom a significant proportion of 
cells counted also had 46 chromosomes. In patient 24 the chro-
mosome constitution was XXYY. The control group consisted of 25 
eugonadal healthy male subjects matched for age (mean + SD 33.8 
+ 9.3 years, range 19 to 55 years). Detailed clinical investi-
gation included search for evidence of eunuchoid body 
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proportions. The upper body segment was evaluated by measuring 
the sitting height and the lower body segment by subtracting 
the sitting height from the standing height. The arm span was 
measured with the patient standing with his back against the 
wall. Detailed information on the growth of facial hair was 
obtained from 21 patients aged 20 years or more. Pubic hair 
distribution was regarded to be feminine if a horizontal lining 
was present. 
Blood samples for testosterone determination were collec-
ted between 8 a.m. and 10 a.m.. After sampling the heparinized 
blood was centrifuged, the plasma removed and aliquots 
immediately frozen and stored at - 20 0C. In 17 out of the 25 
patients with Klinefelter's syndrome at least two separate 
blood samples were collected for testosterone determination. 
Plasma testosterone was assayed by the competitive protein 
binding method of Mayes and Nugent (1968) with slight modifica-
tions (Benraad et al (1972). From duplicate analysis of male 
plasma samples on the same or on separate days an intra-assay 
variation was calculated of 3.2 % and an inter-assay varic.tion 
of 4.2 %. Normal plasma testosterone values found at 8 a.m. in 
56 adult men ranged from 314 to 1337 ng/100 ml with a mean SD 
of 568 + 198 ng/100 ml and from 12 to 69 with a mean of 30 + 15 
ng/100 ml in 23 healthy women. 
Statistical analysis was performed by using Wilcoxon's two 
sample test (P ), Spearman's rank correlation test (P ) 
^ w
 c
 s 
(Spearman (1904) and Fisher's exact test for 2 x 2 table for 
studying the interdependency of dichotomous variables (Pf) 
(Fisher (1948). 
RESULTS 
Plasma testosterone levels. 
In table 1 the individual plasma testosterone levels in patients 
with Klinefelter's syndrome are given and in table 2 values for 
the control group are shown. The mean plasma testosterone 
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concentration (table 3) in the group of Klinefelter patients 
was 290 + 141 (SD) ng/100 ml and was significantly lower (P < 
0.001) than the mean of the control group (603 + 169 (SD) 
ng/100 ml). However in eleven patients the plasma testosterone 
levels ranged from 327 to 684 (SD) ng/100 ml, i.e. values which 
fall in the normal range. Neither in the patient's group (p 
Spearman = - 0.317 (P > 0.10) nor in the age matched controls 
(p Spearman = - 0.104 (P > 0.10) could the plasma testosterone 
levels be correlated with age. It has however to be added that 
age of the patients and controls did not range from more than 
17 to 55 years. 
Plasma testosterone levels and body proportions. 
Individual data on body proportions in patients with Klinefel-
ter' s syndrome and in controls are given in tables 1 and 2. In 
table 3 the means of these data have been compared with those 
of the control group. The differences in height and body weight 
between both groups appeared not to be statistically signifi-
cant. Highly significant differences between both groups were 
found in arm span and the length of the lower body segment 
(P < 0.01). Remarkably the length of the upper body segment was 
almost equal in both groups. As follows from table 3 the mean 
of the ratios between the length of the lower and upper body 
segment (lower/upper body segment ratio) was significantly 
higher in the patients with Klinefelter's syndrome than in the 
controls (P < 0.02). The same conclusion holds true for the 
w 
ratio between arm span and the length of the upper body segment 
(span/upper body segment ratio) (P < 0.01). 
In table 4 the Spearman correlation coefficients are given 
between the individual plasma testosterone concentrations and 
the various body measurements. In the 25 eugonadal control 
subjects testosterone levels were not significantly correlated 
with any of the body measurements. In the group of Klinefelter's 
patients however a significant negative correlation was found 
between the hormone levels and each of the variables: arm span, 
length of the lower body segment and the ratio lower/upper and 
span/upper body segment. The low though still significant 
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Table 
CLINICAL AND CHEMICAL DETAILS OF 25 
SUBJECT AGE KARYO- GYNAECO- MALE SHAVING HEIGHT 
NUMBER (YRS) TYPE MASTIA PUBIC FREQUENCY (CM) 
HAIR (TIMES/WK) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
23 
18 
22 
38 
32.5 
52 
21.5 
19 
55 
19 
21 
25 
29 
45 
17 
40 
35 
20 
30 
30 
26 
37 
39 
53 
35 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XXY 
XY/XXY 
XXY 
XXY 
XXY 
XXY 
XXYY 
XXY 
+ 
+ 
-
-
+ 
-
+ 
-
-
+ 
+ 
+ 
-
+ 
+ 
+ 
-
+ 
-
+ 
+ 
-
+ 
+ 
-
+ 
+ 
+ 
+ 
-
+ 
+ 
-
+ 
-
+ 
+ 
-
+ 
-
-
-
-
+ 
-
-
-
-
-
-
3 
_# 
3 
7 
1 
7 
0 
_# 
7 
_* 
7 
0 
1 
3 
_* 
1 
1 
0 
3 
0 
2 
2 
2 
1 
1 
172 
172 
176 
186 
181 
169 
181 
179 
176 
192 
184 
182 
187 
185 
189 
184 
179 
183 
192 
179 
182 
188 
191 
174 
177 
patients less than 20 years of age 
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1 
PATIENTS WITH KLINEFELTER'S SYNDROME 
WEIGHT SPAN UPPER LOWER 
(KG) (CM) BODY SGT BODY SGT 
(CM) (CM) 
73.5 
65.0 
68.0 
66.0 
85.0 
68.3 
67.0 
56.0 
93.0 
85.0 
72.7 
74.7 
87.8 
99.9 
87.0 
90.0 
59.1 
96.0 
90.5 
61.0 
91.5 
90.0 
95.0 
71.2 
93.5 
172 
177.5 
178 
187 
183 
178 
186.5 
179 
179.5 
198 
180 
185.5 
198 
190 
195 
194 
185 
188 
194 
182 
183.5 
196 
198 
185 
186 
89 
89 
90 
93 
93 
84 
92 
92 
93 
98 
94.5 
91.5 
97 
94.5 
94 
89 
86 
90 
95 
86 
90 
90 
91 
85 
83 
83 
83 
86 
93 
88 
85 
89 
87 
83 
94 
90 
91 
90 
91 
95 
95 
93 
93 
97 
93 
92 
98 
100 
8' 
9· 
RATIO RATIO PLASMA 
LOWER/UPPER SPAN/UPPER TESTOSTERONE 
BODY SGT BODY SGT (ng/100 ml) 
0.932 
0.933 
0.955 
1.000 
0.946 
1.011 
0.967 
0.945 
0.892 
0.959 
0.952 
0.994 
0.927 
0.962 
1.010 
1.067 
1.081 
1.033 
1.021 
1.081 
1.022 
1.088 
1.098 
1.047 
1.138 
1.933 
1.933 
1.978 
2.010 
1.968 
2.119 
2.027 
1.946 
1.930 
2.020 
1.905 
2.027 
2.041 
2.016 
2.074 
2.180 
2.151 
2.089 
2.042 
2.116 
2.039 
2.178 
2.176 
2.177 
2.240 
684 
517 
450 
391 
384 
383 
375 
361 
360 
331 
327 
290 
279 
255 
253 
239 
226 
219 
197 
182 
179 
135 
90 
86 
72 
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Table 
SUBJECT AGE HEIGHT 
NUMBER (YRS) (CM) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
41 
22 
29 
37 
22 
32 
40 
19 
35 
31 
29 
41 
32 
24 
42 
51 
55 
37 
47 
39 
27 
30 
25 
23 
36 
174 
178 
182 
183 
175 
184 
168 
180 
182 
176 
185 
169 
171 
188 
175 
178 
169 
167 
178 
182 
179 
169 
189 
182 
184 
CLINICAL AND CHEMICAL DETAILS 
WFIGHT SDAM UPPER BODY 
(KG) (CM) SEGMENT (CM) 
67.2 
64.5 
70.8 
83.0 
75.0 
88.0 
67.0 
72.4 
73.5 
83.0 
74.0 
73.0 
66.5 
82.0 
89.0 
84.0 
81.5 
73.6 
81.0 
82.0 
71.5 
64.0 
80.0 
72.7 
69.0 
1.79 
1.80 
1.82 
1.85 
1.77 
1.86 
1.68 
1.84 
1.86 
I.79Î5 
1.85 
1.76 
1.74 
1.87 
1.76 
1.80 
1.76 
1.72 
1.83 
1.81 
1.78 
1.69 
1.93 
1.82 
1.92 
92 
90 
96 
94 
89 
91 
88 
93 
90 
90 
95 
88 
85 
94 
93 
90 
87 
90 
91 
93 
95 
86 
96 
93 
90 
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2 
OF 2 5 CONTROL SUBJECTS 
LOWER BODY RATIO RATIO PLASMA 
SEGMENT (CM) LOWER SPAN TESTOSTERONE 
BODY SGT 
UPPER UPPER BODY SEGMENT (ng/100 nl) 
82 
88\ 
86 
89 
86 
93 
80 
87 
92^ 
86is 
90 
81 
86 
94 
82Î5 
88 
82 
77 
87 
89 
84 
83 
93 
89* 
94 
0.891 
0.983 
0.895 
0.946 
0.966 
1.021 
0.909 
0.935 
1.027 
0.961 
0.947 
0.920 
1.011 
1.000 
0.887 
0.977 
0.942 
0.855 
0.956 
0.956 
П.884 
0.965 
0.968 
0.962 
1.044 
1.946 
2.000 
1.896 
1.968 
1.989 
2.022 
1.909 
2.000 
2.066 
1.994 
1.947 
2.000 
2.023 
1.989 
1.892 
2.000 
2.023 
1.911 
1.956 
1.946 
1.873 
1.965 
2.010 
1.957 
2.133 
953 
920 
833 
805 
746 
741 
704 
690 
669 
648 
646 
606 
596 
565 
552 
537 
509 
482 
468 
462 
430 
397 
387 
385 
349 
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Table 3 
PLASMA TESTOSTERONE CONCENTRATION AND BODY MEASUREMENTS (MEAN + SD) IN 25 EUGONADAL 
MALE CONTROL SUBJECTS AND IN 25 PATIENTS WITH KLINEFELTER'S SYNDROME 
о 
PLASMA TESTOSTERONE 
CONCENTRATION (ng/100 ml) 
HEIGHT (cm) 
WEIGHT (kg) 
SPAN (cm) 
UPPER BODY SEGMENT (cm) 
LOWER BODY SEGMENT (cm) 
RATIO ?;°™l* BODY SEGMENT 
RATIO 
UPPER 
SPAN 
CONTROL SUBJECTS 
(n = 25) 
603.0 + 169 
178.0 + 6.4 
75.5 + 7.3 
180 + 6.2 
91.2 + 3.0 
86.8 + 4.6 
UPPER BODY SEGMENT 
0.952 + 
1.976 + 
0.048 
0.058 
KLINEFELTER PATIENTS 
(n = 25) 
290 + 141 
181.7 + 6.4 
79.4 + 13.3 
186.3 + 7.4 
90.8 + 3.9 
90.9 + 4.7 
1.002 + 
2.053 + 
0.064 
0.094 
WILCOXON 
< 0.0001 
0.05 < Ρ < 0.10 
N.S. 
< 0.01 
N.S. 
< 0.01 
< 0.02 
< 0.01 
Table 4 
INTERDEPENDENCY BETWEEN PLASMA TESTOSTERONE CONCENTRATION AND BODY 
PROPORTIONS IN CONTROL SUBJECTS AND PATIENTS WITH KLINEFELTER'S SYNDROME 
CONTROL SUBJECTS 
(n = 25) 
KLINEFELTER PATIENTS 
(n = 25) 
PLASMA TESTOSTERONE 
CONCENTRATION VERSUS 
HEIGHT 
WEIGHT 
SPAN 
UPPER BODY SEGMENT 
LOWER BODY SEGMENT 
RATIO It2ü^ BODY SEGMENT 
RATIO 
UPPER 
SPAN 
UPPER 
ρ SPEARMAN 
- 0.088 
- 0.055 
- 0.037 
- 0.007 
- 0.151 
P
s 
M.S 
N.S 
N.S 
N.S 
N.S 
BODY SEGMENT 
0.111 
0.037 
M.S. 
N.S. 
ρ SPEARMAN 
- 0.341 
- 0.484 
- 0.530 
+ 0.223 
- 0.730 
- 0.798 
- 0.775 
0.05 · 
< 
< 
< 
< 
< 
Ρ 
s 
: P
s
 < 0.10 
0.02 
0.01 
N.S. 
0.001 
0.001 
0.001 
^ahle 5 
C0HPA4IS04 BETWEEN МЕАМЧ OF BODY PROPORTIONS (+ 4D) BPTWEFN "ATIENTS WI^H KLINEF^L^rP'S 
SYNDROM!: ÍHD LOU OR NORMAL PLASMA TESTOSTFRONF LFVFLS AND FUGONAOAL MALF CONTROLS 
NUMBER OF PATIENTS 
HEIGHT (era) 
WEIGHT {Уд) 
SPAN (cm) 
UPPER BODY SEGMENT (cm) 
LOWER BODY SEGMENT (cm) 
LOWE Ρ 
RATIO BODY SGT 
UPPER 
SPAN 
RATIO 
S I G N I F I C A N ' " DIFFFRFNCES 
BETWFEN PAIRS OF MEANS 
PATIENTS WI^H 
KT^IHEFELTR ' S SYVDROMF 
I I I 
NORMAL PliAS^A LOW PLASMA 
TESTOST ,F r ,OtIE ""ES^OSTERONF 
CONCENTRATION CONCENTRATION 
(-- 3 1 4 n g / 1 0 0 m l ) (< 3 1 4 n g / 1 0 0 m l ) 
CONTROL SUBJECTS 
I I I 
w 
I / I I 
Ρ 
w 
I I / I I I 
Ρ 
vi 
τιτ/τ 
179.0 
72.7 
181.7 
91.4 
87.4 
11 
+ 
+ 
+ 
+ 
+ 
6.9 
10.8 
6.9 
3.8 
3.8 
183.8 
84.8 
190.0 
90.1 
93.7 
14 
+ 
+ 
+ 
+ 
+ 
5. 
13. 
5. 
4, 
3. 
.3 
.0 
.7 
.1 
.1 
178, 
75. 
180. 
91, 
86. 
.0 
.7 
.4 
.2 
.8 
25 
+ 6.4 
± 7 · 3 
+ 6.25 
+ 3.0 
+ 4.6 
N.S. 
< 0.02 
< 0.01 
N.S. 
< 0.001 
< 
< 
< 
< 
0.02 
0.01 
0.0001 
N.S. 
0.0001 
N.4. 
N.S. 
N.S. 
N.S. 
N.S. 
0 . 9 5 4 + 0 . 0 2 9 1 . 0 4 1 + 0 . 0 5 7 
1 . 9 7 9 + 0 . 0 6 1 2 . 1 1 0 + 0 . 0 7 0 
0 . 9 5 2 + 0 . 0 4 8 
1 . 9 7 6 + 0 . 0 5 8 
< 0 . 0 0 1 < 0 . 0 0 0 1 N . S . 
< 0 . 0 0 1 < 0 . 0 0 0 1 N . S . 
UPPER BODY SGT 
correlation (ρ = - 0.484] between the plasma testosterone 
levels and body weight needs additional comment. The partial 
correlation coefficient between the hormone levels and the 
body weight data after correction for the arm span data appea­
red to be not statistically significant (partial correlation 
coefficient body weight versus plasma testosterone corrected 
for the arm span- - 0.285 (P > 0.10b 
In table 5 the patients with Klinefelter's syndrome are 
divided in a group with normal plasma testosterone levels and 
another with low levels. Means of body measurements of these 
groups are compared with eachother and with the corresponding 
data in the control subjects. Remarkably the group of Klinefel­
ter patients with normal testosterone levels (> 314 ng/100 ml) 
did not differ significantly from the eugonadal controls in any 
of the variables i.e. weight, height, arm span, length of the 
lower body segment or the ratios lower/upper body segment and 
span/upper body segment. Though the height and body weight in 
the group of patients with Klinefelter's syndrome as a whole 
did not differ significantly from that in the controls (table 
3) , both parameters proved to be significantly higher in the 
group of patients with low plasma testosterone levels (as com­
pared with the control group (P < 0.02) and < 0.01 respecti­
vely). After correction for height however, using the simple 
formula: height (cm) minus weight (kg) the difference in body 
weight between the two groups was no longer statistically sig­
nificant (P > 0.10). 
w 
Plasma testosterone, clinical state of androgenicity, body 
proportions, and gynaecomastia (tables 6 and 7). 
Fourteen patients with Klinefelter's syndrome had a female and 
11 a male pubic hair distribution. Eleven of the patients with 
female pubic hair belonged to the low testosterone group while 
in 8 out of the 11 patients with a male type of hair distribu­
tion the plasma testosterone levels were normal (table 6). 
Hence male pubic hair distribution appeared to occur more 
frequently in the normal testosterone group and accordingly the 
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Table 6 
CORRELATION OF SOME CLINICAL TRAITS IN PATIENTS WITH KLINEFELTER'S SYNDROME 
MALE 
PUBIC HAIR 
FEMALE 
PUBIC HAIR 
MALE FEMALE 
11 
14 
SHAVING FREQUENCY 
>3 x/WEEKLY <3 χ/WEEKLY EE
2**» 
1 
GYNAECOMASTIA 
YES 
6 
9 
HO 
5 
• 5 
PLASMA TES 
NORMAL 
8 
3 
TOSTERONE 
LOW 
з" 
11 
αϊ 
SHAVING 
FREQUENCY 
3 X WEEKLY 
3 χ WEEKLY 13 11 
YES 
GYNAECOMASTIA 
NO 
15 
10 
NORMAL 
PLASMA 
TESTOSTERONE 
LOW 
11 
14 
1 P f < 0.02 
< 0.001 
the mean plasma testosterone level in the group with a male 
appearance (384 + 132 (SD) ng/100 ml) was significantly higher 
(P < 0.01) than in the group with a female pubic hair distri-
bution (217 + 100 (SD) ng/100 ml) (table 7). Eight of the 11 
patients with male pubic hair and aged at least 20 years had 
normal male type facial hair growth i.e. a shaving frequency 
of at least 3 times weekly (table 6). In contrast none of the 
patients with female type hair distribution had normal facial 
hair growth. In 11 out of the 13 patients with poor beard 
growth the plasma testosterone levels were low. Accordingly the 
mean plasma testosterone level in the patients with normal 
shaving frequency (381 + 146 (SD) ng/100 ml was significantly 
higher (?,< 0.01) than in Klinefelter patients who shaved less 
than 3 times weekly (212 + 102 (SD) ng/100 ml). Considering the 
clinical state of androgenicitv and the body build eunuchoid 
body proportion appeared to be more frequent in those patients 
who had poor facial hair growth or a female pubic hair distri-
bution (table 7). 
Significant gynaecomastia was found in 15 patients with 
Klinefelter's syndrome, nine of whom had lower than normal 
plasma testosterone levels. Half of the remaining patients 
without gynaecomastia however, also had subnormal levels. 
Accordingly the mean plasma testosterone level m the patients 
with gynaecomastia (285 + 124 (SD) ng/100 ml) was not signifi-
cantly different from that in the patients without gynaecomas-
tia (294 + 156 (SD) ng/100 ml (P > 0.10). Furthermore it is 
clear from data in table 6 that the occurrence of gynaecomastia 
in Klinefelter's syndrome was not correlated with the state of 
androgenicity nor with any of the parameters measured to 
characterize body proportions (table 7). 
DISCUSSION 
Increased arm span and longleggedness are well known 
features of male hypogonadism existing at least as early as at 
the age of puberty. The data in the present study reconfirm 
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Table 
CLINICAL STATE OF ANDROGENICITY, 
TESTOSTERONE LEVELS IN PATIENTS 
PUBIC HAIR 
4ALE FEMALE 
NUMBER OF PATIENTS 
HEIGHT (CM) 
WEIGHT (CM) 
SPAN (CM) 
UPPER BODY SEGMENT (CM) 
LOWER BODY SEGMENT (CM) 
LOWER 
RATIO BODY SGT 
UPPER 
SPAN 
RATIO 
UPPER BODY SGT 
PLASMA TESTOSTERONE 
CONCENTRATION (ng/100 ml) 
* 0.05 < Ρ < 0.10 
w 
* Ρ < 0.05 
ν? 
** Ρ,, < 0.01 
W 
156 
179.0 
76.2 
182.5 
91.6 
88.3 
11 
+ 7.2 
+ 12.3 
+ 6.5 
+ 3.6 
+ 4.6 
14 
183, 
82, 
189, 
90, 
93. 
.8 
.0 
.3 
.1 
.0 
+ 
+ 
+ 
+ 
+ 
6, 
14, 
6, 
4, 
3, 
.3 
.0 
. 8 * 
Л 
.6» 
0.965 + 0.038 1.032 + 0.066· 
1.992 + 0.064 2.110 + О.ОВО** 
384 + 132 217 + 100** 
7 
BODY PROPORTIONS AND PLASMA 
WITH KLINEFELTER'S SYNDROME 
FACIAL HAIR GROWTH 
SHAVING FRE04ENCY 
» 3 X WEEKLY < 3 X WEEKLY 
GYNAECOMASTIA 
YES NO 
1 8 0 . 0 
7 9 . 0 
1 8 2 . 3 
9 1 . 6 
8 8 . 5 
0 . 9 6 6 
8 
+ 
+ 
+ 
+ 
+ 
+ 
7 . 9 
1 3 . 3 
7 . 3 
3 . 8 
5 . 0 
0 . 4 3 0 
1 8 2 . 2 
8 1 . 7 
1 8 8 . 5 
8 9 . 5 
9 2 . 7 
1 . 0 3 8 
13 
+ 
+ 
+ 
+ 
+ 
+ 
4 . 6 
1 3 . 2 
5 . 8 ( · ) 
3 . 7 
3 . 5 ' * » 
0 . 0 f ¡ 4 * 
1 8 1 . 0 
7 7 . 2 
1 8 6 . 0 
9 0 . 3 
9 0 . 6 
1 . 0 0 6 
10 
+ 
+ 
+ 
+ 
+ 
+ 
7 . 0 
1 5 . 0 
7 . 7 
4 . 7 
5 . 2 
0 . 0 7 9 
1 8 2 , 
8 1 . 
1 8 6 , 
9 1 , 
91 
1 
. 2 
. 0 
. 5 
. 1 
. 1 
. 0 0 0 
15 
+ 
+ 
+ 
+ 
+ 
+ 
6, 
1 2 , 
7 , 
3 , 
4 
0 
.1 
. 4 
. 5 
. 4 
. 5 
. 0 
1.991 + 0.070 2.108 + 0.082** 2.063 + 0+104 2.045 + 0.090 
381 + 146 212 + 102** 294 + 156 285 + 124 
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these findings are also observed in Klinefelter's syndrome as 
was previously reported by others (vide supra). In contrast to 
Raboch (1957), 1964) who reported the length of the trunk to be 
shorter in patients with Klinefelter's syndrome than in eugona-
dal controls, in Stewart's (1959) and in the current study no 
significant difference was found in the upper body segment 
height between patients with Klinefelter's syndrome and eugona-
dal controls. We must admit however that Raboch's (1957, 1964) 
and our own measurements are not strictly comparable since he 
measured the distance between the incisura jugularis and the 
upper border of the symphysis. 
Though obesity has been reported to be an outstanding 
feature in about half of the patients with Klinefelter's syn-
drome (Becker et al (1966), Becker (1972), Zuppinger et al 
(1967) the present data do not substantiate these findings. 
Though the body weight appeared to be significantly higher in 
Klinefelter patients with low plasma testosterone levels than 
in the controls, after correction for height significant diffe-
rences in body weight were no longer found between the two 
groups. Body proportions in the present study have been charac-
terized by the measurements of arm span, body height and the 
length of the upper body segment and their dependent variables: 
length of the lower body segment and the ratios of both span 
and lower body segment over upper body segment. An interesting 
finding of this study was that the lower the plasma testostero-
ne levels in Klinefelter's syndrome, the greater the arm span 
and lower body segments, and the greater the ratio's of both 
arm span and lower body segments over upper body segment. The 
closest correlation was found between the hormone level and 
each of both ratios. This might be explained by the fact that 
both ratios are corrected for the inter-individual variation in 
the length of the upper body segment, which did not correlate 
significantly with the plasma testosterone level. It was found 
that the correlation coefficient between the hormone level and 
each of the ratios lower/upper and span/upper body segment is 
such that measurement of arm span, height and the length of the 
upper body segment in a patient with Klinefelter's syndrome 
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might provide a rough index of the plasma testosterone level. 
The second main finding of this study was that the plasma tes-
tosterone level in Klinefelter's syndrome is closely correlated 
with both the degree of facial hair growth and the type of 
pubic hair distribution. This close correlation between the 
hormone levels in plasma and these signs of androgenicity 
support the view of a qualitatively normal end organ responsi-
veness to testosterone in a number of patients with Klinefel-
ter' s syndrome. This was also substantiated by the fact that 
substitution of the androgen deficiency in patients with Kline-
felter' s syndrome might correct some of the aberrations in 
androgenicity. 
The occurrence of gynaecomastia in Klinefelter's syndrome 
appeared to be neither correlated with the level of plasma 
testosterone or body measurements, nor with the state of andro-
genicity expressed by facial hair growth and the type of pubic 
hair. These data are in contrast with those of Heller and 
Nelson (1945) and Fr^land (1969) who suggested that gynaecomas-
tia is more frequent in non-eunuchoidal Klinefelter patients, 
a suggestion not held by Paulsen (1965) and Becker et al (1966) 
who did not find any correlation between the severity of 
eunuchoidism and the presence of severity of gynaecomastia. 
Furthermore Paulsen (1965) could not detect any correlation 
between the state of Leydig cell function expressed as urinary 
oestrogen excretion and the degree of gynaecomastia. These 
combined findings almost exclude a straight forward role of 
Leydig cell insufficiency in the development of gynaecomastia. 
The data on eunuchoidism in the current study do not 
exclude the possibility that even before puberty the body pro-
portions are different from the normal. In fact Tanner et al 
(1959) collected some data that indicated a tendency to increa-
sed stature due to longleggedness in Klinefelter patients even 
before the age of puberty. The skeletal age of these children 
however was only slightly, and insignificantly retarded as 
compared to controls. Therefore these and other investigators 
(Stewart (1959), Zuppinger et al (1967), Ferguson-Smith (1969) 
stated that the abnormal body proportions in Klinefelter's 
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syndrome could not be due to delayed epiphyseal closure as a 
consequence of androgen deficiency but probably suggest a more 
fundamental deviation in growth rate from early life onwards. 
In addition Zuppinger et al (1967) postulated by analogy with 
the short stature in gonadal dysgenesis due to a defective X 
chromosome, that an X-borne gene favouring growth could be 
responsible for the increased stature in Klinefelter's syndrome. 
On scrutinizing the scanty literature data on body proportions 
in patients with proven Klinefelter's syndrome before the age 
of puberty we found that scarcely more than half of the 
children less than 13 years of age had abnormal high lower/ 
upper body segment ratios. However, it should be added that not 
all these studies give representative controls (Prader et al 
(1958), Court Brown et al (1964), Jackson and Montalvo (1968), 
Myhre et al (1970), Caldwell and Smith (1972). From the data of 
the present study and literature data (Stewart et al (1959) , 
Barr et al (1960), Court Brown et al (1964), Frtfland (1969), 
Zuppinger et al (1967) an almost equal percentage (48 vs 52 %) 
of increased and normal lower/upper body segment ratio's was 
found in about 150 patients with Klinefelter's syndrome 17 to 
83 years of age. In the current study it is unequivocally shown 
that normal body proportions concur frequently with normal 
development of androgenicity and that both these phenomena are 
closely correlated with the level of plasma testosterone. From 
these observations one might deduce that the genetic constitu-
tion in Klinefleter's syndrome predisposes in about half of the 
cases to pubertal growth aberrations as well as to clearly 
defective testosterone production by the testes. The resulting 
androgen deficiency after the age of puberty leads mainly to 
lack of androgenicity and to a maximal expression of aberrant 
body proportions. This hypothesis does not exclude the possibi-
lity that even in foetal and early life androgen deficiency 
might be the responsible factor for the aberrant growth pattern 
so far reported in about half of the children with proved 
Klinefelter's genetic constitution (c.f. Caldwell and Smith 
(1972). To test the hypothesis a follow-up study of plasma 
testosterone levels and body proportions and the development of 
160 
signs of androgenicity from birth up to adult life is 
necessary. Such a study could abridge the gap between genetic 
constitution and dependent endocrine profile both of which 
seem to be equally indispensible in explaining the aberrant 
morphogenesis in a number of genetic endocrine diseases. 
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SUMMARY 
Chapter I presents a short historical review on the iden-
tification and quantitation of testosterone in body fluids. In 
addition, in this chapter some brief remarks are made on the 
history and incidence of Klinefelter's syndrome. 
Chapter II outlines the specific objectives of the studies 
in this thesis. 
In chapter III the competitive protein binding method for 
the determination of plasma testosterone has been described in 
detail and special attention has been paid to aspects of its 
reliability. The specificity, sensitivity and accuracy of the 
method have been illustrated. An account is given of its 
clinical usefulness by reporting observations on the androgen 
status in representative samples of eugonadal males and females 
and patients with either primary or secondary hypogonadism both 
before and after human chorionic gonadotropin administration. 
Chapter IV is devoted to some temporally related changes 
in plasma testosterone levels in both eugonadal males and 
patients with Klinefelter's syndrome. It appears from this 
study that the plasma testosterone level not only varies sig-
nificantly throughout the day (Chapter V) but fluctuates 
slightly though significantly from day to day. This intraperso-
nal day-to-day variation was calculated to be as high as 14 % 
in both groups. In this chapter also the influence of ageing on 
the plasma testosterone levels in the eugonadal males and 
Klinefelter patients has been discussed. 
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In the chapters VI, VII and VIII studies have been presen-
ted which together try to evaluate to some detail aspects of 
the pituitarv-gonadal relationship in Klinefelter's syndrome. 
In most studies devoted to this subject so far, Klinefelter's 
syndrome has been conceived as a simple form of primary hypo-
gonadism with secondary hvpergonadotropism as a consequence of 
Leydig cell insufficiency. In other studies it has been claimed 
that the Leydig cells are functioning at maximal gear by virtue 
of this hypergonadotropism. The simple observation of a diurnal 
testosterone variation qualitatively similar to that observed 
in eugonadal males (Chapter V) is not easilv intelligible from 
a functional unit working at its maximal capacity as a conse-
quence of continuing hypergonadotropism (Chapter VI). It was 
shown that the diurnal testosterone variation neither m 
eugonadal males nor m patients with Klinefelter's syndrome 
can be readilv explained bv an ACTH dependent diurnal varia-
tion of adrenal activitv (Chapter V and VI). The second pheno-
menon not readilv conceivable bv the concept of gonadal 
functioning at maximum capacity was the observation that exo-
genouslv administered gonadotropins could elicit significant 
stimulation of Leydig cell function to such a degree that in 
the practice of medicine gonadotropin treatment of these 
patients under certain circumstances would deserve thorough 
evaluation. This finding suggests that the Leydig cells in 
Klinefelter's syndrome still have functional reserve (Chapter 
VII). Chapter VIII further elaborates on the functional inte-
gritv of the hypothalamic-pituitary-gonadal axis by comparing 
the suppressive effect of near physiological and higher doses 
of estrogens on plasma gonadotropins and testosterone levels in 
eugonadal males with the response observed in patients with 
Klinefelter's syndrome. It was demonstrated that the hypotha-
lamic-pituitary-gonadal feedback is still operative in these 
patients and is Qualitatively similar to that in eugonadal 
males though auantitativelv less efficient. 
In view of the large variation in the phenotvpe of 
patients with Klinefelter's svndrome, in Chapter IX some body 
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characteristics and signs of androgenicity have been related 
with the plasma testosterone levels in a number of patients and 
eugonadal males. In the patients only a significant correlation 
was demonstrated between the hormone's level and each of the 
variables body weight, arm span, lower body segment and the 
ratio's lower/upper body segment and span/upper body segment. 
A close relation was also found between the plasma testosterone 
levels and the clinical state of androgenicity in Klinefelter 
patients. Both findings are in favour of a qualitatively normal 
target organ responsiveness to testosterone in most patients 
with Klinefelter's syndrome. 
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SAMENVATTING 
In Hoofdstuk I werd een kort historisch overzicht gegeven 
betreffende de biologische identificatie en de chemische bepa-
ling van testosteron in bloed en urine. Bovendien werd in dit 
hoofdstuk ingegaan op historische aspecten en op de frequentie 
van voorkomen van het syndroom van Klinefelter. 
In Hoofdstuk II zijn de doelstellingen van de in dit 
proefschrift gerapporteerde studies nader uiteengezet. 
In Hoofdstuk III is een gedetailleerde beschrijving gege-
ven van de competitieve eiwitbindingsmethode, die gebruikt werd 
om het plasmatestosterongehalte te bepalen. De klinische bruik-
baarheid van deze bepaling werd geïllustreerd aan de hand van 
plasmatestosteronmetingen bi] eugonadale mannen en vrouwen en 
bij patiënten met een primair of secundair hypogonadisme, zowel 
vóór als ná toediening van gonadotrophmen. 
Hoofdstuk IV is gewijd aan tijdsfactoren die het plasma-
testosterongehalte kunnen beïnvloeden. Zowel bij eugonadale 
mannen als patiënten met het syndroom van Klinefelter bleek het 
plasmatestosterongehalte niet alleen gedurende de dag signifi-
cant te variëren (Hoofdstuk V), maar ook van dag tot dag. Bij 
beide groepen personen bleken de gemiddelde, relatieve dag tot 
dag variaties van de zelfde orde van grootte te zijn (14 % ) . 
Zowel bij de eugonadale mannen als bij de patiënten met het 
syndroom van Klinefelter werd de invloed van de belangrijkste 
tijdsvanabele, de leeftijd, op het plasmatestosterongehalte 
bestudeerd en bediscussieerd. 
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In de Hoofdstukken VI, VII en Vili zijn enkele aspecten 
van de hypothalamus-hypophyse-gonade-as bij patiënten met het 
syndroom van Klinefelter bestudeerd. De meeste studies die tot 
dusverre aan dit onderwerp zijn gewijd, beschouwden het syn-
droom van Klinefelter als een vorm van primair hypogonadisme, 
met secundair verhoogde gonadotrophinenspiegels m plasma en 
urine als gevolg. Andere studies echter benadrukten, dat de 
Leydigcellen bij dit syndroom juist maximaal zijn gestimuleerd, 
dankzij deze verhoogde gonadotrophinenspiegels. Het feit dat de 
diurne testosteronvanatie bij patiënten met het syndroom van 
Klinefelter qualitatief van dezelfde orde van grootte was als 
bij normale mannen, is niet gemakkelijk te rijmen met de op-
vatting, dat de Leydig-cellen bij deze patiënten reeds maximaal 
zouden zijn gestimuleerd (Hoofdstuk VI). Deze diurne variatie 
was noch bij de eugonadale controlepersonen, noch bij de pa-
tienten met het syndroom van Klinefelter ongedwongen te verkla-
ren door de ACTH afhankelijke diurne variatie van de bijnier-
schorsactiviteit (Hoofdstuk V en VI). 
Ook in tegenspraak met de opvatting dat de Leydig-cellen 
bij het syndroom van Klinefelter reeds maximaal zouden zijn 
gestimuleerd, was de bevinding, dat zowel na kortdurende als 
chronische toediening van gonadotrophinen een significante 
stijging van de plasmatestosteronspiegels werd waargenomen bij 
alle patiënten (Hoofdstuk VII). In Hoofdstuk VIII werd de 
functie van de hypothalamus-hypophyse-gonade-as verder geëva-
lueerd door het effect na te gaan van toediening van lage en 
hoge doses oestrogenen op de plasmagonadotrophinen en testoste-
ronspiegels bij patiënten met het syndroom van Klinefelter, in 
vergelijking met het effect waargenomen bij eugonadale mannen. 
Aangetoond werd dat de hypothalamus-hypophyse-gonade-terug-
koppeling bij patiënten met het syndroom van Klinefelter nog 
steeds in tact is, zij het minder efficient in vergelijking 
met die bij eugonadale personen. 
Gezien de grote variatie in het phenotype van patiënten 
met het syndroom van Klinefelter werd nagegaan of er een rela-
tie bestaat tussen het plasmatestosterongehalte enerzijds 
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en de mate van virilisatie en de lichaamsbouw anderzijds 
(Hoofdstuk IX). Inderdaad werd een significante negatieve 
correlatie aangetoond tussen het plasmatestosterongehalte en 
elk van de variabelen lichaamsgewicht, spanwijdte, beenlengte 
en de ratio's beenlengte/zithoogte en spanwijdte/zithoogte. 
Ook bleek er een nauwe relatie te bestaan tussen het plasma-
testosterongehalte en de mate van virilisatie. Deze bevindingen 
pleiten voor een qualitatief normale gevoeligheid van de doel-
witorganen voor testosteron bij de meeste patiënten met het 
syndroom van Klinefelter. 
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STELLINGEN 
1 Baker e.a. maakten het waarschijnlijk om aan te nemen dat op 
het zuidelijke halfrond een seizoensvariatie bestaat in de 
plasmatestosteronspiegels van de man, met hogere spiegels in 
de lente dan in de herfst. Eigen waarnemingen suggereren 
dat deze seizoensvariatie ook op het noordelijke halfrond 
voorkomt. 
H.W. Baker e.a. (unpublished observations) In: Burger 
е.a. (1972) 'Gonadotropic and gonadal function in the 
normal adult male': In B. Saxena, C G . Beling, H.M. 
Gandy (eds) 'Gonadotropins', Wiley Interscience, New 
York biz. 573. 
A.G.H. Smals e.a. (ongepubl. waarneming) 1973. 
2 Persky e.a. rapporteerden dat de plasmatestosteronspiegels 
van 12 vrouwen op verschillende tijdstippen van de cyclus 
significant van elkaar verschilden, respectievelijk 19.5 + 
2.4, 33.7 + 3.0 en 25.7 + 4.6 (SE) ng/100 ml in de follicu­
laire, de ovulatoire en de luteale fase. Ook de mate van 
agressiviteit van deze vrouwen varieerde significant in de 
genoemde perioden met 'agression factor scores' van respec­
tievelijk 5.5, 9.3 en 7.2. Uit deze bevindingen concludeer­
den de auteurs dat de wisselende mate van agressie bij de 
vrouw tijdens de cyclus door de gevonden verschillen in 
testosteronspiegels van het plasma kan worden verklaard. 
Deze verklaring is even intrigerend als onwetenschappelijk. 
H. Persky e.a., abstract 252, 55th Endocr. Soc. Meeting, 
1973. 
3 Bij het bestaan van een onverklaarde haemolytische anaemie 
bij vrouwen in het eerste trimester van de zwangerschap 
dient de diagnose 'gerupteerde extra-uteriene graviditeit' 
te worden overwogen. 
Een 33-jarige, II gravida, II para (laatste menstruatie: 
20 3 an u a r l 1972) wordt 15 maart 1972 met spoed op de 
gynaecologische afdeling van het St. Radboud Ziekenhuis 
opgenomen wegens ernstige bloedarmoede (Hb: 3.8 mmol/1). 
Vier dagen ббг opneming had zi] gedurende één dag ge-
ring vaginaal bloedverlies opgemerkt. Bi] opneming wer-
den behoudens genoemde anaemie geen afwijkingen vastge-
steld. Laboratoriumonderzoek wees op het bestaan van een 
haemolytische anaemie (verhoogde serumbilirubine-, LDH-, 
en i]zergehalten, een verhoogd aantal reticulocyten, 
128 0/oo, en een verlaagd serumhaptoglobmegehalte) , 
waarvoor geen verklaring kon worden gevonden. Een week 
na opneming trad echter manifest vaginaal bloedverlies 
op en werd vrij vocht in de buik aantoonbaar, dat bij 
punctie sanguinolent bleek te zijn. Bij laparoscopie 
en aansluitende laparotomie werd het klassieke beeld 
van een tubaire abortus gevonden met 3 liter bloed in 
de buikholte. 
J.D. Reeve, Letter to the editor, Brit. Med. J. 1971, 2: 
654. 
E.V. van Hall, A. van Lindert en A.G.H. Smals (ongepu-
bliceerde waarneming, 1972). 
4 De door Valk ontwikkelde meetwijze van de ulnalengte is zeer 
bruikbaar voor de diagnostiek van groeistoornissen op korte 
termijn. 
I.M. Valk, Growth 35, 1971, 297. 
I.M. Valk, Growth 36, 1972, 291. 
I.M. Valk, Growth, 1974, ter perse. 
5 Bi] patiënten met een verminderde reukzin dient naast een 
rhinologisch en neurologisch onderzoek ook een endocrinolo-
gisch onderzoek te geschieden. 
A.G.H. Smals e.a., Neth. J. Med. 1974, ter perse. 
6 De asvmptomatische hvpernatnaemie die bij ongeveer de helft 
van 14 onderzochte patiënten met het svndroom van Steinert-
Curschmann werd gevonden, kan worden verklaard door de com-
binatie van gestoorde osmoreceptie en hypodipsie. Ook deze 
waarneming illustreert dat de ziekte van Steinert-Curschmann 
als een systeemziekte moet worden beschouwd. 
A.G.H. Smals en P.W.C. Kloppenborg, Acta Endocr. Kbh., 
155, 1971, 175. 
7 Aangezien de gangbare hairsprays een vernauwing van de 
kleine luchtwegen veroorzaken (Zuskin en Bouhuys) moet het 
gebruik ervan tenminste aan patiënten met asthma bronchiale 
worden ontraden. 
E. Zuskin and A. Bouhuys, New. Eng. J. Med. 290 (1974) 
660. 
8 Door Preston e.a. (1974) werden bi] 30 % van de stewardessen, 
werkzaam op de lange transmeridionale vliegroutes, signifi-
cante afwijkingen in de cyclusduur gevonden, welke deze 
auteurs toeschreven aan de stress, voortvloeiende uit de 
tijdszone-veranderingen. Deze verklaring zou meer steekhou-
dend zijn geweest, wanneer bij een vergelijkbaar onderzoek 
bij stewardessen werkzaam op even lange meridionale vlieg-
routes dergelijke cyclusveranderingen niet gevonden zouden 
zijn. 
F.S. Preston e.a. (1974) (In: M. Ferm, F. Halberg, R.M. 
Richart and R.L. VandeWiele (eds) Biorhythm and human 
reproduction, J. Wiley and sons. New York, biz. 501). 
9 De kosten die zullen voortvloeien uit het invoeren van zoge-
naamde radioimmunologische 'kitmethoden' m de Nederlandse 
ziekenhuizen dreigen de kosten van het geneeskundig labora-
toriumonderzoek onaanvaardbaar te doen stijgen. Nog veel 
bedenkelijker is het dat gebruik op grote schaal ruim zal 
kunnen bijdragen tot schadelijk medisch handelen. 
10 Voor de ontplooiing van de volledige faciliteiten van een 
Academisch Ziekenhuis verdient subsidiering van interna-
tionale ambtelijke dienstreizen met een wetenschappelijk 
oogmerk veel hogere prioriteit dan b.v. een autokilimeter-
onkostenvergoeding van 27 of 33 cent voor ambtelijke dienst-
reizen binnen Nederland of het aanleggen en onderhouden van 
exotische en daardoor dure beplantingen van binnentuinen op 
het terrein van de Medische Faculteit te Nijmegen. 
11 Het getuigt van weinig progressief denken, dat vooral van 
de zijde van zich progressief noemenden de sexuele voor-
lichting aan jeugdigen nog steeds meer een instructie tot 
voorkoming van zwangerschap is, dan een poging de relatie 
tussen man en vrouw beter te doen verstaan. 


